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HEAT-PCI How Effective are Antithrombotic Therapies
in PPCI
HORIZONS-AMI Harmonizing Outcomes with
Revascularization and Stents in Acute
Myocardial Infarction
HR hazard ratio
iFR instantaneous wave-free ratio
i.v. intravenous
IABP intra-aortic balloon pump
IABP-SHOCK Intra-aortic Balloon Pump in Cardiogenic
Shock
ICD implantable cardioverter deﬁbrillator
IMA internal mammary artery
INR international normalized ratio
ISAR-CABG Is Drug-Eluting-Stenting Associated with
Improved Results in Coronary Artery Bypass
Grafts
ISAR-REACT Intracoronary Stenting and Antithrombotic
Regimen–Rapid Early Action for Coronary
Treatment
ISAR-SAFE Intracoronary Stenting and Antithrombotic
Regimen: Safety And eFﬁcacy of a 6-month
DAT after drug-Eluting stenting
IVUS intravascular ultrasound imaging
LAA left atrial appendage
LAD left anterior descending
LCx left circumﬂex
LDL-C low-density lipoprotein cholesterol
LM left main
LMWH low-molecular-weight heparin
LoE level of evidence
LV left ventricle/left ventricular
LVAD left ventricular assist device
LVEF left ventricular ejection fraction
LVESVI left ventricular end-systolic volume index
MACCE major adverse cardiac and cerebrovascular
event
MACE major adverse cardiac event
MADIT II Multicentre Automatic Deﬁbrillator
Implantation Trial II
MADIT-CRT Multicenter Automatic Deﬁbrillator
Implantation Trial – Cardiac
Resynchronization Therapy
MASS II Medical, Angioplasty or Surgery Study II
MDCT multi-detector computed tomography
MI myocardial infarction
MIDCAB minimally invasive direct coronary artery
bypass
MPS myocardial perfusion stress
MRI magnetic resonance imaging
MT medical therapy
NCDR CathPCI National Cardiovascular Database Registry
NOAC non-vitamin K antagonist oral anticoagulant
NSAID non-steroidal anti-inﬂammatory drug
NSTE-ACS non-ST-segment elevation acute coronary
syndrome
NSTEMI non-ST-segment elevation myocardial
infarction
NYHA New York Heart Association
o.d. omni die (every day)
OASIS Optimal Antiplatelet Strategy for
Interventions
OCT optical coherence tomography
On-TIME-2 Continuing TIroﬁban in Myocardial
infarction Evaluation
OPTIMIZE Optimized Duration of Clopidogrel Therapy
Following Treatment With the Zotarolimus-
Eluting Stent in Real-World Clinical Practice
OR odds ratio
p.o. per os (by mouth)
PACCOCATH Paclitaxel-Coated Balloon Catheter
PAD peripheral artery disease
PARIS Patterns of Non-Adherence to Anti-Platelet
Regimens In Stented Patients
PCAT Primary Coronary Angioplasty vs.
Thrombolysis
PCI percutaneous coronary intervention
PEPCAD Paclitaxel-Eluting PTCA–Catheter In
Coronary Disease
PES paclitaxel-eluting stent
PET positron emission tomography
PLATO Study of Platelet Inhibition and Patient
Outcomes
PRAMI Preventive Angioplasty in Acute Myocardial
Infarction
PRECOMBAT Premier of Randomized Comparison of
Bypass Surgery vs. Angioplasty Using
Sirolimus-Eluting Stent in Patients with Left
Main Coronary Artery Disease
PROCAT Parisian Region Out of Hospital Cardiac
Arrest
PRODIGY PROlonging Dual Antiplatelet Treatment In
Patients With Coronary Artery Disease After
Graded Stent-induced Intimal Hyperplasia
studY
PROTECT AF Watchman Left Atrial Appendage System for
Embolic Protection in Patients with Atrial
Fibrillation
q.d. quaque die
RCT randomized clinical trial
REPLACE Randomized Evaluation in PCI Linking
Angiomax to Reduced Clinical Events
RESET Real Safety and Efﬁcacy of a 3-month Dual
Antiplatelet Therapy Following Zotarolimus-
eluting Stents Implantation
RIVAL RadIal Vs. femorAL access for coronary
intervention
RR risk ratio
RRR relative risk reduction
s.c. subcutaneous
SAVOR-TIMI Saxagliptin and Cardiovascular Outcomes in
Patients with Type 2 Diabetes Mellitus
SCAD stable coronary artery disease
SCAAR Swedish Coronary Angiography and
Angioplasty Registry
SCD-HEFT Sudden Cardiac Death in Heart Failure Trial
SES sirolimus-eluting stent
SHOCK Should We Emergently Revascularize
Occluded Coronaries for Cardiogenic
Shock
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SPECT single photon emission computed
tomography
STE-ACS ST-segment elevation acute coronary
syndrome
STEEPLE Safety and Efﬁcacy of Intravenous
Enoxaparin in Elective Percutaneous
Coronary Intervention Randomized
Evaluation
STEMI ST-segment elevation myocardial infarction
STICH Surgical Treatment for Ischemic Heart
Failure
STREAM STrategic Reperfusion Early After Myocardial
infarction
STS Society of Thoracic Surgeons
SVG saphenous vein graft
SVR surgical ventricular reconstruction
SYNTAX Synergy between Percutaneous Coronary
Intervention with TAXUS and Cardiac
Surgery.
TACTICS-TIMI 18 Treat angina with Aggrastat and determine
Cost of Therapy with an Invasive or
Conservative Strategy–Thrombolysis in
Myocardial Infarction
TARGET Do Tiroﬁban and Reo-Pro Give Similar
Efﬁcacy Outcome Trial
TASTE Thrombus Aspiration during PCI in Acute
Myocardial Infarction
TAVI transcatheter aortic valve implantation
TIA transient ischaemic attack
TIMACS Timing of Intervention in Patients with Acute
Coronary Syndromes
TIME Trial of Invasive Medical therapy in the
Elderly
TIMI Thrombolysis in Myocardial Infarction
TRIGGER-PCI Testing Platelet Reactivity In Patients
Undergoing Elective Stent Placement on
Clopidogrel to Guide Alternative Therapy
With Prasugrel
TRITON TIMI-38 TRial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet
InhibitioN with Prasugrel–Thrombolysis In
Myocardial Infarction 38
TVR target vessel revascularization
UFH unfractionated heparin
VAD ventricular assist device
VF ventricular ﬁbrillation
VKA vitamin K antagonist
VSD ventricular septal defect
VT ventricular tachycardia
WOEST What is the Optimal antiplatElet and
anticoagulant therapy in patients with





Stent, or PacliTaxel-Eluting Stent
Implantation for Coronary Lesions - Late
Coronary Arterial Thrombotic
Events/REAL-world Patients Treated
with Drug-Eluting Stent Implantation
and Late Coronary Arterial Thrombotic
Events
1. PREAMBLE
Guidelines summarize and evaluate all available evidence, at the
time of the writing process, on a particular issue with the aim of
assisting health professionals in selecting the best management
strategies for an individual patient with a given condition, taking into
account the impact on outcome, as well as the risk–beneﬁt ratio of
particular diagnostic or therapeutic means. Guidelines and recom-
mendations should help health professionals to make decisions in
their daily practice; however, the ﬁnal decisions concerning an indi-
vidual patient must be made by the responsible health professional
(s), in consultation with the patient and caregiver as appropriate.
A great number of guidelines have been issued in recent years
by the European Society of Cardiology (ESC) and the European
Association for Cardio-Thoracic Surgery (EACTS), as well as by
other societies and organisations. Because of their impact on clin-
ical practice, quality criteria for the development of guidelines
have been established in order to make all decisions transparent
to the user. The recommendations for formulating and issuing
ESC/EACTS Guidelines can be found on the ESC web site (http://
www.escardio.org/guidelines-surveys/esc-guidelines/about/
Pages/rules-writing.aspx). These ESC/EACTS guidelines represent
the ofﬁcial position of these two societies on this given topic and are
regularly updated.
Members of this Task Force were selected by the ESC and
EACTS to represent professionals involved with the medical
care of patients with this pathology. Selected experts in the ﬁeld
undertook a comprehensive review of the published evidence
for management (including diagnosis, treatment, prevention
and rehabilitation) of a given condition, according to the ESC
Committee for Practice Guidelines (CPG) and EACTS Guidelines
Committee policy. A critical evaluation of diagnostic and thera-
peutic procedures was performed, including assessment of the
risk–beneﬁt ratio. Estimates of expected health outcomes for
larger populations were included, where data exist. The level of
evidence and the strength of recommendation of particular man-
agement options were weighed and graded according to pre-
deﬁned scales, as outlined in Tables 1 and 2.
The experts of the writing and reviewing panels completed
‘declarations of interest’ forms which might be perceived as real
or potential sources of conﬂicts of interest. These forms were
compiled into one ﬁle and can be found on the ESC web site
(http://www.escardio.org/guidelines). Any changes in declarations
of interest that arise during the writing period must be notiﬁed to
the ESC/EACTS and updated. The Task Force received its entire ﬁ-
nancial support from the ESC and EACTS, without any involve-
ment from the healthcare industry.
The ESC CPG supervises and co-ordinates the preparation of
new guidelines produced by Task Forces, expert groups or con-
sensus panels. The Committee is also responsible for the endorse-
ment process of these guidelines. The ESC and Joint Guidelines
undergo extensive review by the CPG and partner Guidelines
Committee and external experts. After appropriate revisions it is
approved by all the experts involved in the Task Force. The ﬁna-
lized document is approved by the CPG/EACTS for simultaneous
publication in the European Heart Journal and joint partner
journal, in this instance the European Journal of Cardio-Thoracic
Surgery. It was developed after careful consideration of the scien-
tiﬁc and medical knowledge and the evidence available at the
time of their dating.
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The task of developing ESC/EACTS Guidelines covers not only
the integration of the most recent research, but also the crea-
tion of educational tools and implementation programmes for
the recommendations. To implement the guidelines, condensed
pocket versions, summary slides, booklets with essential messages,
summary cards for non-specialists, electronic versions for digital
applications (smart phones etc.) are produced. These versions are
abridged and thus, if needed, one should always refer to the full-
text version, which is freely available on the ESC and EACTS web
sites. The national societies of the ESC and of the EACTS are encour-
aged to endorse, translate and implement the ESC Guidelines.
Implementation programmes are needed because it has been
shown that the outcome of disease may be favourably inﬂuenced
by the thorough application of clinical recommendations.
Surveys and registries are needed to verify that real-life daily prac-
tice is in keeping with what is recommended in the guidelines, thus
completing the loop between clinical research, writing of guidelines,
disseminating them and implementing them into clinical practice.
Health professionals are encouraged to take the ESC/EACTS
Guidelines fully into account when exercising their clinical judg-
ment, as well as in the determination and the implementation of
preventive, diagnostic or therapeutic medical strategies; however,
the ESC/EACTS Guidelines do not, in any way whatsoever,
override the individual responsibility of health professionals to
make appropriate and accurate decisions in consideration of the
condition of each patient’s health and in consultation with that
patient and, where appropriate and/or necessary, the patient’s
caregiver. It is also the health professional’s responsibility to verify
the rules and regulations applicable to drugs and devices at the
time of prescription.
2. INTRODUCTION
Fifty years of myocardial revascularization
In 2014, coronary artery bypass grafting (CABG) celebrates the
50th anniversary of the ﬁrst procedures performed in 1964 [1].
Thirteen years later, the ﬁrst percutaneous coronary intervention
(PCI) was performed [2]. Since then both revascularization techni-
ques have undergone continued advances, in particular the system-
atic use of arterial conduits in the case of CABG, and the advent of
stents. In the meantime, PCI has become one of the most frequent-
ly performed therapeutic interventions in medicine [3]; and pro-
gress has resulted in a steady decline of periprocedural adverse
events, resulting in excellent outcomes with both revascularization
techniques. Notwithstanding, the differences between the two
revascularization strategies should be recognized. In CABG, bypass
grafts are placed to the mid-coronary vessel beyond the culprit
lesion(s), providing extra sources of bloodﬂow to the myocardium
and offering protection against the consequences of further prox-
imal obstructive disease. In contrast, coronary stents aim at restor-
ing normal bloodﬂow of the native coronary vasculature by local
treatment of obstructive lesions without offering protection against
new disease proximal to the stent.
Myocardial revascularization has been subject to more rando-
mized clinical trials (RCTs) than almost any other intervention
(Figure 1). In order to inform the current Guidelines, this Task
Force performed a systematic review of all RCTs performed since
1980, comparing head-to-head the different revascularization
strategies—including CABG, balloon angioplasty, and PCI with
bare-metal stents (BMS) or with various US Food and Drug
Table 1: Classes of recommendations
Table 2: Levels of evidence
Level of 
evidence A 
Data derived from multiple randomized 
clinical trials or meta-analyses. 
Level of 
evidence B 
Data derived from a single randomized 




Consensus of opinion of the experts and/
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Administration-approved drug-eluting stents (DES)—against
medical treatment as well as different revascularization strategies,
and retrieved 100 RCTs involving 93 553 patients with 262 090
patient-years of follow-up [4].
Formulation of the best possible revascularization approach,
also taking into consideration the social and cultural context, will
often require interaction between cardiologists and cardiac sur-
geons, referring physicians, or other specialists as appropriate.
Patients need help with taking informed decisions about their
treatment and the most valuable advice will probably be provided
to them by the ‘Heart Team’ [5]. Recognizing the importance of
the interaction between cardiologists and cardiac surgeons, the
leadership of both the ESC and the EACTS has given this Joint Task
Force, along with their respective Guideline Committees, and the
reviewers of this document the mission to draft balanced, patient-
centred, evidence-driven practice guidelines on myocardial revas-
cularization. The respective Chairpersons of these two associations
and CPG Chairperson were also given the task to adapt to the dec-
laration of interest policy and to ensure that their Task Force
members followed it throughout the development process of the
Guidelines. In the event that any of the Task Force members had a
potential conﬂict of interest to declare, he/she did not participate
in the ﬁnal decision of the Task Force on the given subject.
3. SCORES AND RISK STRATIFICATION
Myocardial revascularization in the elective setting is appropriate
when the expected beneﬁts, in terms of survival or health out-
comes (symptoms, functional status, and/or quality of life), exceed
the expected negative consequences of the procedure. Whether
medical therapy, PCI, or CABG is preferred should depend on the
risk–beneﬁt ratios of these treatment strategies, weighting the risks
of periprocedural death, myocardial infarction and stroke against
improvements in health-related quality of life, as well as long-term
freedom from death, myocardial infarction or repeat revasculari-
zation. The Heart Team should take into consideration the coron-
ary anatomy, disease, age and comorbidities, patient preference,
and hospital/operator experience.
Numerous models have been developed for risk stratiﬁcation, fo-
cussing on anatomical complexity or clinical risk, and have demon-
strated their value during decision-making [6]. Those models most
frequently used in a clinical setting are summarized in the Tables of
recommendation [risk models to assess short-term (in-hospital or
30-day) and medium-to-long-term (≥1 year) outcomes].
(1) The EuroSCORE predicts surgical mortality [7,8]. It is based on
an old data set and has been shown to overestimate the risk of
mortality, and should therefore no longer be used [9,10].
(2) The EuroSCORE II is an update of the logistic EuroSCORE model
and is derived from a more contemporary data set better
reﬂecting current cardiac surgical practice [11]. Its value has
been demonstrated in speciﬁc cohorts of patients undergoing
CABG [12]. Compared with its original version, the EuroSCORE II
may have a better ability to predict mortality [12–14].
(3) The Society of Thoracic Surgeons (STS) score is a risk-
prediction model, validated in patients undergoing cardiac
surgery, with a speciﬁc model for CABG surgery and combined
CABG and valve surgery [15,16]. It can be used to predict
in-hospital or 30-day mortality (whichever occurs last) and
in-hospital morbidity.
(4) The SYNTAX score (Table 3) was developed to grade the ana-
tomical complexity of coronary lesions in patients with left
main or three-vessel disease, and was found to be an inde-
pendent predictor of long-term major adverse cardiac and
cerebrovascular event (MACCE) in patients treated with PCI
but not CABG [17,18]. It facilitates the selection of optimal
treatment by identifying patients at highest risk of adverse
events following PCI. The interobserver variability of the
Synergy between Percutaneous Coronary Intervention with
TAXUS and Cardiac Surgery (SYNTAX) score is signiﬁcant [19]
although development of non-invasive assessments may sim-
plify calculation of the SYNTAX score [20].
(5) The National Cardiovascular Database Registry (NCDR
CathPCI) risk score has been developed to predict risk in PCI
patients and should only be used in this context [21].
(6) The age, creatinine, ejection fraction (ACEF) model is a simple
























































































































Revascularization vs. MT Balloon angioplasty vs. CABG BMS vs. CABG DES vs. CABG
BMS = bare-metal stent; CABG = coronary artery bypass grafting; DES = drug-eluting stent.
Figure 1: Randomized trials in myocardial revascularization therapy over the past ﬁve decades.
ESC/EACTS Guidelines / European Journal of Cardio-Thoracic Surgery524
data from a cohort of surgical patients [22]. ACEF has also been
validated to predict mortality in patients undergoing PCI [23].
(7) The clinical SYNTAX score is a combination of the ACEF and
SYNTAX scores. Originally established as an additive model,
the subsequent development of a logistic model has provided
more tailored risk assessment [24].
(8) The SYNTAX II score is a combination of anatomical and clinical
factors [age, creatinine clearance, left ventricular (LV) function,
Table 3: Guide to calculate the SYNTAX score
Steps Variable assessed Description
Step 1 Dominance The weight of individual coronary segments varies according to coronary artery dominance (right or 
left). Co-dominance does not exist as an option in the SYNTAX score.
Step 2 Coronary segment The diseased coronary segment directly affects the score as each coronary segment is assigned a 
weight, depending on its location, ranging from 0.5 (i.e. posterolateral branch) to 6 (i.e. left main in case 
of left dominance).
Step 3 Diameter stenosis The score of each diseased coronary segment is multiplied by 2 in case of a stenosis 50–99% and by 5
in case of total occlusion. 
In case of total occlusion, additional points will be added as follows: 
- Age >3 months or unknown
- Blunt stump                           
- Bridging                                
- First segment visible distally    
- Side branch at the occlusion    
                                               
 
Step 4 Trifurcation lesion The presence of a trifurcation lesion adds additional points based on the number of diseased segments:
- 1 segment  +3
- 2 segments +4
- 3 segments +5
- 4 segments +6
Step 5 Bifurcation lesion The presence of a bifurcation lesion adds additional points based on the type of bifurcation according 
- Medina 1,0,0 or 0,1,0 or 1,1,0: add 1 additional point
- Medina 1,1,1 or 0,0,1 or 1,0,1 or 0,1,1: add 2 additional point
Additionally, the presence of a bifurcation angle <70° adds 1 additional point. 
Step 6 Aorto-ostial lesion The presence of aorto-ostial lesion segments adds 1 additional point.
Step 7 Severe tortuosity The presence of severe tortuosity proximal of the diseased segment adds 2 additional points.
Step 8 Lesion length Lesion length >20 mm adds 1 additional point.
Step 9
Step 10 Thrombus The presence of thrombus adds 1 additional point.
Step 11 Diffuse disease/small vessels The presence of diffusely diseased and narrowed segments distal to the lesion (i.e. when at least 75% of 





+1 per non visible segment
+1 if <1.5 mm diameter
+1 if both <1.5 and ≥1.5 mm diameter
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ACEF = age, creatinine, ejection fraction; (i) CABG = (isolated) coronary artery bypass grafting; NCDR = National Cardiovascular Data Registry; PCI =
percutaneous coronary intervention; STS = Society of Thoracic Surgeons.
aReferences.
bWhichever occurs last.
cPermanent stroke, renal failure, prolonged ventilation, deep sternal wound infection, re-operation, length of stay <6 or >14 days.
dIf creatinine is >2 mg/dl.
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IIa B <5 - 24
ASCERT = American College of Cardiology Foundation–Society of Thoracic Surgeons Database Collaboration (ACCF–STS) on the comparative effectiveness of
revascularization strategies; (i) CABG = (isolated) coronary artery bypass grafting; MACCE = major adverse cardiac and cerebrovascular events; PCI =
percutaneous coronary intervention; SYNTAX = synergy between percutaneous coronary intervention with TAXUS and cardiac surgery.
aReferences.
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gender, chronic obstructive pulmonary disease, and peripheral
vascular disease] and predicts long-term mortality in patients
with complex three-vessel or left main (LM) coronary artery
disease (CAD) [25]. It was found to be superior to the convention-
al SYNTAX score in guiding decision-making between CABG and
PCI in the SYNTAX trial, and subsequently validated in the drug-
eluting stent for left main coronary artery disease DELTA registry.
(9) For the American College of Cardiology Foundation–Society of
Thoracic Surgeons Database Collaboration (ASCERT) study [26],
two large datasets from the National Cardiovascular Data Registry
(NCDR) and STS were used to develop several models to predict
mortality at different time points following CABG and PCI [27,28].
Comparative analyses of these models are limited because avail-
able studies have largely evaluated individual risk models in differ-
ent patient populations, with different outcome measures being
reported at various time points, and most models are restricted to
one type of revascularization. In addition, several important vari-
ables, such as frailty, physical independence and porcelain aorta,
are not incorporated in current risk scores. An ideal risk–beneﬁt
model enables comparison of the short-term beneﬁts of PCI to
the long-term beneﬁts of CABG; however, even though risk
models may provide useful information for predicting mortality
and major adverse events, prediction of which patients will
receive beneﬁt in terms of quality of life is so far unavailable.
These limitations restrict the ability to recommend one speciﬁc
risk model. It is also important to acknowledge that no risk score
can accurately predict events in an individual patient. Moreover,
limitations exist in all databases used to build risk models, and dif-
ferences in deﬁnitions and variable content can affect the per-
formance of risk scores when they are applied across differing
populations. Ultimately, risk stratiﬁcation should be used as a
guide, while clinical judgement and multidisciplinary dialogue
(The Heart Team) remain essential [25].
4. PROCESS FOR DECISION-MAKING AND
PATIENT INFORMATION
4.1 Patient information and informed consent
The process of medical decision-making and patient information
is guided by the ‘four principles’ approach to healthcare ethics:
autonomy, beneﬁcence, non-maleﬁcence, and justice [31]. The
informed consent process should not be regarded as a necessary
legal requirement but as an opportunity to optimize decision-
making. Patient-related factors, institutional factors and referral
patterns may impact the decision-making process.
Informed consent requires transparency, especially if there is
controversy over various treatment options. Collaborative care
requires the pre-conditions of communication, comprehension,
and trust. Treatment decisions should not be based solely on re-
search results and the physician’s appraisal of the patient’s circum-
stances, since active patient participation in the decision-making
process may yield better outcomes. Patients are subject to bias by
labels when considering coronary revascularization [32], and
patient preference may sometimes contradict evidentiary best
practice. Patients may have limited understanding of their disease
and sometimes unreasonable expectations with regard to the out-
comes of a proposed intervention. As many as 68% of patients are
not aware of an alternative revascularization strategy [33]. Short-
term procedure-related and long-term risks and beneﬁts—such
as survival, relief of angina, quality of life, potential need for late
re-intervention, and uncertainties associated with different treat-
ment strategies—should be thoroughly discussed. Patients can
only weigh this information in the light of their personal values
and cultural background and must therefore have the time to
reﬂect on the trade-offs imposed by the outcome estimates.
In order to seek a second opinion or to discuss the ﬁndings and
consequences with referring physicians, enough time should be
allowed—up to several days, as required—between diagnostic
catheterization and intervention. Patient information needs to be
unbiased, evidence-based, up-to-date, reliable, accessible, rele-
vant, and consistent with legal requirements. Consistent use of ter-
minology, that the patient understands, is essential. A written
patient information document is needed. These recommenda-
tions pertain to patients in stable condition, for whom various
treatment options exist and who can make a decision without the
constraints of an urgent or emergency situation (Table 4).
Anonymous treatment should be avoided. The patient has the
right to obtain information on the level of expertise of the oper-
ator, the workload of the centre and whether all treatment
options including surgery are available on site. Patients considered
for revascularization should also be clearly informed of the con-
tinuing need for medical therapy, as well as lifestyle modiﬁcation
and other secondary prevention strategies (section 20).
4.2 Multidisciplinary decision-making
(Heart Team)
The Heart Team, made up of clinical or non-invasive cardiologists,
cardiac surgeons and interventional cardiologists, provides a
balanced, multidisciplinary decision-making process [5]. Add-
itional input may be needed from other specialties involved in the
care of the patient. The Heart Team should meet on a regular
basis to analyse and interpret the available diagnostic evidence,
put into context the clinical condition of the patient, determine
the need—or otherwise—for an intervention and the likelihood of
safe and effective revascularization with either PCI or CABG. Ad
hoc meetings of the Heart Team should facilitate and support
efﬁcient clinical workﬂows.
The demand for an interdisciplinary approach is underlined by
reports on (i) underuse of revascularization procedures in 18–40%
of patients with CAD [34], and (ii) inappropriate use of revasculariza-
tion strategies and a lack of case discussions [35]. The large variabil-
ity between European countries in PCI-to-CABG ratios (ranging
from 2.0 to 8.6 in 2007) has raised concerns regarding the appropri-
ate selection of revascularization in Europe [36]. Rates for the in-
appropriate use of PCI (11–15%) or doubt over the appropriateness
of PCI (40–50% [5,37] and, to a lesser degree for CABG (1–2% and
0–9%, respectively) are reported [5,38]. The increasing underuse of
CABG is in part explained by PCI treatment in patients with indica-
tions for surgery [39,40]. Multidisciplinary decision-making in a
Heart Team can minimize specialty bias and prevent self-referral
from interfering with optimal patient care [32,41].
Standard evidence-based, interdisciplinary, institutional proto-
cols may be used for common case scenarios, to avoid the need for
the systematic case-by-case review of all diagnostic angiograms,
but complex cases should be discussed individually. In these cases,
revascularization should not be performed at the time of diagnostic
angiography, to allow sufﬁcient time to assess all available informa-
tion, and clearly explain and discuss the ﬁndings with the patient
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revascularization treatment should be documented on the patient’s
chart. In hospitals without a cardiac surgical unit or in an ambula-
tory setting, protocols should be designed in collaboration with an
expert interventional cardiologist and a cardiac surgeon. Decisions
made by a Heart Team seem to be reproducible [42].
4.3 Timing of revascularization and ad hoc
percutaneous coronary intervention
Studies of patients scheduled for revascularization have revealed
that considerable morbidity and mortality are associated with
extended delay of treatment [43,44]. The waiting period for diag-
nostic catheterization should therefore be minimal. Once the de-
cision for revascularization has been reached after diagnostic
coronary angiography, the Task Force recommends that patients
with severe symptoms Canadian Cardiovascular Society (CCS)
Class 3 and those with high-risk anatomy [left main disease or
equivalent; three-vessel disease or proximal left anterior descend-
ing (LAD) or depressed ventricular function] preferably undergo
revascularization (PCI or CABG) within 2 weeks. For all other
patients with stable coronary artery disease (SCAD) and an indica-
tion for revascularization, it is desirable to perform revasculariza-
tion (PCI or CABG) within 6 weeks (Table 4) [44].
Ad hoc PCI is deﬁned as a therapeutic intervention performed
within the same procedure as the diagnostic coronary angiography.
Ad hoc PCI is convenient, associated with fewer access site compli-
cations, and often cost-effective and safe [45]. In the USA, however,
up to 30% of patients undergoing ad hoc PCI are potential candi-
dates for CABG [45]. Although this number may be lower in Europe
[35], ad hoc PCI should not be applied as a default approach [45,46].
Ad hoc PCI in stable patients is only justiﬁed after adequate informa-
tion given to the patient (see section 4.1) and if a full diagnostic
work-up, including functional testing (section 5) is available.
Institutional protocols developed by the Heart Team in accordance
with current guidelines should deﬁne speciﬁc anatomical criteria
Table 4: Multidisciplinary decision pathways, patient informed consent, and timing of intervention








during the acute 
phase.
Mechanical circulatory 
support according to 
Heart-Team protocol.
Not mandatory 
during the acute 
phase.
Not mandatory 
during the acute 
phase.
After stabilization 
























Urgency: within 24 
hours if possible 
and no later than 
72 hours.
For patients with severe symptoms 
(CCS 3) and for those with high–
risk anatomy (left main disease or 
equivalent, three-vessel disease or 
proximal LAD or depressed ventricular
function),  revascularization (PCI or 
CABG) should be performed within 
2 weeks.
For all other patients with SCAD, 
revascularization (PCI or CABG) 
should be performed within 6 weeks.
Ad hoc
Procedure Proceed with 
intervention based 
on best evidence/ 
availability. 
Non-culprit lesions 
treated according to 
institutional protocol 


















protocol or Heart 
Team decision.
Plan most appropriate intervention 
allowing enough time from diagnostic 
catheterization to intervention.
Proceed with intervention 
according to institutional 
ACS = acute coronary syndromes; CABG = coronary artery bypass grafting; CCS = Canadian Cardiovascular Society; LAD = left anterior descending;
NSTE-ACS = non—ST-segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention; SCAD = stable coronary artery disease;
STEMI = ST-segment elevation myocardial infarction.
aThis may not apply to countries that legally do not ask for written informed consent. ESC and EACTS advocate documentation of patient consent for all
revascularization procedures.
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and clinical subsets that may be—or should not be—treated ad hoc.
Complex pathologies in stable patients, including lesions of the LM
or proximal LAD and three-vessel disease, should in general not be
treated ad hoc, but discussed by the Heart Team.
Recommendations for decision-making and patient infor-
mation in the elective setting
Recommendations Classa Levelb Ref c
It is recommended that patients
undergoing coronary angiography
are informed about benefits and
risks as well as potential
therapeutic consequences
ahead of the procedure. 
I C –
It is recommended that patients
are adequately informed about
short- and long-term benefits and
risks of the revascularization
procedure as well as treatment






It is recommended that institutional
protocols are developed by the
Heart Team to implement the
appropriate revascularization
strategy in accordance with current
guidelines. In case of PCI centres
without on-site surgery,
institutional protocols should be
established with partner institutions
providing cardiac surgery.
I C
It is recommended that patients for
whom decision-making is complex
or who are not covered by the
institutional protocol are discussed
by the Heart Team. 
I C




5. STRATEGIES FOR DIAGNOSIS: FUNCTIONAL
TESTING AND IMAGING
Exercise testing and cardiac imaging are used to conﬁrm the diagno-
sis of CAD, to document ischaemia in patients with stable symptoms,
to risk-stratify patients, and to help choose treatment options and
evaluate their efﬁcacy as explained in detail in the ESC Guidelines
on the management of stable coronary artery disease [47].
Another indication for non-invasive imaging before revasculari-
zation is the detection of myocardial viability in patients with poor
LV function.
5.1 Non-invasive tests
The documentation of ischaemia using functional testing is recom-
mended in patients with suspected SCAD before elective invasive
procedures, preferably using non-invasive testing before invasive
angiography. Although several tests can be used, it is important
to avoid unnecessary diagnostic steps. The current evidence sup-
porting the use of various tests for the detection of CAD is based on
meta-analyses and multicentre studies, and using only anatomical
evaluation of invasive coronary angiography as the reference stand-
ard [47]. The risks of exercise, pharmacological stressors, contrast
agents, invasive procedures, and cumulative ionizing radiation must
be weighed against the risk of disease or delayed diagnosis [48].
Multi-detector computed tomography (MDCT) can detect cor-
onary atherosclerosis and stenoses and is reliable for ruling out sig-
niﬁcant CAD in patients with low-to-moderate probability of CAD
[49]. The tests for detection of ischaemia are based on either reduc-
tion of perfusion or induction of ischaemic wall motion abnormal-
ities during exercise or pharmacological stress. The best-established
stress imaging techniques are echocardiography and perfusion
scintigraphy. Both may be used in combination with exercise stress
or pharmacological stress. Newer stress imaging techniques also
include stress magnetic resonance imaging (MRI), positron emission
tomography (PET), and combined approaches. The term ‘hybrid
imaging’ refers to imaging systems in which two modalities [MDCT
and PET; MDCT and single photon emission computed tomog-
raphy (SPECT)] are combined in the same scanner, allowing both
studies to be performed in a single imaging session. Ischaemia
imaging has been regarded the most appropriate in patients with
intermediate pre-test probability (15–85%) of signiﬁcant CAD [47],
while in asymptomatic patients or in those with low or high pre-test
probability, the tests are generally not recommended. More
detailed information about the imaging tests in the detection of
CAD are available in the ESC Guidelines on the management of
SCA [47] and in the Web addenda.
5.2 Invasive tests
Invasive coronary angiography has been regarded as the reference
standard for the detection and the assessment of the severity of
CAD but, as an invasive procedure, it is associated with speciﬁc
procedure-related adverse events. Even experienced interventional
cardiologists cannot, without functional information, accurately
predict the signiﬁcance of many intermediate stenoses on the basis
of visual assessment or quantitative coronary angiography. When
non-invasive stress imaging is contraindicated, non-diagnostic, or
unavailable, the measurement of fractional ﬂow reserve (FFR) or
coronary ﬂow reserve is helpful during diagnostic coronary angiog-
raphy [50]. Deferral of PCI or CABG in patients with FFR >0.80
appears safe [51–53]. Fractional ﬂow reserve measurement is indi-
cated for the assessment of the functional consequences of moder-
ate coronary stenoses. FFR-guided PCI with medical therapy has
been shown to decrease the need for urgent revascularization com-
pared with the best available medical therapy alone [54].
5.3 Detection of myocardial viability
Non-invasive assessment of myocardial viability has been used to
guide the management of patients with chronic ischaemic systolic
LV dysfunction. Multiple imaging techniques, including PET,
SPECT, and dobutamine stress echocardiography, have been eval-
uated for assessment of viability and prediction of clinical
outcome after myocardial revascularization [55]. In general,
nuclear imaging techniques have a high sensitivity, whereas tech-
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sensitivity but higher speciﬁcity. MRI has a high diagnostic accur-
acy for assessing the transmural extent of myocardial scar tissue
and can also assess contractile reserve, but its ability to detect via-
bility and predict recovery of wall motion is no better than other
imaging techniques. The differences in performance between the
various imaging techniques are small, and experience and avail-
ability commonly determine which technique is used. The evi-
dence is mostly based on observational studies or meta-analyses.
One RCT, relating to PET imaging, showed that patients with a sub-
stantial amount of dysfunctional but viable myocardium are likely
to beneﬁt from myocardial revascularization [56].
6. REVASCULARIZATION FOR STABLE CORONARY
ARTERY DISEASE
6.1 Rationale for revascularization
Prior to revascularization, patients with SCAD must receive
guideline-recommended medical treatment, due to its established
beneﬁts in terms of prognosis and symptom relief [47].
Revascularization, by either PCI or CABG, may be indicated in
ﬂow-limiting coronary stenoses to reduce myocardial ischaemia
and its adverse clinical manifestations [85–87]. The indications for
revascularization in patients with SCAD are persistence of symp-
toms despite medical treatment and/or improvement of progno-
sis [47]. Consequently, revascularization and medical therapy
should be seen as complementary, rather than competitive treat-
ment strategies. Speciﬁc evidence and recommendations for dia-
betic patients are addressed in section 10.
Angina is associated with impaired quality of life, reduced physical
endurance, mental depression, and recurrent hospitalizations and
outpatient visits [88]. Revascularization by PCI or CABG more effect-
ively relieves angina, reduces the use of anti-angina drugs, and
improves exercise capacity and quality of life, compared with a strat-
egy of medical therapy alone (Table 2 Web addenda) [54,89–96].
Ischaemia is of prognostic importance in patients with
SCAD, particularly when occurring at low workload [97,98].
Revascularization relieves myocardial ischaemia more effectively
than medical treatment alone [92,97,99,100]. The extent, location,
and severity of coronary artery obstruction as assessed by coron-
ary angiography or coronary computed tomography (CT) angiog-
raphy are important prognostic factors in addition to ischaemia
and left ventricular function [101–103].
6.2 Evidence basis for revascularization
The evidence basis for revascularization with PCI and/or CABG,
compared with medical treatment, is derived from several RCTs
that are summarized in Table 5. It is important to consider that the
best current revascularization results achieved with PCI are with
new-generation drug-eluting stents (DES) and for CABG with
maximal use of arterial grafts. Although revascularization procedures
are associated with the risk of biomarker-deﬁned periprocedural
myocardial infarction, several studies indicate that pre-PCI—but not
post-PCI—biomarker elevations impact adversely on prognosis [104].
While spontaneous myocardial infarction has a well established
adverse impact on prognosis and notably mortality, recent studies
suggest that, compared with medical treatment, PCI is associated
with a lower risk of spontaneous myocardial infarction [105].









Classc Leveld Classc Leveld Classc Leveld Classc Leveld Refe
Anatomical detection of CAD
Invasive angiography III A III A IIb A I A 50–52,54
CT angiographyf,g III B III C IIa A III B 57–62
Functional test
Stress echo III A III A I A III A 63–65
Nuclear imaging III A III A I A III A 60,66–70
Stress MRI III B III C I A III B 71–75
PET perfusion III B III C I A III B 67,69,70,76,77
Combined or hybrid imaging test
III C III C IIa B III B 78–83
CAD = coronary artery disease; CT = computed tomography; MRI = magnetic resonance imaging; PET = positron emission tomography.
aScreening for silent (asymptomatic) myocardial ischaemia may be considered in selected high-risk patients, such as those with diabetes mellitus [84].




fThis refers to CT angiography, not calcium scoring.
gCT is considered to perform best in the lower range of pre-test probability (15—50%) [47].
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ACS = acute coronary syndromes; BMS = bare-metal stents; CABG = coronary artery bypass grafting; DES = drug-eluting stents; EF = ejection fraction; MI =
myocardial infarction; MT = medical therapy; MV = multivessel; MVD = multivessel disease; NYHA = New York heart Association; Revasc = revascularization; y
= years.
aP<0.05; bCardiac death; cInclusion criteria; dNo statistical analyses performed; eRepeat CABG, excluding PCI.
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Although individual RCTs and subsequent meta-analyses
constitute the highest hierarchical form of evidence-based medi-
cine [106–108], extrapolation of their results to routine clinical
practice has its limitations. The majority of RCTs included mainly
male patients who were relatively young [with the exception of
Trial of Invasive Medical therapy in the Elderly (TIME)], had pre-
served LV function, and had not previously undergone revasculari-
zation. Patients were highly selected, as randomization was usually
performed following delineation of coronary anatomy by angiog-
raphy without routine assessment of ischaemia. By design, all the
RCTs compared treatment strategies that allowed subsequent
revascularization when patients deteriorated on medical therapy.
As a result, the proportion of patients who did not undergo revas-
cularization progressively declined during follow-up, camouﬂa-
ging differences between the two strategies and making analysis
according to the intention-to-treat principle more problematic.
Finally, limited duration of follow-up (usually <5 years) incom-
pletely depicts the advantages of CABG related to arterial grafts,
which accrue with time but which may also eventually be eroded
by progressive vein graft failure.
6.2.1 Revascularization with the use of percutaneous
coronary intervention. The efﬁcacy of PCI in addition to
medical therapy in patients with SCAD has been addressed in
several RCTs [54,91,94], meta-analyses [106,107,117–120], and
large-scale registries [121]. The most important recent studies and
their data are summarized in Table 5.
The Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation (COURAGE [91] trial included 2287
patients with SCAD, who showed objective evidence of ischaemia
and signiﬁcant CAD, randomizing them to medical therapy alone
or medical therapy plus PCI with BMS. At a median follow-up of
4.6 years, there were no signiﬁcant differences between the PCI
and medical therapy groups in the composite of death, myocar-
dial infarction and stroke. Freedom from angina was signiﬁcantly
greater in the PCI group at 1 year and 3 years but the advantage
was eroded by 5 years, by which time 21% of the PCI group and
33% of the medical therapy group had received additional revas-
cularization (P < 0.001). The severity of CAD in COURAGE was
moderate and the majority of patients (70%) had no or mild is-
chaemia at baseline and most patients had normal LV function
[122]. Patients with LM disease were excluded.
The Medical, Angioplasty or Surgery Study II (MASS II) trial, cov-
ering 611 patients with multivessel disease, all recruited at a single
institution, is the only RCT comparing medical therapy with PCI
(72% with BMS; 28% with balloon angioplasty only) and with CABG.
Over 10 years, comparing medical therapy with PCI, the respective
rates for all-cause mortality were 31% and 24.1% (P = 0.09), for myo-
cardial infarction 20.7% and 13.3% PCI (P = 0.01), and for freedom
from angina 43% and 59% (P < 0.001) [94].
In the Fractional Flow Reserve versus Angiography for
Multivessel Evaluation 2 (FAME-2) trial [54], patients with SCAD and
at least one functionally signiﬁcant stenosis (invasive FFR ≤0.80)
were randomly assigned to medical therapy alone or to medical
therapy plus FFR-guided PCI. The trial was planned to include 1632
patients but the data safety monitoring board stopped the study
prematurely after enrolment of 888 patients, due to a highly signiﬁ-
cant difference in the incidence of the primary endpoint (a com-
posite of death, myocardial infarction, and urgent revascularization)
in favour of FFR-guided PCI that was unlikely to be neutralized with
recruitment of more patients. Final analysis showed an incidence of
the primary endpoint of 4.3% in the PCI group and 12.7% in the
medical therapy group (P < 0.001) but without a difference in rates
of death or myocardial infarction between the two groups.
Interpretation of FAME-2 is complicated, in that the decision for
urgent revascularization may have been inﬂuenced by the open
nature of the trial. The deﬁnition of ’urgent revascularization’ met
the criteria for the clinical presentation of an acute coronary syn-
drome (ACS) and 50% of the patients undergoing urgent revascular-
ization displayed objective evidence of continuing ischaemia.
Most meta-analyses comparing a strategy of PCI against initial
medical therapy found no evidence in favour of an invasive strategy,
in terms of survival or myocardial infarction [117,118,123,125]. Two
reported a small survival beneﬁt for PCI over medical therapy, al-
though this might have been inﬂuenced by the inclusion of a subset
of patients who had had a recent (<4 weeks) myocardial infarction
[107,119]. One meta-analysis, updated for more recent RCTs,
showed that, compared with an initial strategy of medical therapy,
PCI was not associated with signiﬁcant improvement in all-cause
mortality [risk ratio (RR) 0.85; 95% conﬁdence interval (CI) 0.71–
1.01], cardiac death (RR 0.71; 95% CI 0.47–1.06), myocardial infarc-
tion (RR 0.93; 95% CI 0.70–1.24), or repeat revascularization (RR
0.93; 95% CI 0.76–1.14) during short- or long-term follow-up [96]. In
a meta-analysis of ﬁve RCTs covering 5286 patients and
site-reported ischaemia at baseline, there were no differences
between PCI and medical treatment in terms of death, myocardial
infarction, unplanned revascularization or angina during a median
follow-up of 5 years [100].
In the New York State’s Cardiac Diagnostic Catheterization
Database, 9586 patients were identiﬁed between 2003 and 2008,
who had either PCI (n = 8486; 89%) or medical therapy (n = 1100;
11%). A comparison of 933 propensity-score matched patients in
each group showed, with PCI over 4 years, a lower incidence of
the composite of mortality and myocardial infarction (16.5% vs.
21.2%, respectively; P = 0.003) as well as the individual compo-
nents: death (10.2% vs. 14.5%, respectively; P = 0.02) and myocar-
dial infarction (8.0% vs. 11.3%, respectively; P = 0.007) [121]. The
authors caution that part of the difference in outcomes might be
explained by the differences between the groups in their use of
routine medical therapy.
6.2.2 Percutaneous coronary intervention with drug-
eluting stents vs. bare-metal stents. The major limitation of
most of the previous comparisons is the lack of use of DES. Several
meta-analyses of RCTs comparing early-generation DES with
bare-metal stents (BMS) reported similar rates of death, cardiac
death, and non-fatal myocardial infarction, but a 50−70% relative
risk reduction (RRR) in the need for subsequent or repeat target
vessel revascularization (TVR) with DES [124,125].
New-generation DES, with thin strut stent platforms, biocom-
patible durable or biodegradable polymers and limus-based anti-
proliferative agents, have further advanced efﬁcacy and safety
compared with early-generation DES and BMS (see section 17 for
more information). Compared with early-generation DES, repeat
revascularization was reduced by 10–20% [126–129]. Compared
with bare-metal stents and early-generation DES, new-generation
DES have also improved safety outcomes including death, myo-
cardial infarction and stent thrombosis. Several studies have
reported an approximately 50% lower risk of deﬁnite or probable
stent thrombosis, than with early-generation DES, particularly
during the late phase [128–131], and some studies reported a
lower risk of stent thrombosis than with BMS [125,131]. A mixed-
treatment comparison of DES and BMS, embracing 76 RCTs and
117 762 patient-years of follow-up, did not report a lower risk of
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death but a lower risk (20–35%) of myocardial infarction with DES
(except paclitaxel-eluting stents) than with BMS [132]. The rando-
mized Basel Stent Kosten Effektivitäts Trial–Prospective Validation
Examination (BASKET–PROVE) trial, comparing DES with BMS
among patients with large vessels (>3 mm) showed no signiﬁcant
differences between sirolimus-eluting, everolimus-eluting, and
bare-metal stents in terms of the rate of death or myocardial in-
farction; however, there was a lower risk of cardiac death or myo-
cardial infarction with DES (pooled DES vs. BMS: RR 0.60; 95% CI
0.39–0.93; P = 0.02) at 2 years of follow-up [133]. An individual
patient-data meta-analysis of three RCTs including 4989 patients,
which compared new-generation everolimus-eluting stents with
early-generation paclitaxel-eluting stents, reported a lower risk of
death (3.2% vs. 5.1%; hazard ratio (HR) 0.65; 95% CI 0.49–0.86; P =
0.003), cardiac death or myocardial infarction (4.4% vs. 6.3%; HR
0.70; 95% CI 0.54–0.90; P = 0.005), and stent thrombosis (0.7% vs.
1.7%; HR 0.45; 95% CI 0.26–0.78; P = 0.003) after 3 years of follow-
up [126]. A patient-level pooled analysis of 26 RCTs in 11 557
women, reported a lower incidence of the composite of death or
myocardial infarction in female patients treated with new-
generation DES (9.2%) compared with both early-generation DES
(10.9%) and BMS (12.8%; P = 0.001) at 3 years [129]. Similarly, the
incidence of deﬁnite or probable stent thrombosis was lowest
with new-generation DES (1.1%) followed by BMS (1.3%), and
early-generation DES (2.1%; P = 0.01).
6.2.3 Revascularization with the use of coronary artery
bypass grafting. The superiority of CABG to a strategy of initial
medical therapy for speciﬁc subsets of SCAD was established in a
meta-analysis of seven RCTs [108]. It demonstrated a survival
beneﬁt from CABG in patients with LM or three-vessel SCAD,
particularly when the proximal LAD coronary artery was involved.
Beneﬁts were greater in those with severe symptoms, early
positive exercise tests, and impaired LV function. Notably, in these
early studies only 10% of CABG patients received an internal
mammary artery (IMA), which is an important prognostic
component of CABG. Furthermore, 40% of patients in the medical
group crossed over to CABG during follow-up. A more recent
meta-analysis has reported a reduction in the risk of death with
CABG vs. medical therapy (HR 0.62; 95% CI 0.50–0.77) [107].
The MASS II trial randomly compared medical therapy with PCI
and CABG. At 10 years, compared with medical therapy, CABG was
associated with reduced rates of cardiac mortality, myocardial in-
farction and angina [94]. In the Surgical Treatment IsChemic Heart
failure (STICH) trial, 1212 patients with CAD and a left ventricular
ejection fraction (LVEF) of ≤35% were randomized to medical
therapy or CABG. Patients with LM disease were excluded, and 17%
of patients on medical therapy underwent CABG and 6% of patients
underwent PCI by the end of the follow-up period. In the
intention-to-treat analysis, all-cause mortality was not signiﬁcantly
lower with CABG than with medical therapy (36% vs. 41%; HR 0.86;
95% CI 0.72–1.04; P = 0.12); however, all-cause mortality or hospital-
ization for cardiovascular causes occurred less frequently among
patients undergoing CABG (58% vs. 68%; HR 0.74; 95% CI 0.64–0.85;
P < 0.001). The results with respect to all other secondary clinical
outcomes also favoured CABG. In addition, CABG was associated
with a reduced risk for the primary outcome, death, in the ‘as
treated’ analysis (HR 0.70; 95% CI 0.58–0.84; P < 0.001) [112].
6.3 Percutaneous coronary intervention vs.
coronary artery bypass grafting
The multitude of studies comparing these two revascularization
strategies has shown that neither PCI nor CABG alone can provide
a solution for the entire spectrum of SCAD patients who need
revascularization; however, CABG results in more complete revas-
cularization than PCI, and the placement of bypass grafts on the
mid-coronary vessel makes the complexity of proximal lesions less
relevant for the procedure, especially when there are chronic
proximal occlusions. The evidence derived from RCTs comparing
CABG with PCI is summarized in Table 6.
Indications for revascularization in patients with stable angina or silent ischaemia
Extent of CAD (anatomical and/or functional) Classb Levelc References
For prognosis
Left main disease with stenosis >50%a I A 108,134,135
Any proximal LAD stenosis >50%a I A 94,108,135,136
Two-vessel or three-vessel disease with
stenosis >50%a with impaired LV function (LVEF<40%)a
I A 93,94,108,112,121,135,137–142
Large area of ischaemia (>10% LV) I B 54,91,97,99,143,144




Any coronary stenosis >50%a in the presence of
limiting angina or angina equivalent, unresponsive to
medical therapy
I A 54,96,105,108,118–120,145
CAD = coronary artery disease; FFR = fractional flow reserve; LAD = left anterior descending coronary artery; LV = left ventricular.
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6.3.1 Proximal left anterior descending coronary artery
disease. Two meta-analyses—one including nine RCTs involving
1210 patients with isolated proximal LAD lesions followed for up
to 5 years [160], and the other including six RCTs and two
non-randomized studies with a total of 1952 patients with isolated
proximal LAD lesions, who were followed for up to 4 years
[161]—reported no signiﬁcant difference in mortality, myocardial
infarction, or stroke, but a three-fold increase in recurrent angina
and a ﬁve-fold increase in repeat revascularization with PCI
compared with CABG. Most of the above-mentioned studies have
used BMS in the PCI arm, while DES have markedly reduced the
risk of repeat revascularization. Similarly, only few trials in patients
with isolated proximal LAD lesions have reported long-term
outcomes, although the angiographic patency of the IMA has
been documented to be >90% at two decades of follow-up.
Furthermore, the survival beneﬁt of a single IMA in patients with
multivessel CAD, initially reported after a decade of follow-up, has
now been extended into the second and third decades, especially
with bilateral IMAs [162–165].
6.3.2 Left main coronary artery disease. For several decades,
CABG was regarded as the standard of care for signiﬁcant LM
disease in patients eligible for surgery, largely based on the
Coronary Artery Surgery Study (CASS) registry [108]. It has been
suggested that two important pathophysiological features mitigate
against the success of PCI in LM lesions: (i) up to 80% of LM disease
involves the bifurcation, which is known to be at higher risk of
restenosis and (ii) up to 80% of LM patients also have multivessel
SCAD, where CABG offers a survival advantage independent of the
presence of LM disease [159,166,167]. More recent evidence
suggests, however, that PCI provides at least equivalent results to
CABG for lower-severity LM lesions at up to 5 years of follow-up.
The SYNTAX trial included a pre-speciﬁed subgroup analysis of
limited power in 705 patients with predominant distal LM disease,
who were randomly assigned to CABG or PCI. The primary
endpoint of 1-year MACCE—the composite of death, myocardial
infarction, stroke, and repeat revascularization—was comparable
for both revascularization strategies (CABG 13.7% vs. PCI 15.8%;
P = 0.44) [168]. At 5 years’ follow-up, rates of death (CABG = 14.6%
vs. PCI = 12.8%; P = 0.53) and myocardial infarction (CABG = 4.8%
vs. PCI = 8.2%; P = 0.10) were not signiﬁcantly different, whereas
CABG was associated with a higher rate of stroke (4.3% vs. 1.5%;
P = 0.03) and a lower risk of repeat revascularization (15.5% vs.
26.7%; P < 0.001) with no signiﬁcant difference in the overall
MACCE rates (31.0% vs. 36.9%; P = 0.12) [17,169]. MACCE out-
comes were comparable for PCI and CABG in the lower (0–22:
30.4% vs. 31.5%; P = 0.74) and intermediate (23–32: 32.7% vs.
32.3%; P = 0.88) SYNTAX score tertiles. In patients with SYNTAX
scores >32, CABG was associated with numerically lower mortality
(14.1% vs. 20.9%; P = 0.11) and a signiﬁcantly reduced need for
repeat revascularization (11.6% vs. 34.1%; P < 0.001) albeit at a nu-
merically higher risk of stroke (4.9% vs. 1.6%; P = 0.13).
The Premier of Randomized Comparison of Bypass Surgery vs.
Angioplasty Using Sirolimus-Eluting Stent in Patients with Left
Main Coronary Artery Disease (PRECOMBAT) trial randomized
600 patients with LM disease to PCI or CABG [159]. The primary
endpoint—the 1-year composite rate of death, myocardial infarc-
tion, stroke, or repeat revascularization—was 6.7% in the CABG
group and 8.7% in the PCI group (P = 0.37). The 1-year composite
rate of death, myocardial infarction or stroke was 4.0% for CABG
and 3.3% for PCI (P = 0.66). The lack of signiﬁcant differences
between the two groups was maintained over 2 years from
randomization and was also valid for mortality (3.4% in the CABG
group and 2.4% in the PCI group; P = 0.45) and for the composite
rate of death, myocardial infarction, or stroke (4.4% in the CABG
group and 4.7% in the PCI group; P = 0.83). In contrast to the ﬁnd-
ings in SYNTAX, the incidence of stroke was similar for PCI (0.4%)
and CABG (0.7%).
A meta-analysi [170] pooled the results of three dedicated RCTs
on PCI vs. CABG for LM diseas [158,159,171] and one pre-
speciﬁed LM lesion subset from the largest RCT [168]. In total, this
meta-analysis assessed the 1-year outcomes of 1611 patients. The
composite of death, myocardial infarction, stroke, or TVR was
observed in 11.8% of the CABG group and 14.5% of the PCI group
(P = 0.11); the composite of death, myocardial infarction, or stroke
was 6.8% in the CABG group and 5.3% in the PCI group (P = 0.26).
Whilst there was no signiﬁcant difference in mortality (4.1% in the
CABG group and 3.0% in the PCI group; P = 0.29) or myocardial in-
farction (2.8% in the CABG group and 2.9% in the PCI group;
P = 0.95), the CABG group showed a higher rate of stroke (1.7% vs.
0.1%; P = 0.01) but a lower rate of TVR (5.4% vs. 11.4%; P < 0.001).
The ASAN Medical Centre-Left Main Revascularization Registry
compared the outcomes of patients with LM disease who were
treated by either PCI or CABG within the same period. In two ana-
lyses—one of 10-year outcomes among 100 patients treated with
BMS and 250 patients with CABG, and the other of 5-year out-
comes among 176 patients with DES and 219 patients with CABG
—neither mortality nor the composite of death, myocardial infarc-
tion, or stroke was signiﬁcantly different between the two treat-
ment approaches. CABG was associated with a decreased risk of
revascularization in both comparisons [172]. In a registry of 810
patients with LM disease treated by CABG (335 patients) or PCI
(475 patients), which ran in parallel with the RCT, no signiﬁcant
difference was observed between the two treatment options in
terms of the composite of death, myocardial infarction, or stroke
over 2 years, whereas the risk of re-intervention was signiﬁcantly
lower with CABG [159].
6.3.3 Three-vessel coronary artery disease. A meta-analysis,
based on individual patient data from RCTs that were performed
before the introduction of DES, reported no difference in
mortality between PCI and CABG, although mortality was reduced
by CABG in diabetic patients and those aged 65 years or more
[106]. A meta-analysis of six randomized trials involving 6055
patients, which compared CABG with arterial grafts and PCI
(balloon angioplasty, BMS and DES), reported a signiﬁcant
reduction in mortality (RR 0.73; 95% CI 0.62–0.86), myocardial
infarction (RR 0.58; 95% CI 0.48–0.72) and repeat revascularization
(RR 0.29; 95% CI 0.21–0.41) in favour of CABG [173]. There was a
trend toward excess strokes with CABG (RR 1.36; 95% CI 0.99–1.86;
P = 0.06). Several RCTs and meta-analyses indicate that CABG is
associated with a greater risk of stroke than PCI, which diminishes
during long-term follow-up [174,175].
SYNTAX randomly assigned 1800 patients with LM and/or
three-vessel CAD to either an early-generation paclitaxel-eluting
stent or CABG [157]. At 1 year, 12.4% of CABG and 17.8% of PCI
patients (P = 0.002) reached the primary composite endpoint of
MACCE. At 5 years, CABG, as compared with PCI, signiﬁcantly
reduced overall MACCE with respective rates of 26.9% vs. 37.3%
(P < 0.001), 11.4% vs. 13.9% had died (P = 0.10), 3.8% vs. 9.7%
(P < 0.0001) had a myocardial infarction, 3.7% vs. 2.4% (P = 0.09)
incurred a cerebrovascular accident, and 13.7% vs. 25.9%
(P < 0.0001) of the patients required repeat revascularization [17].
In the 1095 patients with three-vessel CAD, in comparison with
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BMS = bare-metal stents; CABG = coronary artery bypass grafting; EF = ejection fraction; MI = myocardial infarction; MV = multivessel; MVD = multivessel
disease; PES = paclitaxel-eluting stents; Revasc = revascularization; SES = sirolimus-eluting stents; TVR = target-vessel revascularization; y = years.
aP<0.05.
bNon-inferiority met.
cNon-inferiority failed only trials with at least 100 patients per treatment arm were included.
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PCI, CABG resulted in lower total death (9.2% vs.14.6%; P = 0.006),
cardiac death (5.3% vs. 9.0%; P = 0.003), myocardial infarction
(3.3% vs. 10.6%; P < 0.001) and repeat revascularization (12.6% vs.
25.4%; P < 0.001) [176]. In these patients with low SYNTAX score
(0–22), rates of MACCE were similar (26.8% vs. 33.3%; P = 0.21) for
CABG and PCI, respectively. Conversely, when compared with PCI
in patients with intermediate and high SYNTAX scores, CABG
showed lower rates of MACCE (22.6% vs. 37.9%; P = 0.0008 and
24.1% vs. 41.9%; P = 0.0005, respectively), including its mortality,
myocardial infarction and repeat revascularization components
[176]. Notably, patients who were included in the CABG registry of
the SYNTAX trial because of ineligibility for PCI had lower MACCE
rates than the randomized CABG cohort (23.3% vs. 26.9%, respect-
ively), this being potentially related to more complete revasculari-
zation (76% vs. 63%, respectively) [17].
An observational study based on the New York State registry
assessed patients with CAD who had been treated with either iso-
lated bypass surgery (13 212 patients) or DES (20 161 patients)
between 2003 and 2005, with focus on 5-year survival [177]. The
difference in absolute survival in the overall population was small
(CABG 78.5% vs. PCI 76%). The main analysis was performed after
propensity matching of 8121 pairs of patients, with survival at 5
years of 80.4% for CABG and 73.6% for PCI with DES (HR 0.71;
95% CI 0.67–0.77; P < 0.001). A lower risk of death was noted in all
subgroups, except for those with two-vessel CAD without prox-
imal LAD lesions. Two main ﬁndings can be highlighted from this
study: (i) the presence of LAD disease conferred a survival beneﬁt
to CABG and (ii) the survival beneﬁt with CABG became evident
only during the second half of the 5-year follow-up. In the
ASCERT registry of elective patients >65 years of age with two- or
three-vessel CAD, 86 244 patients underwent CABG and 103 549
patients underwent PCI (78% with early-generation DES). Using
propensity scores and inverse probability adjustment, mortality at
4 years—but not at 1 year—was lower for CABG than for PCI (16.4%
vs. 20.8%; RR 0.79; 95% CI 0.76–0.82) [26]. The observational
nature of the studies does not permit assessment of how each
patient was selected for each kind of treatment and, despite statis-
tical adjustments, residual confounders cannot be excluded.
Early-generation DES were used, which are devoid of the
advantages of the newer generation [125–131,133]. There is
notable consistency in the ﬁndings on the survival advantage of
CABG over PCI for more severe three-vessel CAD.
7. REVASCULARIZATION IN NON-ST-SEGMENT
ELEVATION ACUTE CORONARY SYNDROMES
Non-ST-segment elevation acute coronary syndrome (NSTE-ACS) is
the most frequent manifestation of ACS, and mortality and morbid-
ity remain high and equivalent to those of patients with ST-segment
elevation myocardial infarction (STEMI) during long-term follow-up.
The key objectives of coronary angiography and subsequent revas-
cularization are symptom relief and improvement of prognosis.
Overall quality of life, length of hospital stay, and potential risks asso-
ciated with invasive and pharmacological treatments must also be
considered when deciding on a treatment strategy.
Early risk stratiﬁcation is important, in order to identify patients
at high immediate- and long-term risk for death and cardiovascu-
lar events, in whom an early invasive strategy with adjunctive
medical therapy may reduce that risk. Patients in cardiogenic
shock, or after resuscitation, should undergo immediate angiog-
raphy (within 2 hours) because of the high likelihood of critical
CAD, but it is equally important to identify patients at low risk, in
whom invasive and medical treatments provide little beneﬁt or
may even cause harm. Details on risk stratiﬁcation, particularly
with respect to the interpretation of troponins, are found in the
ESC Guidelines on NSTE-ACS [180].
7.1 Early invasive vs. conservative strategy
A meta-analysis of seven RCTs that compared routine angiography
followed by revascularization against a selective invasive strategy,
showed reduced rates of combined death and myocardial infarc-
tion [odds ratio (OR) 0.82; 95% CI 0.72–0.93; P = 0.001] [181]. The
routine revascularization strategy was associated with a risk of
early death and myocardial infarction during the initial hospital-
ization; however, four of the seven trials included in this
Recommendation for the type of revascularization (CABG or PCI) in patients with SCAD with suitable coronary anatomy for both
procedures and low predicted surgical mortality
Recommendations according to extent of CAD CABG PCI
Classa Levelb Classa Levelb Ref c
One or two-vessel disease without proximal LAD stenosis. IIb C I C
One-vessel disease with proximal LAD stenosis. I A I A 107,108,160,161,178,179
Two-vessel disease with proximal LAD stenosis. I B I C 108,135,137
Left main disease with a SYNTAX score 22. I B I B 17,134,170
Left main disease with a SYNTAX score 23–32. I B IIa B 17
Left main disease with a SYNTAX score >32. I B III B 17
Three-vessel disease with a SYNTAX score 22. I A I B 17,157,175,176
Three-vessel disease with a SYNTAX score 23–32. I A III B 17,157,175,176
Three-vessel disease with a SYNTAX score >32. I A III B 17,157,175,176
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meta-analysis were not contemporary, due to marginal use of
stents and glycoprotein (GP) IIb/IIIa receptor inhibitors. Another
meta-analysis, covering seven trials with more up-to-date adjunct-
ive medication, showed a signiﬁcant reduction in risk for all-cause
mortality (RR = 0.75; 95% CI 0.63–0.90; P < 0.001) and myocardial
infarction (RR = 0.83; 95% CI 0.72–0.96; P = 0.012), for an early in-
vasive vs. conservative approach at 2 years without excess of
death and myocardial infarction at 1 month [182]. A further
meta-analysis of eight RCTs showed a signiﬁcant lower incidence
of death, myocardial infarction, or rehospitalization for ACS
(OR = 0.78; 95% CI 0.61–0.98) for the invasive strategy at 1 year
[183]. The beneﬁt was carried mainly by improved outcomes in
biomarker-positive (high-risk) patients. In a gender-speciﬁc ana-
lysis, a similar beneﬁt was found in biomarker-positive women,
compared with biomarker-positive men. Importantly, biomarker-
negative women tended to have a higher event rate with an early
invasive strategy, suggesting that early invasive procedures should
be avoided in low-risk, troponin-negative, female patients. A more
recent meta-analysis, based on individual patient data from three
studies that compared a routine invasive against a selective inva-
sive strategy, revealed lower rates of death and myocardial infarc-
tion at 5-year follow-up (HR = 0.81; 95% CI 0.71–0.93; P = 0.002),
with the most pronounced difference in high-risk patients [184].
Age, diabetes, previous myocardial infarction, ST-segment depres-
sion, hypertension, body mass index (<25 kg/m2 or >35 kg/m2),
and treatment strategy were found to be independent predictors
of death and myocardial infarction during follow-up. All results
supported a routine invasive strategy but highlight the importance
of risk stratiﬁcation in the decision-making process management.
7.2 Timing of angiography and intervention
Patients at highest risk (i.e. those with refractory angina, severe
heart failure or cardiogenic shock, life-threatening ventricular
arrhythmias, or haemodynamic instability) were generally not
included in RCTs, in order not to withhold potentially life-saving
treatments. It has been generally accepted that such patients
should be taken for an immediate (<2 hours) invasive evaluation,
regardless of electrocardiogram (ECG) or biomarker ﬁndings [180].
An early invasive strategy (0.5–14 hours of diagnosis), as opposed
to a delayed invasive strategy (within 21–86 hours), was tested in
several RCTs. In a meta-analysis of three recent trials, early catheter-
ization, followed by coronary intervention on the ﬁrst day of hospi-
talization, was shown to be safe and superior in terms of lower risk
of recurrent ACS (–41%) and shorter hospital stay (–28%) [185].
Similar ﬁndings were reported in a more recent meta-analysis [186].
There is growing evidence to suggest beneﬁt from an invasive
strategy within 24 hours in patients with a high-risk proﬁle. The
Timing of Intervention in Patients with Acute Coronary Syndromes
(TIMACS) trial revealed a signiﬁcant 38% lower incidence of death,
myocardial infarction, or stroke at 6 months in high-risk patients
(Global Registry of Acute Coronary Events (GRACE) score >140),
with an early (≤24 hours), as compared with a delayed (≥36 hours)
strategy [187]. No signiﬁcant difference was observed in patients
with a low- to intermediate-risk proﬁle (GRACE score ≤140).
Notably, there was no safety issue relating to an early invasive strat-
egy. In the Acute Catheterization and Urgent Intervention Triage
strategY (ACUITY) data analysis, a delay of more than 24 hours
before PCI was an independent predictor of 30-day and 1-year
mortality [188]. This increased ischaemic event rate was most
evident among moderate- and high-risk patients [according to the
Thrombolysis in Myocardial Infarction (TIMI) risk score].
In summary, the timing of angiography and revascularization
should be based on patient risk proﬁle. Patients at very high risk
(as deﬁned above) should be considered for urgent coronary angi-
ography (in less than 2 hours). In patients at high risk, with at least
one primary high-risk criterion, an early invasive strategy within
24 hours appears to be the reasonable timescale. In lower-risk
subsets, with a GRACE risk score of <140 but with at least one sec-
ondary high-risk criterion (Table 7), the invasive evaluation can be
delayed without increased risk but should be performed during
the same hospital stay, preferably within 72 hours of admission. In
other low-risk patients without recurrent symptoms, a non-
invasive assessment of inducible ischaemia should be performed
before hospital discharge.
7.3 Type of revascularization
There are no speciﬁc RCTs comparing PCI with CABG in patients
with NSTE-ACS. In all trials comparing an early invasive with a late
strategy, or an invasive with a medical management strategy, the
decision on whether to perform CABG or PCI was left to the inves-
tigator’s discretion.
In stabilized patients, the choice of revascularizationmodality can
be made in analogy to patients with SCAD. In approximately
one-third of patients, angiography will reveal single-vessel disease,
allowing ad hoc PCI in most cases. Multivessel disease will be
present in another 50%. Here the decision is more complex and the
choice has to be made between culprit-lesion PCI, multivessel PCI,
CABG, or a combined (hybrid) revascularization. The distribution of
PCI vs. CABG in patients with multivessel disease suitable for revas-
cularization is approximately 80% vs. 20% [189]. The revasculariza-
tion strategy in patients with multivessel CAD should be determined
early by the Heart Team and based on the patient’s clinical status, as
well as the severity and distribution of the CAD and the characteris-
tics of the lesion. The SYNTAX score has proved to be strongly pre-
dictive of death, myocardial infarction and TVR [190].
Culprit-lesion PCI is usually the ﬁrst choice in most patients
with NSTE-ACS and multivessel disease; however, there are no
Table 7: Criteria for high risk with indication for invasive
management
Primary criteria
1. Relevant rise or fall in troponin
2. Dynamic ST- or T-wave changes (symptomatic or silent)
3. GRACE score >140
Secondary criteria
4. Diabetes mellitus
6. Reduced LV function (ejection fraction <40%)
5. Renal insufficiency (eGFR <60 ml/min/1.73 m2)
7. Early post-infarction angina
8. Recent PCI
9. Prior CABG
10. Intermediate to high GRACE risk score (http://www.gracescore.org)
CABG = coronary artery bypass grafting; eGFR = estimated glomerular
filtration rate; GRACE = Global Registry of Acute Coronary Events; LV =
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prospective studies comparing culprit-lesion PCI with early CABG.
In stabilized patients with multivessel disease and a high SYNTAX
score (>22), particularly when there is no clearly identiﬁed culprit
lesion, a strategy of urgent CABG should be preferred. The strategy
of multivessel PCI for suitable signiﬁcant stenoses—rather than PCI
limited to the culprit lesion—has not been evaluated in an appro-
priate, randomized fashion. In a large database including 105 866
multivessel CAD patients with NSTE-ACS, multivessel PCI was
compared with single-vessel PCI and was associated with lower
procedural success but similar in-hospital mortality and morbidity
[191]. Complete revascularization at the time of the index proced-
ure did not result in lower mortality rates over 3 years, as com-
pared with a staged procedure strategy [192]. However,
incomplete revascularization appears to be associated with more
1-year adverse event rates [193].
CABG was compared with PCI in a propensity-matched analysis
among patients with multivessel disease from the ACUITY trial
[189]. PCI-treated patients had lower rates of stroke, myocardial
infarction, bleeding, and renal injury, similar 1-month and 1-year
mortality, but signiﬁcantly higher rates of unplanned revasculari-
zation at both 1 month and 1 year. However, only 43% of CABG
patients could be matched and there was a strong trend for a
higher rate of major adverse cardiac events (MACE) at 1 year with
PCI, compared with CABG (25.0% vs. 19.5%, respectively; P = 0.05).
These results are consistent with the 1-year and 5-year outcomes
of the multivessel SYNTAX trial, which included 28.5% of patients
with a recent ACS, in both the PCI and the CABG arms [17,157].
However, a subanalysis of these patients has not been reported.
Culprit-lesion PCI does not necessarily require a case-by-case
review by the Heart Team when, on clinical or angiographic
grounds, the procedure needs to be performed ad hoc after angiog-
raphy. This is the case when there is continuing or recurrent ischae-
mia, haemodynamic instability, pulmonary oedema, recurrent
ventricular arrhythmias, or total occlusion of the culprit coronary
artery requiring urgent revascularization. For all other scenarios,
revascularization should be discussed in a multidisciplinary setting,
with protocols based on the SYNTAX score at each institution, de-
ﬁning speciﬁc anatomical criteria and clinical subsets that can be
treated ad hoc or transferred to CABG. After culprit-lesion PCI,
patients with scores in the two higher terciles of the SYNTAX score
should be discussed by the Heart Team, in the context of functional
evaluation of the remaining lesions. This also includes the assess-
ment of patients’ comorbidities and individual characteristics.
7.3.1 Coronary artery bypass surgery. As there is no
randomized study comparing an early with a delayed CABG
strategy, the general consensus is to wait 48–72 hours in patients
who had culprit-lesion PCI and have residual severe CAD. In a
large database analysis of unselected patients admitted for ACS,
performance of early CABG, even in higher-risk patients, was
associated with low in-hospital mortality [194]. In registries,
unadjusted and adjusted analyses showed no difference in
outcomes between patients undergoing early (≤48 hours) or
in-hospital late (>48 hours) surgery, although CABG was delayed
more often in higher-risk patients, suggesting that timing might be
appropriately determined by multidisciplinary clinical judgement
[195]. Therefore, in patients assigned for CABG, timing of the
procedure should be decided on an individual basis, according to
symptoms, haemodynamic stability, coronary anatomy, and signs
of ischaemia. When there is continuing or recurrent ischaemia,
ventricular arrhythmias, or haemodynamic instability, CABG should
be performed immediately. Patients with LM or three-vessel CAD
involving the proximal LAD should undergo surgery during the
same hospital stay. In this decision process, it is important to
consider the risk of bleeding complications when initially applying
aggressive antiplatelet treatment; however, pre-treatment with a
dual antiplatelet regimen should be considered only as a relative
contraindication to early CABG and does require speciﬁc surgical
measures to minimize bleeding.
7.3.2 Percutaneous coronary intervention. The safety and
efﬁcacy of DES have not been prospectively tested in a speciﬁc
population of patients with NSTE-ACS, but this subset comprises
up to 50% of patients included in most stent trials particularly
those with an all-comer design. There is no particular safety
Recommendations for invasive evaluation and revasculari-
zation in NSTE-ACS
Recommendations Classa Levelb Ref.c
Urgent coronary angiography
(<2 hours) is recommended in
patients at very high ischaemic





instability).       
I C
An early invasive strategy (<24
hours) is recommended in 
patients with at least one
primary high-risk criterion
(Table 7).  
I A 185,187
An invasive strategy (<72 hours
after first presentation) is
indicated in patients with at
least one high-risk criterion 
(Table 7) or recurrent
symptoms.
I A 180




symptoms before deciding on
invasive evaluation.
I A 180,197,198




the clinical status and
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disease severity, i.e. distribution
and angiographic lesion
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ACS = acute coronary syndromes; CABG = coronary bypass graft
surgery; DES = drug-eluting stent; NSTE-ACS = non-ST-segment
elevation acute coronary syndrome; PCI = percutaneous coronary
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concern in NSTE-ACS as new-generation DES have shown super-
ior safety and efﬁcacy in both SCAD and STEMI patients.
Accordingly, new-generation DES are preferred over BMS as the
default option [196]. Dual antiplatelet therapy (DAPT) should be
maintained for 12 months, irrespective of stent type.
8. REVASCULARIZATION IN ST-SEGMENT
ELEVATIONMYOCARDIAL INFARCTION
8.1 Time delays
Delays in the timely implementation of reperfusion therapy are key
issues in the management of STEMI, since the greatest beneﬁt
gained from reperfusion therapy occurs within the ﬁrst 2–3 hours of
symptom onset [201,202]. The total ischaemic time, between
symptom onset and provision of reperfusion therapy (either starting
ﬁbrinolysis or mechanical reperfusion by primary PCI), is probably
the most important factor. The aim is to provide optimal care while
minimizing delays, in order to improve clinical outcomes (Figure 2)
[201]. The reduction of ﬁrst-medical-contact-to-balloon (FMCTB)
time—deﬁned as the time from the (ﬁrst) medical/hospital door to
the time of primary PCI—relies on efﬁcient coordination of care
between ﬁrst medical contact or referral hospitals, the emergency
medical service (EMS), and the receiving hospitals. It is currently esti-
mated that about 66% of patients achieve a guideline-recom-
mended overall ﬁrst-hospital-door-to-balloon time of <120 minutes
[203]. The door-to-balloon (DTB) time refers to patients presenting
in PCI-capable centres and should be less than 60 minutes. Door-in
to door-out (DI–DO) time is a performance measure that assesses
the timeliness and quality of initial reperfusion care. It is deﬁned as
the duration from arrival to discharge at the ﬁrst or STEMI-referral
hospital. A DI–DO time ≤30 minutes is associated with shorter
reperfusion delays (i.e. a ﬁrst-hospital DTB time <120 minutes) and
lower in-hospital mortality, and should be implemented in
non-PCI-capable hospitals as a quality metric [204,205].
8.2 Selection of reperfusion strategy
Primary PCI is deﬁned as percutaneous catheter intervention in
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If cardiogenic shock, immediate transfer to PCI center
DI-DO = door-in to door-out time; DTB = door-to-balloon time; EMS = emergency medical service; FMC = first medical contact; FMCTB = first-medical-contact-to-balloon time;
PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction.
Figure 2: Organization of STEMI patient disposal describing pre- and in-hospital management and reperfusion strategies within 12 hours of ﬁrst medical contact with
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ﬁbrinolysis as the preferred reperfusion strategy in patients with
STEMI, provided it can be performed in a timely manner in high-
volume PCI centres with experienced operators and 24-hour,
7-day catheterization laboratory activation [201,206–209]. In set-
tings where primary PCI cannot be performed in a timely fashion,
ﬁbrinolysis should be considered, particularly if it can be adminis-
tered pre-hospital (e.g. in the ambulance [210–212] and within the
ﬁrst 120 minutes after symptom onset (Figure 2) [213–215]. It
should be followed by transfer to PCI-capable centres for routine
coronary angiography in all patients and for rescue PCI in case of
unsuccessful ﬁbrinolysis.
During the past decade, primary PCI has become established as
the dominant reperfusion therapy in Europe, irrespective of
whether patients present early or the journey to the primary
PCI-capable hospital is long [202,203,216,217]. Four European
Union countries have documented full implementation of
primary PCI as the preferred reperfusion strategy, including coun-
tries in which travelling can be difﬁcult [218]. In most other
European countries, ﬁbrinolysis for STEMI is becoming a rare
therapy; for example 6% of cases in the UK, 7% in Poland, and 8%
in France [218]. It is interesting to note that, even in countries with
a large catchment area, such as Denmark—with one primary PCI
centre per 1.4 million inhabitants and correspondingly long trans-
portion distances—the STEMI case–fatality rate is among the
lowest recorded in Europe, with an in-hospital mortality of only
3%. The initial diagnosis of STEMI is operational and based on
ECG ﬁndings with a predictive value of 85% [205]. False activation
of the catheterization laboratory may therefore occur in 15–30%
of cases [216], in which PCI can be deferred but where ﬁbrinolysis
is a hazard. In either case, there are costs and some inherent risks
associated with the procedure or treatment.
8.3 Primary percutaneous coronary intervention
Key points for optimizing and guiding primary PCI are summar-
ized below:
• The infarct-related artery should be systematically treated
during the initial intervention. Evidence supporting immedi-
ate (preventive) intervention in non-infarct-related lesions is
a matter of debate [233]. On the one hand, patients with ex-
tensive CAD in vessels remote from the infarct-related artery
have reduced success in reperfusion and an adverse progno-
sis following primary PCI [188]. Staged PCI in patients with
multivessel disease and no haemodynamic compromise is an
independent predictor of survival, and more frequent ischae-
mic events have been reported in direct vs. staged revascular-
ization of STEMI patients with multivessel disease [234–236].
In the recent, randomized Preventive Angioplasty in Acute
Myocardial Infarction (PRAMI) trial (n = 465), preventive PCI
in non-infarct-related coronary arteries with stenosis ≥50%,
when compared with PCI limited to the infarct artery, was
associated with a reduced risk of the composite of death,
myocardial infarction, or refractory angina (HR in the
preventive-PCI group 0.35; 95% CI 0.21–0.58; P < 0.001). The
HR for non-fatal myocardial infarction was 0.32 (95% CI 0.13–
0.75). It remains to be determined how clinicians can identify
lesions that should be revascularized beyond the culprit
lesion and whether complete revascularization should be per-
formed in single- or multi-stage procedures. At present,
Primary PCI for myocardial reperfusion in STEMI:
indications and logistics
Recommendations Classa Levelb Ref c
Indication
Reperfusion therapy is indicated 
in all patients with time from 
symptom onset <12 hours 
duration and persistent ST-
segment elevation or (presumed) 
new LBBB.
I A 207–209
Primary PCI is the recommended 
reperfusion therapy over 
fibrinolysis if performed by an 
experienced team in a timely 
fashion.
I A 219,220
In patients with time from 
symptom onset >12 hours, 
primary PCI is indicated in the 
presence of continuing ischaemia, 
life-threatening arrhythmias or if
pain and ECG changes have been  
stuttering.
I C
Primary PCI is indicated for
patients with severe acute heart 
failure or cardiogenic shock due  
to STEMI independent from time 
delay of symptom onset.
I B 221
Reperfusion therapy with primary 
PCI should be considered in 
patients presenting late (12–48 
hours) after symptom onset. 
IIa B 222–224
Logistics
It is recommended that the pre-
hospital management of STEMI 
patients be based on regional 
networks designed to deliver 
reperfusion therapy timely and 
effectively, and to offer primary 
PCI to as many patients as 
possible.
I B 225,226
It is recommended that all EMSs,
emergency departments, coronary
care units, and catheterization
laboratories have a written
updated STEMI management
protocol, preferably shared within
geographic networks.      
I C
It is recommended that primary 
PCI-capable centres deliver a 24-
hour/7-day service and ensure for 
primary PCI to be performed as 
fast as possible and at the latest 
within 60 minutes of hospital 
arrival. 
I B 227–229
Patients transferred to a PCI-
capable centre for primary PCI 
should bypass the emergency 
department and be transferred 
directly to the catheterization 
laboratory. 
IIa B 230–232
ECG = electrocardiogram; EMS = emergency medical service;
LBBB = left bundle branch block; PCI = percutaneous coronary
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multivessel PCI during STEMI should be considered in
patients with cardiogenic shock in the presence of multiple,
critical stenoses or highly unstable lesions (angiographic signs
of possible thrombus or lesion disruption), and if there is per-
sistent ischaemia after PCI on the supposed culprit lesion.
• The radial approach should be the preferred method of access,
as it has been shown to reduce the incidence of acute bleeding
events—especially in ACS—and was associated with lower mortal-
ity in the subset of STEMI patients that were enrolled in the
RadIal Vs. femorAL access for coronary intervention (RIVAL) trial
[237–239]. However, the beneﬁt of radial over femoral
access depends upon the operators’ expertise in the radial
technique [240].
• Stenting should be preferred over balloon angioplasty in the
setting of primary PCI [241,242], as it reduces the risk of
abrupt closure, re-infarction, and repeat revascularization.
Although early-generation DES have not been associated with
an increased risk of death, myocardial infarction, or stent
thrombosis during long-term follow-up [243], there have
been concerns over an increased risk of very late stent throm-
bosis, owing to delayed arterial healing of stents implanted
into lesions with a large necrotic core [244,245]. More recent
evidence has, however, demonstrated the superiority of new-
generation everolimus-eluting stents in reducing major acute
vascular events in STEMI patients, as compared with early-
generation sirolimus-eluting stents [246]. Two dedicated trials
directly compared new-generation DES with BMS among
STEMI patients undergoing primary PCI. The everolimus-
eluting stent vs. BMS in ST-segment elevation myocardial
infarction (EXAMINATION) trial in 1504 STEMI patients
reported no signiﬁcant differences for the primary endpoint
of all-cause death, re-infarction and any revascularization, in
patients assigned to everolimus-eluting stents, compared with
those assigned to BMS, (11.9% vs. 14.2%, respectively, differ-
ence -2.3%; 95% CI -5.8–1.1%; P = 0.19) at 1 year [247].
However, everolimus-eluting stents were associated with a
lower risk of revascularization of the target lesion (2.1% vs.
5.0%; P = 0.003) and deﬁnite stent thrombosis (0.5% vs. 1.9%;
P = 0.02). The Comparison of Biolimus Eluted From an
Erodible Stent Coating With Bare-Metal Stents in Acute
ST-Elevation Myocardial Infarction (COMFORTABLE AMI) trial,
examining patients assigned to either BMS or to
biolimus-eluting stents with a biodegradable polymer,
reported that the latter showed a lower risk of the composite
primary endpoint of cardiac death, target-vessel myocardial
infarction, and target-lesion revascularization (4.3% vs. 8.7%;
HR 0.49; 95% CI 0.30–0.80; P = 0.004) as well as a lower risk of
target-vessel myocardial infarction (0.5% vs. 2.7%; HR 0.20;
95% CI 0.06–0.69; P = 0.01) and a trend towards a lower risk
of deﬁnite stent thrombosis (0.9% vs. 2.1%; HR 0.42; 95% CI
0.15–1.19; P = 0.10) [248]. Results were maintained throughout
2 years of follow-up and a pooled analysis of both trials con-
ﬁrmed a lower risk of stent thrombosis and re-infarction with
DES than with BMS [249]. Overall, these ﬁndings suggest that
new-generation DES are more effective and potentially safer
than BMS during primary PCI in STEMI.
• Thrombus aspiration has been proposed as an adjunct during
primary PCI, to further improve epicardial and myocardial
reperfusion by prevention of distal embolization of throm-
botic material and plaque debris. Individual RCTs and
meta-analyses have suggested that the use of manual aspir-
ation thrombectomy during primary PCI may be beneﬁcial to
improve epicardial and myocardial reperfusion and reduce
the rate of MACE including mortality [250–255]. In the largest
randomized trial to date, the Thrombus Aspiration during PCI
in Acute Myocardial Infarction (TASTE) study (7244 patients),
the primary endpoint of all-cause mortality occurred in 2.8%
of patients in the thrombus aspiration group and in 3.0% in
the PCI-only group (HR 0.94; 95% CI 0.72–1.22; P = 0.63) at
30 days [256]. However, events were evaluated at short-term
follow-up, and there was a trend towards a reduction of non-
adjudicated events including stent thrombosis (0.2% vs. 0.5%,
respectively; HR 0.47; 95% CI 0.20–1.02; P = 0.06) and
re-infarction (0.5% vs. 0.9%, respectively; HR 0.61; 95% CI
0.34–1.07; P = 0.06) in favour of thrombus aspiration. Taken
together, these results suggest that routine use of thrombus
aspiration is not necessary but selected use may be useful to
improve Thrombolysis in Myocardial Infarction (TIMI) 3 ﬂow
or prevent stent thrombosis. No clinical beneﬁt of routine
rheolytic thrombectomy has been demonstrated in primary
PCI [255,257–259].
• Pre- and post-conditioning warrant randomized trials before
these procedures can be recommended in routine clinical prac-
tice. Remote ischaemic pre-conditioning has engendered little
enthusiasm [260]. Early administration of metoprolol before PCI
in STEMI patients presenting with Killip Class II or less has been
shown to reduce infarct size, with a trend toward fewer ischae-
mic events [261]. Trials evaluating the use of antithrombotic and
vasodilator agents have been disappointing.
• Incomplete stent deployment and undersizing should be
avoided [262]. Massive thrombotic burden and low-pressure
delivery, to avoid distal embolization, are the two major con-
tributing factors in stent malapposition in STEMI patients.
Self-expanding stents and stents covered with ultra-thin
micronets have shown favourable preliminary results in terms
of surrogate endpoints [263]. However, large-scale clinical
outcome studies are required before these devices can be
recommended.
8.4 Fibrinolysis
Despite its frequent contraindications, limited effectiveness in in-
ducing reperfusion, and greater associated risk of bleeding, ﬁ-
brinolytic therapy—preferably administered as a pre-hospital
treatment—remains an adjunct to mechanical revascularization if
the latter cannot be performed in time [207,208]. The incremen-
tal beneﬁt of primary PCI over timely ﬁbrinolysis is diminished
when PCI-related delay exceeds 120 minutes, depending on
patient age, duration of symptoms, and infarct location.
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Primary PCI for myocardial reperfusion in STEMI:
procedural aspects (strategy and technique)
Recommendations Classa Levelb Ref c
Strategy
Primary PCI should be
limited to the culprit vessel
with the exception of
cardiogenic shock and
persistent ischaemia after





be considered in STEMI
patients with multivessel
disease in case of
symptoms or ischaemia





lesions during the same
procedure as primary PCI




In patients with continuing
ischaemia and in whom PCI
















Radial access should be
preferred over femoral





be considered in selected
patients.
IIb A 250–256,259
BMS = bare-metal stent; CABG = coronary artery bypass grafting;
DES = drug-eluting stent; PCI = percutaneous coronary intervention;




Pre-hospital ﬁbrinolysis has been compared with primary PCI
in early-presenting patients in the STrategic Reperfusion Early
After Myocardial infarction (STREAM) study [215]. In patients with
early STEMI (onset <3 hours previously) who could not undergo
primary PCI within 60 minutes after ﬁrst medical contact, pre-
hospital ﬁbrinolysis (amended to half dose in patients >75 years of
age) with timely coronary angiography (6–24 hours in stable
patients) and rescue PCI for failed ﬁbrinolysis was as effective as
primary PCI in reducing the primary endpoint, a composite of
death, shock, congestive heart failure, or re-infarction up to 30
days (12.4% vs. 14.3%, respectively; RR 0.86; 95% CI 0.68–1.09;
P = 0.21). However, there was a signiﬁcant increase in intracranial
bleeding (1.0% vs. 0.2%; P = 0.04) particularly in patients >75 years
of age with ﬁbrinolysis. The median times until reperfusion were
100 minutes in the ﬁbrinolysis group and 178 minutes in the
primary PCI group, which are an hour shorter on average than the
delays in the DANish trial in Acute Myocardial Infarction
(DANAMI) trial, which established the superiority of transfer PCI
over in-hospital ﬁbrinolysis [219]. In view of the lack of superior ef-
ﬁcacy and increased rate of intracranial haemorrhage, emphasis
should remain on timely PCI within STEMI networks as the pre-
ferred treatment for STEMI. Facilitated PCI, deﬁned as routine use
of reduced or normal dose ﬁbrinolysis combined with GP IIb/IIIa
inhibitors or other antiplatelet agents followed by coronary angi-
ography, has shown no signiﬁcant advantages over primary PCI
alone [271].
8.5 Secondary percutaneous coronary intervention
Several randomized trials and meta-analyses have shown that
early, routine, post-thrombolysis angiography with subsequent
PCI (if required) reduced the rates of re-infarction and recurrent
ischaemia, compared with a strategy of ‘watchful waiting’, in which
angiography and revascularization were indicated only in patients
with spontaneous or induced severe ischaemia or LV dysfunction
[272–281]. The beneﬁts of early, routine PCI after thrombolysis
were seen in the absence of an increased risk of adverse events
(stroke or major bleeding). Based on data from the four most
recent trials, all of which had a median delay between start of
thrombolysis and angiography of 2–6 hours, a time-frame of 3–24
hours after successful lysis is recommended [215,272–274]. In
cases of failed ﬁbrinolysis, or if there is evidence of re-occlusion or
re-infarction with recurrence of ST-segment elevation, the patient
should undergo immediate coronary angiography and rescue PCI
[282].
Patients presenting between 12 and 48 hours after onset of
symptoms, even if pain-free and with stable haemodynamics, may
still beneﬁt from early coronary angiography and possibly PCI
[223,224]. In patients presenting days after the acute event with a
completed myocardial infarction, only those with recurrent
angina or documented residual ischaemia—and proven viability
on non-invasive imaging in a large myocardial territory—may be
considered for revascularization when the infarct artery is
occluded. Systematic late PCI of an occluded infarct-related artery
after myocardial infarction in stable patients has no incremental
beneﬁt over medical therapy [115].
ESC/EACTS Guidelines / European Journal of Cardio-Thoracic Surgery542
Management and revascularization after ﬁbrinolysis
Recommendations Classa Levelb Ref c
Transfer to a PCI-capable
centre is indicated in all





the intent to revascularize
the infarct-related artery is
indicated after successful






in cardiogenic shock or
acute severe heart failure
after fibrinolysis.
I B 283
Emergency rescue PCI is
indicated when fibrinolysis
has failed (<50% ST-segment
resolution or persistent pain
at 60 minutes).
I A 273,282,284
Emergency PCI is indicated

















8.6 Coronary artery bypass surgery
CABG may be indicated in STEMI patients with unsuitable
anatomy for PCI, but who have a patent infarct-related artery,
since patency of this artery provides time for transfer to the surgi-
cal team and a large myocardial area in jeopardy. It should be
considered in patients in cardiogenic shock if the coronary
anatomy is not amenable to PCI [221], or at the time of repair for
patients with mechanical complications [285].
CABG is infrequently used and its beneﬁts are uncertain in
STEMI patients with failed PCI, coronary occlusion not amenable
to PCI, and in the presence of refractory symptoms after PCI since,
in most of these cases, time for implementation of surgical reper-
fusion will be long and the risks associated with surgery are
increased in this setting [286].
When possible, in the absence of persistent pain or haemo-
dynamic deterioration, a waiting period of 3–7 days appears the
best compromise [286]. Patients with multivessel disease, who are
receiving primary PCI or secondary (post-ﬁbrinolysis) PCI on the
culprit artery, will need risk stratiﬁcation and further, staged revas-
cularization with PCI or surgery following a Heart Team discus-
sion.
9. REVASCULARIZATION IN PATIENTS WITH
HEART FAILURE AND CARDIOGENIC SHOCK
9.1 Chronic heart failure
Coronary artery disease remains the most common cause of
chronic heart failure; patients with depressed LV function remain
at risk of sudden cardiac death with or without revascularization,
and the indication for prophylactic implantable cardioverter de-
ﬁbrillator (ICD) therapy should always be examined [287].
9.1.1 Revascularization. Revascularization with CABG or PCI is
indicated for symptomatic relief of angina pectoris in patients
with heart failure. The prognostic importance of surgical
revascularization in patients with chronic heart failure has recently
been studied in the STICH trial [112], with the aim of comparing
the efﬁcacy of initial medical therapy with that of revascularization
by CABG plus medical therapy in a sample of 1212 patients
with CAD and LV dysfunction (EF ≤35%). Patients with signiﬁcant
LM disease or CCS Classes III and IV were excluded. Most patients
had two-vessel (31%) or three-vessel (60%) CAD, and 68% had a
proximal LAD stenosis. Although the primary outcome of
all-cause mortality was not signiﬁcantly reduced by CABG (HR
with CABG 0.86; 95% CI 0.72–1.04; P = 0.12) in the intention-
to-treat analysis, it offered superior pre-speciﬁed secondary
outcomes, including cardiovascular mortality (HR 0.81; 95% CI
0.66–1.00; P = 0.05) and all-cause mortality or hospitalization for
heart failure (HR 0.84; 95% CI 0.71–0.98; P = 0.03). Among
patients allocated to medical therapy, 17% crossed over to CABG
and 6% to PCI. The ‘as-treated’ analysis compared the outcomes
of 592 patients treated with medical therapy throughout the ﬁrst
year after randomization with those of 620 patients who
underwent CABG—either as a consequence of randomization or
crossover—and reported signiﬁcantly lower all-cause mortality in
favour of CABG (HR 0.70; 95% CI 0.58–0.84; P < 0.001) [112]. These
ﬁndings have been conﬁrmed in a recent propensity-matched
observational cohort of similar patients during long-term
follow-up over 10 years [288]. The choice between CABG and
PCI should be made by the Heart Team after careful evaluation
of the patient’s clinical status and coronary anatomy,
including SYNTAX score, comorbidities, and expected
completeness of revascularization. A specialist in heart failure
should be consulted.
9.1.2 Myocardial viability and revascularization. The risk–
beneﬁt balance for revascularization in patients without angina/
ischaemia or viable myocardium remains uncertain. In an
observational study using cardiac imaging techniques (stress–rest
Rb-82/F-18 ﬂuorodeoxyglucose PET) in 648 patients with an LVEF
of 31% ± 12%, hibernating myocardium, ischaemic myocardium,
and scarred myocardium were associated with all-cause
death (P = 0.0015; P = 0.0038, and P = 0.0010, respectively). An
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present, such that early revascularization in the setting of
hibernating myocardium, when compared with medical therapy,
was associated with improved survival, especially when the extent
of viability exceeded 10% of the myocardium [289,290]. The
viability sub-study of the STICH trial found viable myocardium in
487 of 601 patients (81%) and no viable myocardium in 114 (19%)
[289]. Among patients without viability, 60 were allocated to CABG
and 54 to medical therapy and, among the 487 patients with
myocardial viability, 244 were assigned to CABG and 243 to
medical therapy. The differences in baseline characteristics,
between patients who underwent myocardial viability testing and
those who did not, indicate some selection bias driven by clinical
factors. Viability was arbitrarily deﬁned using different cut-off
values for the different tests used. By univariate analysis, there was
a signiﬁcant association between myocardial viability and
outcome; however, this association was not signiﬁcant on
multivariable analysis that included other prognostic variables. It is
likely that other variables, such as LV volumes and ejection
fraction, are causally determined by the extent of viable
myocardium. The lack of correlation between myocardial viability
status and beneﬁt from CABG in this study indicates that
assessment of myocardial viability should not be the sole factor in
selecting the best therapy for these patients.
9.1.3 Ventricular reconstruction. The aim of surgical
ventricular reconstruction (SVR) is to remove scar tissue from the
LV wall by an endoventricular patch plasty, thereby restoring
physiological volume, and to restore an elliptical rather than
spherical shape. The decision to add SVR to CABG should be
based on a careful evaluation of symptoms (heart failure
symptoms should take priority over angina), measurement of LV
volumes, and assessment of the transmural extent of myocardial
scar tissue, and should be performed only in centres with a high
level of surgical expertise. The STICH trial failed to show a
difference in the primary outcome (death from any cause or
hospitalization for cardiac causes) between CABG and the
combined procedure (CABG and SVR). The reduction in
end-systolic volume index in STICH—smaller than in previously
reported observational studies treating larger aneurysms—might
explain the inconsistent ﬁnding and, thus, the value of reasonable
SVR might be underestimated [291,292]. Subgroup analyses of the
STICH trial suggest that patients with less dilated LV and better
LVEF may beneﬁt from SVR, while those with larger LV and poorer
LVEF may do worse [293]. In the STICH trial, a post-operative left
ventricular end-systolic volume index (LVESVI) of 70 ml/m2 or
lower, after CABG plus SVR, resulted in improved survival
compared with CABG alone. In another study, in patients treated
with CABG and SVR, a post-operative LVESVI of less than 60 ml/
m2 was associated with improved survival compared with a
post-operative LVESVI of 60 ml/m2 or more [294]. In some
patients with large aneurysms, who would have been excluded
from STICH (due to acute heart failure, inotropic support or
violation of other inclusion criteria), surgical ventricular
restoration has shown favourable outcomes although in the
absence of a comparator [295].
Recommendations on revascularizations in patients with
chronic heart failure and systolic LV dysfunction (ejection
fraction ≤35%)
Recommendations Classa Levelb Ref c
CABG is recommended for
patients with significant LM stenosis
and LM equivalent with proximal
stenosis of both LAD and LCx
arteries.
I C -
CABG is recommended for
patients with significant LAD artery
stenosis and multivessel disease to
reduce death and hospitalization
for cardiovascular causes.
I B 112,288
LV aneurysmectomy during CABG
should be considered in patients
with a large LV aneurysm, if there is
a risk of rupture, large thrombus




be considered in the presence of
viable myocardium.
IIa B 55
CABG with surgical ventricular
restoration may be considered in
patients with scarred LAD
territory, especially if a post-
operative LVESV index <70 ml/m²
can be predictably achieved.
IIb B 291–295
PCI may be considered if anatomy
is suitable, in the presence of viable
myocardium, and surgery is not
indicated.
IIb C
CABG = coronary artery bypass grafting; LAD = left anterior descending;
LCx = left circumflex; LM = left main; LVESV = left ventricular
end-systolic volume; PCI = percutaneous coronary intervention;





Acute myocardial infarction accounts for approximately 75% of all
patients with cardiogenic shock, and the incidence has remained
somewhat constant for many years at 6–8% [296–298].
Cardiogenic shock complicating acute myocardial infarction is
caused by LV failure in about 80% of cases. Mechanical complica-
tions, such as papillary muscle rupture with severe mitral valve in-
competence (6.9%), ventricular septal defect (3.9%), or free wall
rupture (1.4%), are other precipitating causes. Because revasculari-
zation is the cornerstone of the treatment in patients with cardio-
genic shock complicating ACS, emergency coronary angiography
is indicated. The general triage and treatment of these complex
patients is presented in Figure 3.
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9.2.1 Revascularization. The Should We Emergently
Revascularize Occluded Coronaries for Cardiogenic Shock
(SHOCK) trial demonstrated that, in patients with cardiogenic
shock due to acute myocardial infarction, emergency
revascularization with PCI or CABG improved long-term survival
when compared with initial intensive medical therapy. All-cause
mortality at 6 months was lower in the group assigned to
revascularization than in the group assigned to medical therapy
(50.3% vs. 63.1%, respectively; RR 0.80; 95% CI 0.65–0.98; P = 0.03)
[221]. Subgroup analysis revealed that the only variable that
correlated signiﬁcantly with treatment both at 30 days and at 6
months was age, with little or no effect of invasive treatment on
mortality in elderly patients (>75 years); however, these ﬁndings
were not corroborated in the SHOCK trial registry, in which a
covariate-adjusted model also suggested a lower mortality among
elderly patients (>75 years) undergoing revascularization, as
compared with initial intensive medical therapy (RR 0.46; 95% CI
0.28–0.75; P = 0.002) [299].
9.2.2 Mechanical circulatory support. Intra-aortic balloon
pump (IABP) counterpulsation has been widely used as
mechanical support in cardiogenic shock [300]. The efﬁcacy of






• Repair of mechanical complications
Mechanical circulatory support for
destination therapy or as bridge to
cardiac transplantation
Patient unstable
Recovery of cardiac function
Patient stable
Irreversible neurological deficit Normal neurological function





Standard therapyAssess neurological/endorgan function













ESC/EACTS Guidelines / European Journal of Cardio-Thoracic Surgery 545
IABP in cardiogenic shock has recently been challenged in the
large, randomized Intraaortic Balloon Pump in Cardiogenic Shock
IABP-SHOCK II trial, which included 600 patients with cardiogenic
shock complicating acute myocardial infarction, who were
assigned to IABP or no IABP. The primary endpoint of 30-day
mortality was not reduced with the use of IABP (39.7% IABP vs.
41.3% control; RR 0.96; 95% CI 0.79–1.17; P = 0.69) and there
was no long-term beneﬁt [301,302]. As a result, the use of IABP for
this indication is not routinely recommended but remains an
adjunct for patients with mechanical complications as a bridge to
surgery.
Three randomized trials and a large registry have demonstrated
superior haemodynamic support with percutaneous mechanical
circulatory assist systems than with IABP, without differences in
mortality but with an increased risk of adverse events [303–306]. A
meta-analysis, comparing the safety and efﬁcacy of percutaneous
left ventricular assist devices (LVAD) in IABP in patients with car-
diogenic shock, found LVAD-treated patients to have a similar
mortality and incidence of lower extremity ischaemia, but more
bleeding than those treated with IABP [307].
In younger patients with no contraindication for cardiac trans-
plantation, LVAD therapy can be implemented as a bridge to
transplantation. In patients not eligible for transplant, LVADs may
be inserted as a bridge to recovery or with the goal of destination
therapy [308–310].
9.2.3 Right ventricular failure. Almost 50% of patients with
inferior acute myocardial infarction show echocardiographic
evidence of right ventricular dysfunction, with haemodynamic
compromise developing in <25% of cases [311–315]. Isolated
right ventricular failure accounts for 2.8% of cases of
cardiogenic shock complicating acute myocardial infarction
[316,317]. Successful primary PCI leads to a haemodynamic
improvement, recovery of right ventricular free wall and global
function and, hence, improved survival compared with
unsuccessful reperfusion [317–319].
9.2.4 Mechanical complications. Mechanical complications of
acute myocardial infarction comprise myocardial rupture,
resulting in either mitral regurgitation due to papillary muscle
rupture, ventricular septal defect (VSD), or free wall rupture with
tamponade [320–322].
Ventricular septal defect, characterized by haemodynamic
compromise, is treated by IABP followed by early surgical repair
[323]. Percutaneous closure devices for patients’ post-infarct VSDs
have been reported in case series and, in centres with appropriate
experience, may be considered in selected cases as alternatives to
surgery [324–326].
Rupture of the free wall, resulting in tamponade, should be sal-
vaged by prompt pericardial drainage and surgical intervention.
Left ventricular free wall rupture accounts for approximately 15%
of in-hospital mortality from myocardial infarction [327]. Data
from the SHOCK trial registry, on patients with and without LV
free wall rupture who underwent surgery, showed similar mortal-
ity rates [327,328].
Acute mitral regurgitation due to rupture of the papillary
muscle should be treated by immediate surgery and revasculariza-
tion [317,329,330].
Recommendations for management of patients with acute
heart failure in the setting of ACS
Recommendations Classa Levelb Ref c
Emergency echocardiography is
indicated to assess LV and
valvular function and exclude
mechanical complications.
I C
Emergency invasive evaluation is
indicated in patients with acute





Emergency PCI is indicated for
patients with cardiogenic shock
due to STEMI or NSTE-ACS if
coronary anatomy is amenable.
I B 221
Emergency CABG is
recommended for patients with
cardiogenic shock if the





acute myocardial infarction is
indicated in case of
haemodynamic instability.
I C
IABP insertion should be 
considered in patients with
haemodynamic instability/cardio-










circulatory support in ACS
patients with cardiogenic shock
may be considered.
IIb C
Percutaneous repair of VSD
may be considered after
discussion by the Heart Team.
IIb C
Routine use of IABP in patients
with cardiogenic shock is not
recommended.
III A 332,333
ACS = acute coronary syndromes; CABG = coronary artery bypass
grafting; IABP = intra-aortic balloon pump; LV = left ventricular;
NSTE-ACS = non-ST-segment elevation acute coronary syndrome;
PCI = percutaneous coronary intervention; STEMI = ST-segment
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10. REVASCULARIZATION IN PATIENTS WITH
DIABETES
10.1 Evidence for myocardial revascularization
Data from randomized trials on revascularization in diabetic
patients are summarized in Table 8. For additional information on
diabetes, we refer to the ESC Guidelines on diabetes [84]. Diabetic
patients undergoing revascularization, either with CABG or PCI,
are at greater risk for kidney injury than patients without diabetes.
10.1.1 Stable coronary artery disease. The Bypass Angio-
plasty Revascularization Investigation 2 Diabetes (BARI-2D) trial
speciﬁcally addressed the question of myocardial revascularization
in diabetic patients with SCAD [334]. A total of 2368 patients with
diabetes and evidence of ischaemia, or symptoms of angina in the
presence of angiographically deﬁned SCAD, were randomized to
medical therapy or to myocardial revascularization in addition to
medical therapy. Before randomization, patients were placed in
either the PCI or CABG stratum of revascularization as deemed
appropriate by the responsible physician. The enrolment
target of 2800 patients was not met and follow-up had to be
extended by 1.5 years to 5.3 years. Patients with LM disease,
those who were unstable, requiring immediate revascularization,
and patients with creatinine values >2.0 mg/dl or moderate-
to-severe heart failure were excluded. The primary endpoint was
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BMS = bare-metal stent; CABG = coronary artery bypass grafting; CV = cardiovascular; DES = drug-eluting stent; EF = ejection fraction; MI = myocardial
infarction; MT = medical therapy; MVD = multivessel disease; PCI = percutaneous coronary intervention; PES = paclitaxel-eluting stent; Revasc =
revascularization; SES = sirolimus-eluting stent; Sx-Score = SYNTAX score; y = years.
aP<0.05.
bRandomization stratified by revascularization modality.
cThree-vessel disease.
dSubgroup analysis.
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all-cause mortality and the principal secondary endpoint was a
composite of death, myocardial infarction, or stroke (MACCE).
The use of DES (35%) was low and restricted to early-generation
devices. A total of 42% of patients in the medical therapy group
underwent clinically indicated revascularization during
follow-up.
At 5 years, survival did not differ between the medical therapy
and revascularization groups, and there were no differences in
MACCE (Table 8). In the PCI group, there was no outcome differ-
ence between PCI and medical therapy. In the CABG stratum,
where patients had more extensive CAD, freedom from MACCE
was signiﬁcantly higher with revascularization than with medical
treatment [334]. Survival, however, was not signiﬁcantly different,
which may reﬂect a power issue or the fact that patients with
more extensive myocardial perfusion abnormalities or LV function
impairment were more likely to receive revascularization over
time in the medical therapy group [335]. Compared with medical
therapy, the revascularization strategy at the 3-year follow-up had
a lower rate of worsening angina (8% vs. 13%, respectively;
P < 0.001), new angina (37% vs. 51%, respectively; P < 0.001), and
subsequent coronary revascularizations (18% vs. 33%, respectively;
P < 0.001), and a higher rate of angina-free status (66% vs. 58%, re-
spectively; P < 0.003).
The investigators speculated that the beneﬁt of CABG over
medical therapy emerged due to a preference for CABG rather
than PCI among patients with more advanced CAD. This was
further substantiated in a study of the impact of angiographic
(BARI-2D score) risk stratiﬁcation on outcomes. Among the CABG
stratum patients with high-risk angiographic scores, the 5-year risk
of death, myocardial infarction or stroke was signiﬁcantly lower
and ampliﬁed for those assigned to revascularization, when com-
pared with medical therapy (24.8% vs. 36.8%, respectively;
P = 0.005) [336].
10.1.2 Acute coronary syndromes. Approximately 20–30% of
patients with NSTE-ACS have known diabetes, and at least as
many have undiagnosed diabetes or impaired glucose tolerance
[337]. Mortality in patients with ACS is two- to three-time
increased in diabetic patients, compared with non-diabetic [338].
Despite the higher risk, revascularization and thienopyridines are
less frequently prescribed among diabetics than non-diabetics,
with an impact on in-hospital and long-term mortality [339–341].
In NSTE-ACS patients, there is no clear correlation between the
treatment effect of myocardial revascularization and diabetic
status [342,343,364]. In both the Fragmin during Instability in
Coronary Artery Disease-2 (FRISC-2) and Treat angina with
Aggrastat and determine Cost of Therapy with an Invasive or
Conservative Strategy–Thrombolysis in Myocardial Infarction 18
(TACTICS-TIMI 18) trials [342,343,364], an early invasive strategy in
ACS patients was associated with better outcomes than with a
conservative strategy; in TACTICS-TIMI 18 [364], the magnitude of
the beneﬁt to diabetic patients was greater than that to non-
diabetic patients. In a recent meta-analysis of nine RCTs with 9904
ACS patients, diabetic patients (n = 1789) had a higher rate of
death (9.3% vs. 3.2%; P < 0.001), non-fatal myocardial infarction
(11.3% vs. 7.1%; P < 0.001), and rehospitalization with ACS (18.1%
vs. 13.0%; P < 0.001) than non-diabetic patients at 1 year post-
procedure. An early invasive strategy was associated with a similar
risk reduction in death, myocardial infarction, or rehospitalization
for ACS in diabetic and non-diabetic patients (RR 0.87; 95% CI
0.70–1.03 vs. 0.86; 95% CI 0.70–1.06; P for interaction 0.83) [338].
Accordingly, diabetes presents a secondary indication for high risk
and for invasive management, and further efforts need to be
made to give diabetic patients with ACS better access to revascu-
larization therapy [180].
Compared with non-diabetic patients, diabetics with STEMI
present later, are more likely to experience haemodynamic instabil-
ity and end-organ damage, and have delayed revascularization. In
STEMI patients, the Primary Coronary Angioplasty vs. Thrombolysis
(PCAT)-2 collaborative analysis of 19 RCTs with individual patient
data from 6315 patients (14% with diabetes mellitus) showed a
similar beneﬁt of primary PCI over ﬁbrinolytic treatment in diabetic
and non-diabetic patients [363]. The OR for mortality in favour of
primary PCI was 0.49 for diabetic patients (95% CI 0.31–0.79).
Recurrent myocardial infarction and stroke were also signiﬁcantly
lower in favour of primary PCI. Patients with diabetes had signiﬁ-
cantly delayed initiation of reperfusion treatments and longer is-
chaemic times, probably related to atypical symptoms causing
signiﬁcant delays in initiating reperfusion therapy. Owing to a
higher absolute risk, the number needed to treat to save one life at
30 days was signiﬁcantly lower for diabetic patients (number
needed to treat = 17; 95% CI 11–28) than for non-diabetic patients
(number needed to treat = 48; 95% CI 37–60).
10.2 Type of myocardial revascularization
The presence of diabetes mellitus deﬁnes the treatment strategy
for an important subset of patients with multivessel CAD.
10.2.1. Randomized clinical trials. The Future
Revascularization Evaluation in Patients with Diabetes Mellitus
(FREEDOM) trial is the only adequately powered, randomized
study comparing CABG against PCI with use of early-generation
DES (94%) in diabetic patients undergoing elective
revascularization for multivessel disease without LM coronary
stenosis [175]. Between 2005 and 2010, 33 966 patients were
screened, of whom 3309 were considered eligible and 1900 (6%)
enrolled. Their mean SYNTAX score was 26 ± 9. The primary
outcome of death from any cause, non-fatal myocardial
infarction, or stroke was lower in the CABG than the PCI group,
with divergence of the curves starting at 2 years. This difference
was driven by a borderline reduction of all-cause mortality
(P = 0.049) and by a markedly lower rate of myocardial infarction
favouring the CABG group (P < 0.001). Conversely, rates of stroke
were doubled in the CABG group (P = 0.03). The superiority of
CABG over PCI was consistent across all pre-speciﬁed subgroups,
including SYNTAX score, the only exception being that patients
recruited outside the USA (n = 1130) had a less-pronounced
relative beneﬁt from CABG than those enrolled in the USA
(n = 770) (P = 0.05 for interaction) [175]. Detailed assessment of
quality of life revealed substantial and durable improvements in
cardiovascular-speciﬁc health status with both PCI and CABG
groups. During the ﬁrst month after treatment, PCI resulted in
more rapid improvement in health status and quality of life, this
changing between 6 months and 2 years in favour of CABG and
differences disappearing beyond 2 years [344].
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It is unclear, however, whether the SYNTAX score was analysed
by a blinded ’core’ laboratory, which is essential for reproducibility.
It should be noted that the SYNTAX score became operational
during the FREEDOM trial and is not mentioned in the FREEDOM
study protocol [345]. Therefore, the validity of the observation that
CABG led to better outcomes than PCI, irrespective of the SYNTAX
score, remains unclear, and it is not consistent with the ﬁndings
related to the diabetic subgroup of the SYNTAX trial. The increased
risk of stroke raises the question of treatment selection, particularly
among elderly patients. In addition, the median follow-up was 3.8
years but only 23% of patients were at risk at 5 years.
In the subset of 452 diabetic patients with multivessel CAD who
were enrolled in the SYNTAX trial, there were no signiﬁcant differ-
ences at 5 years in the composite of all-cause death, myocardial
infarction, or stroke (CABG 19.1% vs. PCI 23.9%; P = 0.26) or in the
individual components such as all-cause death (P = 0.07), stroke
(P = 0.34), or myocardial infarction (P = 0.20) [346]. However,
repeat revascularization was less frequently required in the CABG
group (P < 0.001). Among patients with low SYNTAX score (≤ 22),
rates of MACCE were similar for CABG and PCI (33.7% vs. 42.5%,
respectively; P = 0.38) but repeat revascularization remained more
frequent in the PCI group (18.5% vs. 38.5%, respectively; P = 0.01).
Interestingly, in the SYNTAX trial, diabetes was not an independ-
ent predictor of outcomes once the SYNTAX score was entered
into the multivariable model [25].
In the Coronary Artery Revascularization in Diabetes (CARDia)
trial, 510 diabetic patients with multivessel or complex single-
vessel CAD, enrolled at 24 sites, were randomly assigned to either
CABG or PCI with use of either BMS or DES and routine use of
abciximab. There were no differences between CABG and PCI for
the primary endpoint, the 1-year composite of death, myocardial
infarction, or stroke [347]. Comparing the subset of patients
treated with DES, the primary outcome rates were 12.4% in the
CABG and 11.6% in the PCI group (HR 0.93; 95% CI 0.51–1.71;
P = 0.82). Repeat revascularization was more common among
patients assigned to PCI (P < 0.001), whereas stroke tended to be
less common among patients assigned to PCI (P = 0.07).
Hence, taking currently available evidence into consideration,
CABG is the revascularization modality of choice among diabetic
patients with multivessel CAD; however, PCI can be considered as
a treatment alternative among diabetic patients with multivessel
disease and low SYNTAX score (≤22).
10.2.2 Meta-analyses. A meta-analysis of individual data from
10 RCTs of elective myocardial revascularizatio [106] conﬁrms a
survival advantage for CABG over PCI in diabetic patients,
whereas no difference was found for non-diabetic patients; the
interaction between diabetic status and type of revascularization
was signiﬁcant. In this pooled analysis, PCI patients were treated
with either balloon angioplasty or BMS. A more recent
meta-analysis—dedicated to diabetic patients treated with either
CABG or PCI, with at least 80% of arterial conduit(s) or stents (BMS
and early-generation DES)—showed signiﬁcantly lower mortality
with CABG at 5 years or the longest follow-up (RR 0.67; 95% CI
0.52–0.86; P = 0.002) [349]. On the other hand, this pooled analysis
showed increased rates of stroke using CABG vs. PCI at 5-year
follow-up (RR 1.72; 95% CI 1.18–2.53; P = 0.005). Similarly, a
meta-analysis—restricted to four RCTs covering 3052 patients,
which compared PCI with use of early-generation DES vs. CABG in
diabetic patients with multivessel CAD—reported a higher risk of
death and myocardial infarction with revascularization by
early-generation DES (RR 1.51; 95% CI 1.09–2.10; P = 0.01) but a
lower risk of stroke (2.3% vs. 3.8%; RR 0.59; 95% CI 0.39–0.90;
P = 0.01) [350]. A sensitivity analysis revealed that the superiority of
CABG over early-generation DES for the endpoint MACCE was
most pronounced among patients with high SYNTAX score, but
not signiﬁcant in those with low SYNTAX score. All RCTs have
shown higher rates of repeat revascularization procedures after
PCI compared with CABG, in diabetic patients [106,346].
10.3 Revascularization with the use of
percutaneous coronary intervention
A collaborative network meta-analysis has compared DES with
BMS in 3852 diabetic patients [351]. The need for target-lesion
revascularization was considerably lower with DES than with BMS
[OR 0.29 for sirolimus-eluting stent; 0.38 for paclitaxel-eluting stent].
A more recent mixed-treatment comparison of 42 trials with 22
844 patient-years of follow-up assessed the efﬁcacy and safety of
several early and new-generation DES and BMS in patients with
diabetes. Compared with BMS, all DES showed a rate of TVR that
was lower by 37–69%. Compared with BMS, there were no differ-
ences in rates of death, myocardial infarction, or stent thrombosis
for any DES in diabetic patients [352]. There are no robust data to
support the use of any one DES over another in patients with
diabetes.
10.4 Revascularization with the use of coronary
artery bypass grafting
There is no direct, randomized evidence for or against the use of
one vs. two IMA conduits in diabetic patients. Whether use of bi-
lateral IMA increases the risk of deep sternal wound complications
is still a matter of debate, although diabetic patients are particular-
ly prone to sternal infections in bilateral IMA operations.
However, observational evidence, with follow-up periods up to 30
years, suggests that bilateral IMA use improves long-term out-
comes [23,24]. Pending the long-term results of the randomized
Arterial Revascularisation Trial (ART) trial [353], it is still not clear
whether bilateral IMA grafting produces better outcomes, but the
superior survival observed with bilateral IMA grafting has been
seen not to depend on diabetic status [354]. In a recent analysis,
there was no signiﬁcant correlation with diabetic status over
15-year follow-up when using multiple arterial grafts [355].
Indeed, alternative strategies—including use of the radial artery in
patients with an excessively high risk for sternal complications (e.
g. obese patients)—have been shown to be safe during follow-up,
and to prolong survival compared with using vein grafts [356].
10.5 Antithrombotic pharmacotherapy
There is no indication that antithrombotic pharmacotherapy
should differ between diabetic and non-diabetic patients under-
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status and efﬁcacy of GP IIb/IIIa inhibitors was noted in earlier
trials without concomitant use of thienopyridines, this was not
conﬁrmed in the more recent Early glycoprotein IIb/IIIa inhibition
in non-ST-segment elevation acute coronary syndrome
(EARLY-ACS) trial [357]. In the current context of use of oral P2Y12
inhibitors, diabetic patients do not speciﬁcally beneﬁt from the
addition of GP IIb/IIIa inhibitors.
10.6 Anti-diabetic medications
Only a few speciﬁc trials of anti-diabetic medications have been
conducted in patients undergoing myocardial revascularization.
Metformin
Because of the risk of lactic acidosis in patients receiving iodi-
nated contrast media, it is generally stated that administration of
metformin should be suspended before angiography or PCI, and
resumed 48 hours later, subject to adequate renal function. The
plasma half-life of metformin is 6.2 hours; however, there is no
convincing evidence for such a recommendation. Checking renal
function after angiography in patients on metformin and withold-
ing the drug when renal function deteriorates might be an accept-
able alternative to automatic suspension of metformin. In patients
with renal failure, metformin should preferably be stopped before
the procedure. Accepted indicators for metformin-induced lactic
acidosis are arterial pH <7.35, blood lactate >5 mmol/l (45 mg/dl),
and detectable plasma metformin concentration. Accurate recog-
nition of metformin-associated lactic acidosis and prompt initi-
ation of haemodialysis are important steps towards rapid
recovery.
Other drugs
Observational data have raised concern over the use of sulpho-
nylureas in patients treated with primary PCI for acute myocardial
infarction. Such concern has not been backed up by a post hoc
analysis of the Diabetes, Insulin Glucose Infusion in Acute
Myocardial Infarction (DIGAMI)-2 trial, although the number of
patients undergoing primary PCI in this trial was low [358].
Arrhythmias and ischaemic complications were also less frequent
in patients receiving gliclazide or glimepiride [359]. Thiazoli-
dinediones may be associated with lower rates of restenosis after
PCI with BMS [360], but carry an increased risk of heart failure
resulting from water retention in the kidney.
No trial has demonstrated that the administration of insulin or
glucose–insulin–potassium improves PCI outcome after STEMI.
Observational data in patients undergoing CABG suggest that use
of a continuous intravenous (i.v.) insulin infusion to achieve mod-
erately tight glycaemic control (6.6–9.9 mmol/l or 120–180 mg/dl)
is independently associated with lower rates of mortality and
major complications than those observed after tighter (6.6 mmol/l
or 120 mg/dl) or more lenient (9.9 mmol/l or 180 mg/dl) gly-
caemic control [361]. In the BARI-2D trial, outcomes were similar
in patients receiving insulin sensitization vs. insulin provision to
control blood glucose. In the CABG group, administration of
insulin was associated with more cardiovascular events than the
insulin-sensitization medications [139].
In the Saxagliptin and Cardiovascular Outcomes in Patients with
Type 2 Diabetes Mellitus SAVOR-TIMI 53 trial, dipeptidyl peptid-
ase 4 (DPP-4) inhibition with saxagliptin neither increased nor
decreased the incidence of ischaemic events, although the rate of
hospitalization for heart failure was increased [362].
Speciﬁc recommendations for revascularization in patients
with diabetes
Recommendations Classa Levelb Ref c
In patients presenting with
STEMI, primary PCI is
recommended over fibrinolysis
if it can be performed within
recommended time limits.
I A 363
In patients with NSTE-ACS, an






In stable patients with
multivessel CAD and/or
evidence of ischaemia,
revascularization is indicated in
order to reduce cardiac
adverse events.
I B 93,367
In patients with stable
multivessel CAD and an
acceptable surgical risk, CABG
is recommended over PCI.
I A 106,175,349
In patients with stable
multivessel CAD and SYNTAX 
score




recommended over BMS. I A 351,352
Bilateral mammary artery
grafting should be considered. IIa B 368
In patients on metformin, renal
function should be carefully
monitored for 2 to 3 days after
coronary angiography/PCI.
I C
22, PCI should be
BMS = bare-metal stent; CABG = coronary artery bypass grafting;
CAD = coronary artery disease; DES = drug-eluting stent;
NSTE-ACS = non-ST-segment elevation acute coronary syndrome;





11. REVASCULARIZATION IN PATIENTS WITH
CHRONIC KIDNEY DISEASE
11.1 Evidence-base for revascularization
Myocardial revascularization is underused in patients with chronic
kidney disease (CKD) [369–371]. In all categories of kidney func-
tion (deﬁned in the web addenda), observational studies suggest
that CKD patients with multivessel disease who undergo revascu-
larization have better survival than those who receive medical
therapy [372,373]. Particularly among patients with ACS,
large-scale registries indicate better short- and long-term survival
with early revascularization than with medical therapy across all
CKD stages [371,374]. When there is an indication for PCI, DES
should be preferred over BMS, because of its lower risk of
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revascularization and the absence of safety concerns [375,376].
Notwithstanding, the use of contrast media during diagnostic and
interventional vascular procedures represents the most common
cause of acute kidney injury in hospitalized patients. In addition,
patients with CKD have frequent comorbidities that increase the
risk of periprocedural ischaemic and bleeding events. Notably,
there is little evidence from RCTs, as most therapeutic RCTs on
revascularization have excluded CKD patients. Current treatment
strategies are therefore based on retrospective analyses of RCTs
and data from large registries.
11.1.1 Patients with moderate chronic kidney disease.
Observational studies suggest an increased risk of perioperative and
short-term (12 months) fatal events but lower medium-
to-long-term mortality after CABG compared with PCI [377,378].
The absolute risk for end-stage renal disease is smaller than that for
fatal events in this patient population and the combined incidence
of death or end-stage renal disease may remain lower after CABG
at long-term follow-up. In the post hoc analysis of patients with
CKD (25% of 1205 patients) in the randomized Arterial
Revascularization Therapies Study (ARTS) trial, which compared
CABG against multivessel PCI with the use of BMS, no difference
was observed in the primary endpoint of death, myocardial
infarction, or stroke (19% vs. 17%; HR 0.93; 95% CI 0.54–1.61;
P = 0.80) as well as mortality after 3 years of follow-up; however, the
risk of repeat revascularization was reduced in favour of CABG (25%
vs. 8%; HR 0.28; 95% CI 0.14–0.54; P = 0.01) [379]. There is some
evidence that suggests that the off-pump approach may reduce the
risk of perioperative acute renal failure and/or progression to
end-stage renal disease in these patients [380]. Predictive tools have
been proposed, which hold promise as a means of identifying CKD
patients who are likely to derive the most beneﬁt from one
particular revascularization strategy, but these have not been
systematically validated externally [381].
11.1.2 Patients with severe chronic kidney disease and
end-stage renal disease or in haemodialysis. In the absence
of data from RCTs, results from a large cohort of 21 981 patients
with end-stage renal disease (data from US Renal Data System)
with poor 5-year survival (22–25%) suggest that CABG should be
preferred over PCI for multivessel coronary revascularization in
appropriately selected patients on maintenance dialysis [382].
Compared with PCI, CABG was associated with signiﬁcantly lower
risks for both death and the composite of death or myocardial
infarction [382]. Selection of the most appropriate revascu-
larization strategy must therefore account for the general
condition and life expectancy of the patient, the least invasive
approach being more appropriate in the most fragile and
compromised patients.
Candidates for renal transplantation must be screened for myo-
cardial ischaemia, and those with signiﬁcant CAD should not be
denied the potential beneﬁt of myocardial revascularization.
Renal transplant recipients have been reported to have similar
long-term survival after CABG and PCI [383].
11.2 Prevention of contrast-induced
nephropathy
Especially if glomerular ﬁltration rate (GFR) is <40 ml/min/1.73 m2,
all patients with CKD who undergo diagnostic catheterization
should receive preventive hydration with isotonic saline, to be
started approximately 12 hours before angiography and contin-
ued for at least 24 hours afterwards to reduce the risk of
contrast-induced nephropathy (CIN) [384,385]. The implementa-
tion of high-dose statin before diagnostic catheterization has been
shown to reduce the incidence of CIN and should be considered
as an additional preventive measure in patients without contrain-
dications [386]. The antioxidant ascorbic acid has been explored in
oral and intravenous preparations, for protection against CIN. A
recent meta-analysis of nine RCTs in 1536 patients suggested a
somewhat lower risk of CIN among pre-existing CKD patients who
received ascorbic acid, than in patients who received placebo or
an alternate treatment (9.6% vs. 16.8%, respectively; RR = 0.67;
95% CI 0.47 to 0.97; P = 0.034 [387]. but more evidence is required
to make deﬁnite recommendations. Although performing diag-
nostic and interventional procedures separately reduces the total
volume exposure to contrast media, the risk of renal atheroem-
bolic disease increases with multiple catheterizations. Therefore,
in CKD patients with diffuse atherosclerosis, a single invasive ap-
proach (diagnostic angiography followed by ad hoc PCI) may be
considered, but only if the contrast volume can be maintained
<4 ml/kg. The risk of CIN increases signiﬁcantly when the ratio of
total contrast volume to GFR exceeds 3.7:1 [388,389]. For patients
undergoing CABG, the effectiveness of the implementation of
pharmacological preventive measures—such as clonidine, fenol-
dopam, natriuretic peptides, N-acetylcysteine or elective pre-
operative haemodialysis—remains unproven.
Speciﬁc recommendations for patients with moderate or
severe CKD
Recommendations Classa Levelb Ref c
CABG should be




risk profile is acceptable and
life expectancy is beyond 1
year.
IIa B 25,382,390–392
PCI should be considered
over CABG in patients
with multivessel CAD and
symptoms/ischaemia whose
surgical risk profile is high or
life expectancy is less than 1
year.
IIa B 390,391
It should be considered to
delay CABG after
coronary angiography until
the effect of contrast
media on renal function
has subsided.
IIa B 393–395
Off-pump CABG may be




recommended over BMS. I B 375,376
BMS = bare-metal stent; CABG = coronary artery bypass grafting;
CAD = coronary artery disease; CKD = chronic kidney disease;
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12. REVASCULARIZATION IN PATIENTS
REQUIRING VALVE INTERVENTIONS
12.1 Primary indication for valve interventions
Overall, 40% of patients with valvular heart disease will have con-
comitant CAD. Coronary angiography is recommended in all
patients with valvular heart disease requiring valve surgery, apart
from young patients (men <40 years and pre-menopausal
women) without risk factors for CAD or when the risks of angiog-
raphy outweigh the beneﬁts (e.g. in cases of aortic dissection, a
large aortic vegetation in front of the coronary ostia, or occlusive
prosthetic thrombosis leading to an unstable haemodynamic con-
dition) [411]. In patients undergoing aortic valve replacement
(AVR) who also have signiﬁcant CAD, the combination of CABG
and aortic valve surgery reduces the rates of perioperative myo-
cardial infarction, perioperative mortality, late mortality, and mor-
bidity, when compared with patients not undergoing
simultaneous CABG [412–415]. This combined operation,
however, carries an increased risk of mortality over isolated AVR
[11,416–418]. In a contemporary analysis of a large cohort, the
greater risk of the combined operation than with isolated AVR was
associated with effects of pre-existing ischaemic myocardial
damage and comorbidities [419].
In patients with severe comorbidities, the Heart Team may opt
for transcatheter valve interventions. Although a systematic review
of observational studies has shown no signiﬁcant impact of CAD
on mortality in patients undergoing transcatheter aortic valve
Recommendations for prevention of contrast-induced nephropathy
Recommendations Dose Classa Levelb Ref c
Patients undergoing coronary angiography or MDCT
Patients should be assessed for risk of
contrast-induced AKI.
IIa C
Patients with moderate-to-severe CKD
Hydration with isotonic saline is
recommended.d I A 384,385,397
Use of low-osmolar or iso-osmolar
contrast media is recommended.
<350 ml or <4 ml/kg or total
contrast volume/GFR <3.4. I A 398–400
Short-term, high-dose statin therapy
should be considered.
Rosuvastatin 40/20mg or
atorvastatin 80 mg or simvastatin
80 mg.
IIa A 386,401
Iso-osmolar contrast media should be
considered over low-osmolar contrast
media.
IIa A 398,399,402
Volume of contrast media should be
minimized. IIa B 388,389
Furosemide with matched hydration may be
considered over standard hydration in patients at
very high risk for CIN or in cases where
prophylactic hydration before the procedure cannot
be accomplished.
Initial 250 ml intravenous bolus
of normal saline over 30 min (reduced
to   150 ml in case of LV dysfunction)
followed by an i.v. bolus (0.25–0.5 mg/kg)
of furosemide. Hydration infusion rate
has to be adjusted to replace the
patient's urine output. When the rate of
urine output is >300 ml/h, patients
undergo the coronary procedure.
Matched fluid replacement maintained




of standard hydration is not indicated. III A 405
Infusion of sodium bicarbonate 0.84%




Prophylactic haemofiltration 6 hours
before complex PCI may be considered.
Fluid replacement rate 1000 ml/h
without negative loss and saline
hydration continued for 24 hours
after the procedure.
IIb B 407–409
Prophylactic renal replacement therapy
is not recommended as a preventive
measure.
III B 409,410
AKI = acute kidney injury; CIN = contrast-induced nephropathy; CKD = chronic kidney disease; GFR = glomerular filtration rate; LV = left ventricular; MDCT =




dEspecially in patients with eGFR <40 ml/min/1.73 m2.
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implantation (TAVI) [420], a recent single-centre investigation
found an increased risk of cardiovascular adverse events among
patients with advanced CAD (SYNTAX score >22) [421]. PCI,
among patients with CAD undergoing TAVI, does not appear to in-
crease the short-term risks of death, myocardial infarction, or
stroke, compared with patients undergoing isolated TAVI;
however, its impact on long-term prognosis is not well established
[422–425]. The selection of lesions treated by PCI is usually based
on clinical presentation and angiography, as functional methods
of detecting ischaemia have not been validated among patients
with severe aortic stenosis [422,423,426–428]. Currently, there is
no conclusive evidence as to whether PCI should be performed as
a staged intervention or during the same procedure, and the deci-
sion may be made on an individual basis according to the leading
clinical problem, renal failure, and complexity of the underlying
CAD [422,424,425,428,429]. Published experience with PCI and
percutaneous mitral valve repair is currently limited to case
reports.
Alternative treatments for high-risk patients also include
‘hybrid’ procedures, which involve a combination of scheduled
surgery for valve replacement and planned PCI for myocardial
revascularization. At present, however, the data on hybrid valve/
PCI procedures are very limited, being conﬁned to case reports
and small case series [430]. Individual treatment decisions in these
complex patients are best formulated by the Heart Team.
12.2 Primary indication for coronary
revascularization
Many patients with CAD and reduced LV function have concomi-
tant secondary mitral regurgitation. Observational data from the
STICH trial suggest that adding mitral valve repair to CABG in
patients with LV dysfunction (LVEF ≤35%) and moderate-to-severe
mitral regurgitation offers better survival than CABG alone [431].
Likewise, in patients undergoing CABG for the clinically leading
Recommendations for combined valvular and coronary interventions
Recommendations Classa Levelb Refc
Diagnostic modalities
Coronary angiography is recommended before valve surgery in patients with severe valvular heart
disease and any of the following:
• history of CAD
• suspected myocardial ischaemia
• LV systolic dysfunction
• in men aged over 40 years and in postmenopausal women
• 1 cardiovascular risk factor for CAD.
I C –
Coronary angiography is recommended in the evaluation of secondary
mitral regurgitation.
I C –
CT angiography should be considered before valve surgery in patients with severe valvular heart
disease and low probability for CAD or in whom conventional coronary angiography is technically
not feasible or of high risk.
IIa C –
Primary valve intervention and coronary revascularization
CABG is recommended in patients with a primary indication for aortic/mitral valve surgery and
coronary artery diameter stenosis >70% in a major epicardial vessel.
I C –
CABG should be considered in patients with a primary indication for aortic/mitral
valve surgery and coronary artery diameter stenosis 50–70% in a major epicardial
vessel.
IIa C –
PCI should be considered in patients with a primary indication to undergo TAVI and coronary
artery diameter stenosis >70% in proximal segments.
IIa C –
PCI should be considered in patients with a primary indication to undergo
transcatheter mitral valve interventions and coronary artery diameter stenosis >70% in proximal
segments.
IIa C –
Primary revascularization and non-coronary intervention
Mitral valve surgery is indicated in patients with severe mitral regurgitation
undergoing CABG, and LVEF >30%. I C –
Mitral valve surgery should be considered in patients with moderate mitral
regurgitation undergoing CABG to improve symptoms. IIa B 432
Repair of moderate-to-severe mitral regurgitation should be considered in patients
with a primary indication for CABG and LVEF 35%.
IIa B 431
Stress testing should be considered in patients with a primary indication for CABG and moderate
mitral regurgitation to determine the extent of ischaemia and regurgitation.
IIa C –
Aortic valve surgery should be considered in patients with a primary indication for CABG and
moderate aortic stenosis (defined as valve area 1.0–1.5 cm2 [0.6 cm2/m2 0.9 cm2/m2
area] or mean aortic gradient 25–40 mmHg in the presence of normal flow conditions).
IIa C –to body surface
CABG = coronary artery bypass grafting; CAD = coronary artery disease; CT = computed tomography; LV = left ventricular; LVEF = left ventricular ejection
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problem of CAD, aortic valves with moderate stenosis should be
replaced [411]. Case-by-case decisions by the Heart Team are
needed for patients with an indication for PCI and moderate-to-
severe valve disease.
13. ASSOCIATED CAROTID/PERIPHERAL ARTERY
DISEASE
13.1 Associated coronary and carotid artery
disease
The prevalence of severe carotid artery stenosis increases with the
severity of CAD and is an indicator of impaired prognosis [433].
Although the association between carotid artery stenosis and CAD
is evident, the prevalence of signiﬁcant carotid artery stenosis in
the entire cohort remains relatively low. Conversely, up to 40% of
patients undergoing carotid endarterectomy (CEA) have signiﬁ-
cant CAD and may beneﬁt from pre-operative cardiac risk assess-
ment.
13.1.1 Risk factors for stroke associated with myocardial
revascularization. The incidence of stroke after CABG varies
depending on age, comorbidities and surgical technique. The
FREEDOM trial, which compared PCI with CABG in diabetic patients
with multivessel CAD, showed a 30-day rate of stroke of 1.8% after
CABG and 0.3% after PCI (P = 0.002) [175]. Similarly, a greater risk of
stroke was reported in the SYNTAX trial, which diminished during
long-term follow-up and was no longer signiﬁcant at 5 years (CABG
3.7% vs. PCI 2.4%; P = 0.09) [17]. In a meta-analysis of 19 randomized
trials with 10 944 patients, the risk of strokewas lower among patients
assigned to PCI than in those assigned to CABG after 30 days and at 1
year [131]. These ﬁndings indicate that CABG carries a greater
periprocedural risk of stroke but that the long-term risk of
cerebrovascular events persists with both treatments [17]. The most
common cause of CABG-related stroke is embolization of
atherothrombotic debris from the ascending aorta, particularly
during aortic cannulation. The risk of periprocedural stroke after
CABG in patients with carotid artery stenosis is associated with the
severity of stenosis but even more with a history of stroke or transient
ischaemic attack (TIA) (within 6 months) [434]. There is a lack of
strong evidence that CAD is a signiﬁcant cause of perioperative stroke
[435]. The extension of atherosclerotic disease to intracerebral and
extracerebral territories, radiographic demonstration of previous
stroke and aortic atheromatous disease, are the most important
factors for predicting an increased risk of perioperative stroke [435].
Although symptomatic carotid artery stenosis is associated with
a greater risk of stroke, 50% of patients suffering strokes after
CABG do not have signiﬁcant carotid artery disease and 60% of
territorial infarctions on CT scan/autopsy cannot be attributed to
carotid disease alone. Furthermore, only around 40% of strokes
following CABG are identiﬁed within the ﬁrst day after surgery,
while 60% of strokes occur after uneventful recovery from anaes-
thesia. In a recent study including 45 432 patients undergoing
CABG, 1.6% experienced a stroke and risk factors for all strokes
were age, smaller body surface area, emergency surgery, previous
stroke, pre-operative atrial ﬁbrillation (AF), and on-pump CABG
with hypothermic circulatory arrest. For intraoperative strokes,
additional risk factors were peripheral and carotid artery disease,
previous cardiac surgery, worse clinical condition, LV dysfunction,
left circumﬂex (LCx) coronary artery stenosis >70%, and on-pump
CABG with arrested heart or hypothermic circulatory arrest [436].
Although the risk of stroke is low among patients with carotid
artery disease undergoing PCI, ACS, heart failure, and extensive
atherosclerosis are independent risk factors for this adverse event.
In a large registry of 348 092 PCI patients, the rates of stroke and
TIA amounted to only 0.11% and did not differ between transfe-
moral and radial access [437].
13.1.2 Preventive measures to reduce the risk of stroke
after coronary artery bypass grafting. Detection of severe
carotid artery bifurcation disease may lead to concomitant carotid
revascularization in selected cases. Identiﬁcation of an
atherosclerotic aorta is believed to be an important step in
reducing the risk of stroke after CABG. Pre-operative CT scan or
intraoperative ultrasound epiaortic scanning—better than aortic
palpation—can lead to modiﬁcations in the operative
management that may reduce the risk of stroke associated with
CABG [438,439]. There is conﬂicting evidence regarding the
inﬂuence of off-pump CABG on the incidence of stroke [440]. A
recent randomized trial showed no difference in the incidence of
stroke between off-pump CABG and on-pump CABG at 30 days
[441]. However, studies employing a ’minimal touch’ technique for
the aorta reported a lower risk of stroke and MACCE with
off-pump CABG [442,443].
Perioperative medical therapy plays a fundamental role in the
prevention of neurological complications following CABG. Statins
in combination with beta-blockers have shown a protective effect
on the risk of stroke after CABG [444].
Carotid artery screening before CABG
Recommendations Classa Levelb Ref c
In patients undergoing CABG, Doppler
ultrasound scanning is recommended in
patients with a history of stroke/TIA or
carotid bruit.
I C
Doppler ultrasound should be
considered in patients with multivessel
CAD, PAD, or >70 years of age.
IIa C
MRI, CT, or digital subtraction
angiography may be considered if
carotid artery stenosis by ultrasound is
>70% and myocardial revascularization
is contemplated.
IIb C
Screening for carotid stenosis is not
indicated in patients with unstable CAD
requiring emergency CABG with no
recent stroke/TIA.
III B 433
CABG = coronary artery bypass grafting; CAD = coronary artery disease;
CT = computed tomography; MRI = magnetic resonance imaging;




13.1.3 Carotid revascularization in patients scheduled for
myocardial revascularization. In patients with previous TIA or
stroke and the presence of carotid artery stenosis (50–99% in men;
70–99% in women), CEA performed by experienced teams may
reduce the risk of perioperative stroke or death [434]. Conversely,
isolated myocardial revascularization should be performed
among patients with asymptomatic unilateral carotid artery
stenosis because of the small risk reduction in stroke and death
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achieved by concomitant carotid revascularization (1% per year)
[434]. Carotid revascularization may be considered in
asymptomatic men with bilateral severe carotid artery stenosis or
contralateral occlusion, provided that the risk of stroke or death
within 30 days can be reliably documented to be <3% in the
presence of a life expectancy >5 years. In women with
asymptomatic carotid disease or patients with a life expectancy of
<5 years, the beneﬁt of carotid revascularization remains unclear
[434]. In the absence of clear proof that staged or synchronous
CEA or carotid artery stenting (CAS) is beneﬁcial in patients
undergoing CABG, patients should be assessed on an individual
basis by a multidisciplinary team including a neurologist. This
strategy is also valid for patients scheduled for PCI. The strategy of
combining PCI with CAS in the same procedure in elective
patients is not routinely recommended, except in the infrequent
circumstance of concomitant acute severe carotid and coronary
syndromes.
13.1.4 Type of revascularization in patients with
associated carotid and coronary artery disease. Few patients
scheduled for CABG require synchronous or staged carotid
revascularization [445–448]. In the absence of randomized trials
comparing management strategies in patients with concomitant
CAD and carotid disease, the choice of carotid revascularization
modality (CEA vs. CAS) should be based on patient comorbidities,
supra-aortic vessel anatomy, degree of urgency for CABG and
local expertise [449]. Operator proﬁciency impacts on results of
both carotid revascularization methods but even more in CAS,
with higher mortality rates in patients treated by low-volume
operators or early in their experience [450]. If CAS is performed
before elective CABG, the need for dual antiplatelet therapy
(DAPT) usually delays cardiac surgery for 4–5 weeks [451,452].
Type of carotid artery revascularization
Recommendations Classa Levelb Refc
Choice of carotid revascularization
modality (CEA vs. CAS) in patients
undergoing CABG should be
based on patient comorbidities,
supra-aortic vessel anatomy,





ASA is recommended immediately
before and after carotid
revascularization.
I A 454
Dual antiplatelet therapy with ASA
and clopidogrel is recommended
for patients undergoing CAS for a
duration of at least 1 month.
I B 455,456
CAS should be considered in
patients with:
• post-radiation or post-
surgical stenosis
• obesity, hostile neck,
tracheostomy, laryngeal
palsy
• stenosis at different






ASA = acetylsalicylic acid; CABG = coronary artery bypass grafting;




Carotid artery revascularization in patients scheduled for CABG
Recommendations Classa Levelb Ref c
CEA or CAS should be performed by teams achieving a combined death/stroke rate at
30 days of:
<3% in patients without previous neurological symptoms
<6% in patients with previous neurological symptoms.
I A 434
It is recommended to individualize the indication for carotid revascularization after discussion by a
multidisciplinary team including a neurologist. I C
The timing of the procedures (synchronous or staged) should be determined by local expertise and
clinical presentation, targeting the most symptomatic territory first. IIa C
In patients with a <6-month history of TIA/stroke
Carotid revascularization is recommended for 70–99% carotid stenosis. I C
Carotid revascularization may be considered for 50–69% carotid stenosis depending on patient
-specific factors and clinical presentation. IIb C
In patients with no previous TIA/stroke within 6 months
Carotid revascularization may be considered in men with bilateral 70–99% carotid stenosis or 70–99%
carotid stenosis and contralateral occlusion.
IIb C
Carotid revascularization may be considered in men with 70–99% carotid stenosis and ipsilateral
previous silent cerebral infarction.
IIb C
CABG = coronary artery bypass grafting; CAS = carotid artery stenting; CEA = carotid endarterectomy; TIA = transient ischaemic attack.
The term carotid artery stenosis refers to a stenosis of the extracranial portion of the internal carotid artery, and the degree of stenosis is according to the
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13.2 Associated coronary and peripheral arterial
disease
Peripheral artery disease (PAD) is an important predictor of
adverse outcome after myocardial revascularization, and portends
a poor long-term outcome [457,458]. Patients with clinical evi-
dence of PAD are at increased risk for procedural complications
after either PCI or CABG. When comparing the outcomes of CABG
vs. PCI in patients with PAD and multivessel disease, CABG is asso-
ciated with a trend for better survival. Risk-adjusted registry data
have shown that patients with multivessel disease and PAD under-
going CABG have better survival at 3 years than similar patients
undergoing PCI, in spite of higher in-hospital mortality. In the
case of CABG, surgeons should avoid harvesting veins from legs
that are affected by signiﬁcant clinical symptoms of PAD; however,
with no solid data available in this population, the two myocardial
revascularization approaches are probably as complementary in
patients with PAD as they are in other CAD patients.
Non-cardiac vascular surgery in patients with associated coron-
ary artery disease
Patients scheduled for non-cardiac vascular surgery are at
greater risk of cardiovascular morbidity and mortality due to a
high incidence of underlying symptomatic or asymptomatic CAD
[451,459]. Results of the largest RCT have demonstrated that,
among 510 patients randomized to prophylactic myocardial
revascularization (by either PCI or CABG) or to medical therapy
alone, there is no advantage in terms of incidence of perioperative
myocardial infarction, early or long-term mortality before major
vascular surgery [460]. Patients included in this study had pre-
served LV function and SCAD. A RCT with 208 patients at moder-
ate or high cardiac risk, who were scheduled for major vascular
surgery, reported similar results: patients undergoing systematic
pre-operative coronary angiography and revascularization had
similar in-hospital outcomes but greater freedom from cardiovas-
cular events at 4 years than with a selective strategy [461]. In
summary, selected high-risk patients may beneﬁt from staged or
concomitant myocardial revascularization, with options varying
from a one-stage surgical approach to combined PCI and periph-
eral endovascular repair or hybrid procedures.
RCTs involving high-risk patients, cohort studies, and
meta-analyses provide consistent evidence, in patients undergoing
high-risk non-cardiac vascular surgery or endovascular procedures,
of lower incidences of cardiac mortality and myocardial infarction
related to medical therapy including statins [458]. In summary,
perioperative cardiovascular complications are common in PAD
patients with associated CAD and result in signiﬁcant morbidity fol-
lowing non-cardiac vascular surgery. All patients require pre-
operative screening to identify and minimize immediate and future
risk, with a careful focus on known CAD, risk factors for CAD, and
functional capacity [451,462].
14. REPEAT REVASCULARIZATION AND HYBRID
PROCEDURES
14.1 Early graft failure
Early graft failure after CABG is reported in up to 12% of grafts (left
IMA 7%; saphenous vein graft 8%) as evaluated by intraoperative
angiographic control [463], but only a minority, around 3%, are
clinically apparent [464]. Graft failure can be due to conduit
defects, anastomotic technical errors, poor native vessel run-off,
or competitive ﬂow with the native vessel. When clinically rele-
vant, acute graft failure may result in myocardial infarction with
consequently increased mortality and major cardiac events. The
suspicion of graft failure should arise in the presence of ECG signs
of ischaemia, ventricular arrhythmias, important biomarker modi-
ﬁcations, new wall motion abnormalities, or haemodynamic in-
stability [465]. Owing to the low speciﬁcity of ECG modiﬁcations
and echocardiographic wall motion abnormalities during the
post-operative course and the delay in appearance of biomarker
changes, a careful assessment of all variables will inﬂuence the
decision-making for angiographic evaluation.
Perioperative angiography is recommended in cases of sus-
pected myocardial ischaemia to detect its cause and help decide
on appropriate treatment [463,465,466]. In symptomatic patients,
early graft failure can be identiﬁed as the cause of ischaemia in
about 82% of cases [467]. In early post-operative graft failure,
emergency PCI may limit the extent of myocardial infarction com-
pared with re-do surgery [467]. The target for PCI is the body of
the native vessel or the IMA graft, while the acutely occluded sa-
phenous vein graft (SVG) and the anastomosis should be avoided
due to concerns over embolization or perforation. Re-do surgery
should be favoured if anatomy is unsuitable for PCI, or if several im-
portant grafts are occluded. Early mortality in the range of 9–15%
has been reported in this group of patients, without any difference
between the two revascularization strategies [467]. In asymptomatic
patients, repeat revascularization should be considered if the artery
is of appropriate size and supplies a large territory of myocardium.
The optimal treatment strategy in patients with acute graft failure
should be decided by ad hoc consultation between cardiovascular
Management of patients with associated CAD and PAD
Recommendations Classa Levelb Refc
In patients with ACS, it is
recommended to postpone
vascular surgery and first treat
CAD, except when vascular
surgery cannot be delayed due
to a life- or limb-threatening
condition.
I C
The choice between CABG and
PCI should follow the
general recommendations
for revascularization considering





risk vascular surgery may be
considered in stable patients if
they have persistent signs of
extensive ischaemia or are at
high cardiac risk.d
IIb B 461,462
ACS = acute coronary syndrome; CABG = coronary artery bypass
grafting; CAD = coronary artery disease; PAD = peripheral artery




d High cardiac risk (reported cardiac risk often >5%): 1) aortic and other
major vascular surgery; 2) peripheral vascular surgery [462].
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surgeon and interventional cardiologist, on the basis of the patient’s
clinical condition and extent of myocardium at risk.
14.2 Disease progression and late graft failure
Ischaemia after CABG may be due to progression of disease in
native vessels or disease of bypass grafts (Table 9). Repeat revascu-
larization in these patients is indicated in the presence of signiﬁ-
cant symptoms despite medical treatment, and in asymptomatic
patients with objective evidence of myocardial ischaemia (>10%
LV) [54,143]. The survival of patients with patent left IMA to LAD
and ischaemia in the territories of the right- and circumﬂex arter-
ies does not appear to be inﬂuenced by mechanical revasculariza-
tion when compared with medical therapy alone [468].
Re-do coronary artery bypass grafting or percutaneous coron-
ary intervention
Percutaneous coronary intervention in patients with previous
CABG has worse acute and long-term outcomes than in patients
without prior CABG. Re-do CABG has a two- to four-fold
increased mortality compared with ﬁrst-time CABG [477,478].
There are limited data comparing the efﬁcacy of PCI vs. re-do
CABG in patients with previous CABG. In the Angina With
Extremely Serious Operative Mortality Evaluation (AWESOME)
RCT and registry, overall in-hospital mortality was higher with
re-do CABG than with PCI [151,479]. More recent observational
data have shown similar long-term results in patients treated by
re-do CABG and PCI, with a higher revascularization rate for the
PCI group [479,480]. In view of the higher risk of procedural mor-
tality with re-do CABG and the similar long-term outcome, PCI is
the preferred revascularization strategy in patients with patent left
internal mammary artery (LIMA) and amenable anatomy. CABG is
preferred for patients with extensively diseased or occluded
bypass grafts, reduced systolic LV function, several total occlusions
of native arteries and absence of patent arterial grafts. The IMA is
the conduit of choice for revascularization during re-do CABG
[481].
Percutaneous coronary intervention via the by-passed native
artery should be the preferred approach provided the native
vessel is not chronically occluded. Percutaneous coronary inter-
vention for a chronic total occlusion (CTO) may be indicated
when ischaemic symptoms are present with evidence of signiﬁ-
cant ischaemia and viable myocardium in the territory supplied. If
PCI in the native vessel fails, PCI in the diseased SVG remains an
option.
Percutaneous coronary intervention for saphenous vein graft
lesions
Percutaneous coronary intervention for SVGs is associated with
an increased risk of distal coronary embolization, resulting in peri-
procedural myocardial infarction [482]. Percutaneous coronary
intervention of de-novo SVG stenosis is considered a high-risk
intervention because SVG atheroma is friable and more prone to
distal embolization. A pooled analysis of ﬁve RCTs reported that GP
IIb/IIIa inhibitors are less effective for interventions in SVGs than in
native vessels [483]. Several different approaches have been evalu-
ated to prevent distal embolization of particulate debris, including
distal occlusion/aspiration, proximal occlusion, suction, ﬁlter
devices or mesh-covered stents [484]. Unlike occlusive devices,
distal protection using ﬁlters offers the inherent advantage of main-
taining antegrade perfusion and the opportunity for contrast injec-
tions. Combined data, mostly from comparative studies between
devices and surrogate endpoints, support the use of distal embolic
protection during SVG PCI [485,486]. In an RCT comparing different
distal-protection devices in SVG PCI, the only independent predict-
or of 30-day MACE was plaque volume, and not the type of protec-
tion device used [487]. Experience with other devices used for SVG
PCI, such as mesh-based stents, is limited [488].
Implantation of DES in SVG lesions is associated with a lower risk
of repeat revascularization than with BMS [489–497]. In the Swedish
Coronary Angiography and Angioplasty Registry (SCAAR) of 3063
procedures with 4576 stents—including BMS and DES in SVG
lesions—the incidence of death was lower among patients who
received DES [489]. However, no differences in terms of death,
myocardial infarction, or stent thrombosis were observed in the
randomized Is Drug-Eluting-Stenting Associated with Improved
Results in Coronary Artery Bypass Grafts (ISAR-CABG) trial [495].
Long-term results (up to 7 years post-procedure) of early-
generation DES in SVG lesions are satisfactory, with no excess risk
of stent thrombosis and maintained lower rate of restenosis than
with BMS [494,496]. Compared with PCI of native coronary
vessels, patients undergoing PCI of SVGs have impaired long-term
clinical outcomes [498].
14.3 Acute percutaneous coronary intervention
failure
Most PCI-related complications (including dissections, vessel oc-
clusion, intracoronary thrombosis, and coronary perforation) are
successfully treated in the catheterization laboratory [499,500],
Table 9: Graft patency after CABG
Graft Patency at  1 year Patency at 4-5 years Patency at  ≥10 years References
Saphenous vein graft 75–95% 65–85% 32–71% 473–477
Radial artery 92–96% 90% 63–83% 473,474,478–480
Left IMA >95% 90–95% 88–95% 475,480
Right IMA >95% >90% 65–90% 475
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on-site or stand-by surgery is therefore not required during these
procedures. The need for urgent surgery to manage PCI-related
complications is uncommon and only required in patients with
major complications that cannot be adequately resolved by per-
cutaneous techniques [499,500]. This is mainly conﬁned to
patients with a large, evolving myocardial infarction due to iatro-
genic vessel occlusion that cannot be salvaged percutaneously,
and to those with iatrogenic cardiac tamponade with failed peri-
cardiocentesis or recurrent tamponade [499,500]. When severe
haemodynamic instability is present, IABP or mechanical circula-
tory assistance may be desirable before emergency surgery.
14.4 Repeat percutaneous coronary intervention
Recurrence of symptoms or ischaemia after PCI is the result of re-
stenosis, incomplete initial revascularization, or disease progres-
sion. Infrequently, patients may require repeat PCI due to late and
very late stent thrombosis.
Restenosis
Restenosis associated with angina or ischaemia should be
treated by repeat revascularization and repeat PCI remains the
strategy of choice for these patients if technically feasible.
Originally, balloon angioplasty was frequently used in this setting,
with good initial results but high rates of recurrence [501,502].
Bare-metal stents provided superior early results in patients with
in-stent restenosis but produced unfavourable late outcomes and
were therefore reserved for patients with suboptimal initial results
after balloon angioplasty or for those with large vessels [501,502].
Ablative techniques (including rotational atherectomy and laser)
have failed to improve results in such patients. Although brachy-
therapy was effective for in-stent restenosis, it never achieved
widespread use, mainly due to logistical issues. Currently DES im-
plantation is recommended in patients with BMS or DES in-stent
restenosis. In this setting, the results from DES are superior to
those obtained with balloon angioplasty, BMS implantation or
brachytherapy [501–505]. Drug-coated balloons are also effective
in these patients and are particularly attractive when more than
two stent layers are already present in the vessel. Drug-coated bal-
loons are superior to balloon angioplasty and give results similar
to early-generation DES in patients with BMS or DES in-stent re-
stenosis [506–512]. The use of intracoronary imaging may provide
insights into the underlying mechanisms of in-stent restenosis.
The presence of an underexpanded stent should, if possible, be
corrected during the repeat procedure. In patients with recurrent
episodes of diffuse in-stent restenosis—and in those with asso-
ciated multivessel disease, especially in the presence of other
complex lesions such as chronic total occlusions—CABG should be
considered before a new PCI attempt.
Disease progression
Patients with symptomatic disease progression after PCI account
for up to 50% of re-interventions [513,514]. They should be
managed using criteria similar to patients without previous revascu-
larization if angiographic and functional results of previous inter-
ventions remain satisfactory. Percutaneous coronary intervention is
an excellent therapy for these patients but care should be taken to
identify the sites of prior patent stents as, occasionally, these may
complicate re-interventions in the same vessel. Preventive pharma-
cological strategies should be maximized in this population.
Stent thrombosis
Although stent thrombosis is very rare it may have devastating
clinical consequences. Stent thrombosis usually presents as a large
myocardial infarction and patients should undergo emergency
primary PCI [515]. Owing to the rarity of this complication, the inter-
ventional strategy of choice remains unsettled but the use of throm-
boaspiration and intracoronary IIb/IIIa platelet inhibitors is
frequently advocated. Aggressive, high-pressure balloon dilation
should be used to correct underlying, stent-related, predisposing,
mechanical problems [516]. In this challenging setting, it has been
suggested that intracoronary diagnostic techniques be used to
correct mechanical problems and optimize ﬁnal results [516,517].
While optical coherence tomography (OCT) provides superior near-
ﬁeld resolution to intravascular ultrasound imaging (IVUS) and is
able to identify red thrombus, thrombus shadowing may interfere
with imaging of the underlying structures [516]. Some patients with
very late stent thrombosis actually have neoatherosclerosis as the
underlying pathological substrate, and this can be recognized with
intracoronary imaging [516]. Although the value of repeat stenting in
patients with stent thrombosis is under debate and should be
avoided when satisfactory results are obtained with balloon dilation,
a new stent may be required to overcome edge-related dissections
and adjacent lesions or to optimize ﬁnal results [517]. Detection and
correction of any predisposing thrombogenic milieu remains im-
portant during these interventions [516].
Adequate inhibition of platelet aggregation is of great importance
in minimizing the risk of stent thrombosis, as well as its recurrence.
Hence, in patients presenting with stent thrombosis, particular care
should be taken to select the most appropriate P2Y12 inhibitor and
ensure the importance of compliance by adequate patient informa-
tion. There is no evidence to suggest that platelet function testing is
effective in guiding the decision-making process with respect to
type of P2Y12 inhibitor in this speciﬁc setting. Since prasugrel and
ticagrelor lower the risk of primary ST [341,518], these agents should
be preferred over clopidogrel, if clinically indicated. Duration of
treatment should be at least 12 months after the acute event and
potentially longer if well tolerated. In cases where these new agents
are not available or contra-indicated, doubling the dose of clopido-
grel may be reasonable [519].
14.5 Hybrid procedures
Hybrid myocardial revascularization is a planned intervention com-
bining cardiac surgery with a catheter-based intervention per-
formed within a predeﬁned time [520–523]. Procedures can be
performed consecutively in a hybrid operating room, or sequential-
ly on separate occasions in the conventional surgical and PCI envir-
onments. The Heart Team discussion and the design of a joint
strategy are critical for these patients. Hybrid procedures consisting
of IMA to LAD and PCI of other territories appear reasonable when
PCI of the LAD is not an option or is unlikely to portend good long-
term results or when achieving a complete revascularization during
CABG might be associated with an increased surgical risk [520,521].
Although in most centres the number of hybrid procedures is rela-
tively small, it remains important to consider when they may be
clinically indicated. Options include:
(1) Selected patients with single-vessel disease of the LAD, or in
multivessel disease but with poor surgical targets except for
the LAD territory, in whom minimally invasive direct coronary
artery bypass grafting (MIDCAB) can be performed to graft the
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LAD using the LIMA. The remaining lesions in other vessels are
subsequently treated by PCI.
(2) Patients who had previous CABG and now require valve
surgery, and who have at least one important patent graft (e.g.
IMA to LAD) and one or two occluded grafts with a native
vessel suitable for PCI.
(3) Combination of revascularization with non-sternotomy valve
intervention (e.g. PCI and minimally invasive mitral valve
repair, or PCI and transapical aortic valve implantation).
In addition, some patients with complex multivessel disease
presenting with STEMI initially require primary PCI of the
culprit vessel, but subsequently may require complete surgi-
cal revascularization. A similar situation occurs when patients
with combined valvular and CAD require urgent revasculari-
zation with PCI. Finally, when a heavily calciﬁed aorta is
found in the operating room the surgeon may elect not
to attempt complete revascularization and to offer delayed
PCI.
Repeat revascularization
Recommendations Classa LoEb Ref c
Early post-operative ischaemia and graft failure
Coronary angiography is recommended for patients with:
• symptoms of ischaemia and/or abnormal biomarkers suggestive of perioperative myocardial infarction
• ischaemic ECG changes indicating large area of risk
• new significant wall motion abnormalities
• haemodynamic instability.
I C
It is recommended to make the decision on re-do CABG or PCI by ad hoc consultation in the Heart Team
and based on feasibility of revascularization, area at risk, comorbidities and clinical status.
PCI should be considered over re-operation in patients with early ischaemia after CABG if technically feasible.
I C
IIa C
If PCI is performed, revascularization of the native vessels or IMA grafts rather than occluded or heavily




Repeat PCI is recommended, if technically feasible. I C
DES are recommended for the treatment of in-stent restenosis (within BMS or DES). I A
501,502,508
511,524
Drug-coated balloons are recommended for the treatment of in-stent restenosis (within BMS or DES). I A 507– 511,524
IVUS and/or OCT should be considered to detect stent-related mechanical problems. IIa C
Stent thrombosis
Emergency PCI is recommended to restore stent and vessel patency and myocardial reperfusion. I C
DAPT with use of potent P2Y12 inhibitors (prasugrel or ticagrelor) is recommended over clopidogrel. I C
Adjunctive thrombus aspiration and high-pressure balloon dilation should be considered. IIa C
IVUS and/or OCT should be considered to detect stent-related mechanical problems. IIa C
Hybrid procedures
Hybrid procedure, defined as consecutive or combined surgical and percutaneous revascularization may be
considered in specific patient subsets at experienced centres. IIb C
Disease progression and late graft failure
I B 54,143
PCI should be considered as a first choice if technically feasible, rather than re-do CABG. 
PCI of the bypassed native artery should be the preferred approach, if technically feasible. 
IMA, if available, is the conduit of choice for re-do CABG.
Re-do CABG should be considered for patients without a patent IMA graft to the LAD.







PCI may be considered in patients with patent IMA graft if technically feasible.
DES are recommended for PCI of SVGs.
Distal protection devices are recommended for PCI of SVG lesions if technically feasible.
IIb C
I A 489–495
Repeat revascularization is indicated in patients with severe symptoms or extensive ischaemia despite medical
therapy if technically feasible.
BMS = bare-metal stent; CABG = coronary artery bypass grafting; CTO = chronic total occlusions; DAPT = dual antiplatelet therapy; DES = drug-eluting stent;
ECG = electrocardiogram; IMA = internal mammary artery; LAD = left anterior descending artery; IVUS = intravascular ultrasound; LV = left ventricular;
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15. ARRHYTHMIAS
15.1 Ventricular arrhythmias
15.1.1 Revascularization for prevention of sudden cardiac
death in patients with stable coronary artery disease and
reduced left ventricular function. Revascularization plays
an important role in reducing the frequency of ventricular
arrhythmias in normal and mildly reduced LV function (CASS
study [525]. European Coronary Surgery Study) [109]. Thus,
revascularization signiﬁcantly decreased the risk for sudden
cardiac death in patients with CAD and LVEF <35% [Studies of Left
Ventricular Dysfunction (SOLVD)] [526]. Likewise, simultaneous
ICD implantation during CABG did not improve survival in
patients with reduced LV function (CABG Patch) [527]. Conversely,
an adjusted increased risk of ventricular tachycardia (VT) or
ventricular ﬁbrillation (VF) of 5% or 8%, respectively, was observed
with every 1-year increment of time elapsed from revascularization,
irrespective of the mode of revascularization, potentially related
to a gradual progression of CAD (Multicenter Automatic
Deﬁbrillator Implantation Trial – Cardiac Resynchronization Therapy
(MADIT-CRT) [528]. Indirect evidence for a protective effect of
coronary revascularization in terms of sudden cardiac death is
provided by retrospective analysis of data from the Multicentre
Automatic Deﬁbrillator Implantation Trial II (MADIT II) and
Sudden Cardiac Death in Heart Failure Trial (SCD-HEFT) studies, in
which ICD implantation was performed for primary prophylaxis of
sudden cardiac death in patients with CAD and an ejection
fraction <30–35%, respectively. In these studies, ICD implantation
did not reduce sudden death if revascularization had been
performed within 6 months (MADIT II [608] or 2 years (SCD-HEFT
[529] prior to ICD implantation. Finally, the STICH trial, which
investigated the effect of revascularization (CABG) in patients with
reduced LV function (<35%) revealed a non-signiﬁcant trend
towards lower overall mortality in the CABG group but a
signiﬁcant beneﬁt in cardiovascular endpoints (e.g. death from
cardiac causes including sudden death) [112]. Because of the
protective effect of revascularization of ventricular arrhythmias,
patients with ischaemic LV dysfunction (LVEF <35%) who are
considered for primary preventive ICD implantation should be
evaluated for residual ischaemia and for potential
revascularization targets.
Since revascularization by CABG led to a 46% risk reduction of
sudden cardiac death in the SOLVD study, and in view of the low
risk for sudden cardiac death within 2 years after revascularization
in MADIT-II, reassessment of LV function up to 6 months after
revascularization may be considered before primary preventive
ICD implantation in patients with CAD and LVEF <35%. This is
based on the observation that reverse LV remodelling and im-
provement of LV function may occur up to 6 months after revas-
cularization procedures [530,531].
15.1.2 Revascularization for treatment of electrical storm.
Electrical storm is a life-threatening syndrome related to incessant
ventricular arrhythmias, which is most frequently observed in
patients with ischaemic heart disease, advanced systolic heart
failure, valve disease, corrected congenital heart disease, and
genetic disorders such as Brugada syndrome, early repolarisation
and long-QT syndromes. In the MADIT-II study, the occurrence of
interim post-enrolment ischaemic events (angina or myocardial
infarction) was independently predictive of the electrical storm,
although there was no close correlation between the timing of the
two [532]. Urgent coronary angiography and revascularization
should be part of the management of patients with electrical
storm, as well as antiarrhythmic drug therapy and/or ablation of
ventricular tachycardia.
15.1.3 Revascularization after out-of-hospital cardiac
arrest. Approximately 70% of survivors of out-of-hospital cardiac
arrest have CAD, with acute vessel occlusion observed in 50%
[533]. Multiple non-randomized studies suggest that emergency
coronary angiography and PCI after out-of-hospital cardiac arrest
yields a favourable survival rate of up to 60% at 1 year, which is
considerably higher than the 25% overall survival rate in patients
with aborted cardiac arrest [534,535]. More recent data suggest
that almost one-quarter of patients, resuscitated from cardiac
arrest but without ST-segment elevation, show a culprit lesion
(either vessel occlusion or irregular lesion) [536,537]. Notably, in
the prospective Parisian Region Out of Hospital Cardiac Arrest
(PROCAT) registry, 96% of patients with STEMI and 58% without
STEMI after out-of-hospital cardiac arrest revealed at least one
signiﬁcant coronary artery lesion, and hospital survival rates
were signiﬁcantly higher if immediate PCI was performed
successfully [538,539]. Thus, in survivors of out-of-hospital cardiac
arrest, early coronary angiography and PCI—if appropriate—
should be performed irrespective of the ECG pattern if no obvious
non-cardiac cause of the arrhythmia is present [540].
15.2 Atrial arrhythmias
15.2.1 Atrial ﬁbrillation complicating percutaneous
coronary intervention. New-onset AF in patients undergoing
PCI occurs in 2–6% of procedures and increases with age,
pre-existing heart failure, acute myocardial infarction and arterial
hypertension [541–544]. Notably, new-onset AF (deﬁned as
change from sinus rhythm at admission to AF during/after PCI)
typically occurs during the ﬁrst 4 days after acute myocardial
infarction and is associated with impaired prognosis, more than
doubling the risk of death, congestive heart failure and stroke.
The use of oral anticoagulation in addition to antiplatelet
therapy appears to decrease the risk of stroke after PCI as found in
observational studies [543,545,546]. Information on the duration
of new-onset AF after PCI is scarce but most of these episodes are
probably of paroxysmal nature or are terminated by cardioversion
during the hospital stay. It is not clear whether AF represents an
independent risk factor for cardiovascular events after PCI, or
merely mirrors the severity of underlying heart disease.
Antithrombotic treatment for stroke prevention, in patients with
AF occurring during or after PCI, should follow the guidelines for
antithrombotic treatment of AF that occurs outside the setting of
PCI, although prospective studies are scarce (see section 18). A po-
tentially higher bleeding risk in this patient population should be
assessed as outlined in the ESC Guidelines for AF [547].
15.2.2 Atrial ﬁbrillation complicating coronary artery
bypass grafting. Continuous telemetry during the entire
hospital stay revealed that new-onset post-operative AF may
occur in one-third of patients undergoing isolated CABG [548].
The presence of post-operative AF after CABG is independently
associated with increased cardiac morbidity and mortality,
prolonged hospitalization, increased healthcare expenditure, and
poor long-term prognosis [549,550]. Several attempts to prevent
and manage post-operative AF have been evaluated, including
magnesium, statins, steroids and antioxidative drugs [547].
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Pre-operative anti-arrhythmic drug treatment may be initiated
but will have to be weighed against side-effects. Beta-blockers sig-
niﬁcantly decrease the risk of AF after CABG [551–557]. Because
beta-blockers are effective for prevention of post-operative AF
and can be applied with low risk, they are recommended for de-
creasing the incidence of AF after CABG; however, beta blockers
may be discontinued after CABG if AF was not present and other
reasons for beta-blockade do not apply (e.g. reduced LV systolic
function). The optimum treatment period before discontinuing
beta blockade is unknown but a 3-month period seems reason-
able, given the fact that the occurrence of post-operative AF
declines rapidly after CABG [631].
Amiodarone is effective in preventing post-operative AF
[552,558,559], but may cause bradycardia.
15.2.3 Post-operative atrial ﬁbrillation and stroke risk.
Post-operative AF carries a two- to fourfold increased risk for
embolic events. A recent analysis of >16 000 patients undergoing
CABG revealed that oral anticoagulation, initiated at discharge in
20% of patients with post-operative AF, led to a 22% relative risk
reduction for death [560]. In patients with post-operative AF, the
cumulative risk for embolic death increases during the ﬁrst year after
CABG and continues to increase until 2 years after surgery before
plateauing, thus indicating that stroke risk in CABG patients with
post-operative AF is not just a perioperative issue. Antithrombotic
treatment for stroke prevention in patients with post-operative AF
should follow the Guidelines for antithrombotic treatment of AF
occurring outside the setting of CABG [547]. Anticoagulation with
heparin or non-vitamin K antagonist oral anticoagulants (NOAC)
should be initiated if post-operative AF persists for more than 48
hours and should be maintained for at least 4 weeks after restoration
of sinus rhythm; longer in the case of stroke risk factors [547]. The
absence of documented AF during follow-up—even on subsequent
intensiﬁed monitoring for AF and stroke risk—should not necessarily
result in withholding anticoagulation therapy in light of the high
incidence of asymptomatic ‘silent’ AF episodes [561]. There are no
data on whether prophylactic intraoperative ablation of AF has an
impact on the occurrence of post-operative AF.
15.3 Concomitant surgical procedures for atrial
ﬁbrillation or stroke treatment
The original cut-and-sew ’maze’ procedure for AF, described by
Cox et al. [562]. included removal or ligation of the left atrial ap-
pendage (LAA). In addition, a retrospective analysis demonstrated
that surgical LAA occlusion independent of intraoperative AF
surgery reduces the risk of stroke [563]. Likewise, transcatheter
LAA occlusion in the Watchman Left Atrial Appendage System for
Embolic Protection in Patients with Atrial Fibrillation (PROTECT
AF) trial was non-inferior to oral anticoagulation with vitamin K
antagonists in patients with AF [564]. Whether surgical LAA oblit-
eration (which does not employ a prosthesis in direct contact with
the blood, thus potentially obviating the need for prolonged anti-
platelet/anticoagulation therapy) reduces stroke risk has not yet
been investigated in randomized, prospective studies. Currently,
concomitant surgical LAA obliteration may be considered to
reduce stroke risk in CABG patients with a history of AF, but rando-
mized studies are needed to further clarify this issue. Removal or
closure of the LAA should be considered as an adjunct to anticoa-
gulation and not as an alternative for anticoagulant therapy until
more and longer-term data are available.
Recommendations for treatment of arrhythmias after revas-
cularization
Recommendations Classa Levelb Ref c
Beta-blockers are recommended
to decrease the incidence of atrial






amiodarone should be considered
as prophylactic therapy for patients




The risk of stroke and embolism
is increased in patients with new-
onset atrial fibrillation during/after
PCI despite antiplatelet therapy.
Therefore, anticoagulation should
be considered following the guide-
lines for antithrombotic therapy of
atrial fibrillation occurring outside










stroke risk and contraindication
for long-term combined antiplatelet
+ oral anticoagulation therapy is
present.
IIb B 564,566
Since the risk of stroke and
embolism is increased in patients
with new-onset atrial fibrillation
after CABG, anticoagulation should
be considered for at least 3




removal of the LAA during CABG
may be considered for stroke redu-
ction in atrial fibrillation patients.
IIb C
Recommendations for prevention of ventricular arrhyth-
mias by revascularization
Recommendations Classa Levelb Ref c
In survivors of out-of-hospital
cardiac arrest, immediate
coronary angiography and reva-
scularization, if appropriate,
should be considered irres-
pective of the ECG pattern if no





In patients with electrical storm,




In patients with CAD and LVEF
<35%, testing for residual
ischaemia and subsequent
revascularization should be
considered prior to primary
prophylactic ICD implantation.
After revascularization, assess-
ment for reverse LV remod-
elling up to 6 months should be






AF = atrial fibrillation; CABG = coronary artery bypass grafting;
CAD = coronary artery disease; ECG = electrocardiogram;
ICD = implantable cardioverter defibrillator; LV = left ventricular;
LVEF = left ventricular ejection fraction; LAA = left atrial appendage;
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16. PROCEDURAL ASPECTS OF CORONARY
ARTERY BYPASS GRAFTING
16.1 Pre-operative management
Most patients admitted for surgical revascularization are already
medically treated with angiotensin-converting enzyme (ACE) inhi-
bitors, statins, antiplatelet drugs, beta-blockers, and/or other anti-
anginal drugs. Beta-blockers should not be stopped to avoid acute
ischaemia and statins should be continued until surgery—or
initiated if not previously introduced. Angiotensin-converting
enzyme inhibitors might be discontinued 1–2 days before CABG,
to avoid the potential deleterious consequences of perioperative
hypotension.
The section on antithrombotic and antiplatelet therapy (section
18) will cover perioperative care around CABG relating to this par-
ticular aspect.
16.2 Blood management
16.2.1 Blood salvage interventions. There is strong evidence
that use of cell-savers reduces allogenic blood product exposure
(OR 0.63; 95% CI 0.43–0.94; P < 0.02) but also reduces red blood
cells and the mean volume of total allogenic blood products
transfused per patient (P < 0.002) [569].
16.2.2 Pharmacological strategies. Antiﬁbrinolytic drugs are
effective in reducing blood loss, the need for allogenic red blood
cell transfusion, and the need for re-operation due to continued
post-operative bleeding in cardiac surgery [570]. Lysine analogues
(e.g. tranexamic acid) are effective and relatively free from serious
adverse events.
16.2.3 Blood transfusion. There is ample evidence that the
number of transfused red blood cell units is an independent risk
factor for worse outcomes after cardiac surgery [571,572].
Transfusion trigger to a target haematocrit of around 24% is as
safe as a liberal strategy of 30% with respect to 30-day mortality
and complications [573]. Platelet transfusion should be considered
in patients recently exposed to P2Y12 inhibitors if there are clinical




Saphenous vein harvest can be accomplished using open and
endoscopic techniques. Endoscopic vein graft harvesting, as well
as radial artery harvesting, have been introduced into clinical prac-
tice in the past decade. While a reduced rate of leg wound infec-
tion and impaired wound healing are well documented in almost
all studies, short- and long-term patency of endoscopically har-
vested vein grafts, compared with openly harvested grafts, has
been challenged [574,575]. Although there is no unequivocal evi-
dence concerning patency rates, most recent data from
meta-analyses and randomized and non-randomized trials do not
demonstrate inferior clinical outcomes with endoscopic vein
harvest [576–579]. Endoscopic vein graft harvest should be under-
taken by experienced surgeons or physician assistants with appro-
priate training and reasonable caseload [580–582]. Endoscopic
radial harvesting is likewise possible but robust clinical-scientiﬁc
evidence concerning its safety and efﬁcacy is scarce [583]. If
performed ‘open’, the ‘no-touch’ SVG harvesting technique may
reduce graft injury and improve patency [584,585].
Mammary artery harvesting
Internal mammary arteries are dissected from the chest wall,
either as a pedicle or as an isolated (skeletonized) vessel. While
the skeletonized technique has a higher theoretical potential for
injury during harvest, the beneﬁts include a longer conduit, more
versatility (sequential anastomosis), higher blood ﬂow and, most
importantly, fewer wound healing problems [586–590].
16.3.2 Coronary vessel. Coronary artery bypass grafting aims at
revascularizing coronary arteries with a ﬂow-reducing luminal
stenosis, supplying a viable and sizable area that is otherwise at risk.
The patency of a bypass graft is inﬂuenced by the characteristics
of the anastomosed vessel, the run-off area, the graft material, its
manipulation, and its construction [1]. Important coronary charac-
teristics are the internal lumen size, the severity of proximal sten-
osis, the quality of the wall at the site of anastomosis, and the
distal vascular bed.
16.3.3 Completeness of revascularization. Ideally, a gene-
rally accepted deﬁnition of completeness of myocardial
revascularization would comprise (i) the size of the vessel, (ii) the
severity of the lesion, (iii) the ischaemic burden caused by the
lesion and (iv) the viability of the depending myocardial territory
[591–593]. Current surgical practice is based on an anatomical
deﬁnition of complete revascularization, deﬁned as bypass
grafting to all epicardial vessels ≥1.5 mm with a diameter
reduction ≥50% in at least one angiographic view [594]. However,
in other clinical trials, several different deﬁnitions of completeness
of revascularization have been used. Coronary artery bypass graft
patients with incomplete revascularization had an outcome that
was either similar [595–599] or inferior [594,598,600,601] to that of
patients with complete revascularization. A pivotal interventional
study has shown superior results from FFR-guided functionally
complete revascularization than those obtained by anatomically
complete revascularization by PCI [50]. Currently, however, these
results cannot be extrapolated to this group of CABG patients [53].
16.3.4 Construction of central anastomosis. Use of in situ
grafts, still connected to their native take-off (LIMA, right IMA,
right gastroepiploic artery) avoids the need for a proximal
anastomosis. If free conduits (vein grafts, radial artery) are used,
additional central anastomosis for arterial inﬂow into the bypass
vessels is utilized in the majority of cases. Partial or total aortic
cross-clamping allows the construction of central anastomoses to
the ascending aorta. With a higher atherosclerotic risk proﬁle, the
likelihood of atherosclerotic changes in the ascending aorta
increases and requires strategies that reduce or avoid
manipulation. A single cross-clamp technique may be preferred to
multiple manipulations, with the aim of reducing atheroembolic
events, but a strict no-touch technique most effectively reduces
embolization of atherosclerotic material [442]. In this situation,
grafts are anastomosed end-to-side in a Y- or T-shaped
conﬁguration to the IMAs, to facilitate arterial inﬂow. Devices for
clampless aortic anastomoses are also available.
16.3.5 Bypass grafts. The long-term beneﬁt of CABG is
maximized with the use of arterial grafts, speciﬁcally the IMA
[602,603]. Available grafts include the IMA, radial, and
gastroepiploic arteries, although the latter is seldomly used in
current practice [17,18]. Except in rare circumstances, almost all
patients should receive at least one arterial graft—the LIMA—
preferentially to the LAD [602,604].
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Data from non-randomized studies reveal unequivocally that
the use of bilateral IMA is associated with improved long-term sur-
vival, as well as fewer non-fatal events such as myocardial infarc-
tion, recurrent angina, and need for re-operation [165,368,605–
610]. These advantages have also been demonstrated for diabetic
patients. Conversely, BIMA grafting is associated with a small in-
crease in sternal dehiscence and increased rate of mediastinitis;
obese and diabetic patients being at particular risk
[368,586,605,611–614]. Thus BIMA grafting is recommended if life
expectancy exceeds 5 years and to avoid aortic manipulation.
The radial artery constitutes a reasonable alternative as the
second arterial graft, in patients in whom BIMA grafting is contrain-
dicated (e.g. obese, diabetic, old women). Available evidence indi-
cates its superiority (in terms of survival and non-fatal events) over
the saphenous vein [615–617], but inferiority to use of the IMA
[606]. This patency is strongly related to target vessel size and sever-
ity of stenosis. Numerous studies have demonstrated a strong,
adverse inﬂuence on radial artery patency when the native coron-
ary artery stenosis is <70% [618]. Furthermore, using radial artery
grafts increases the number of arterial anastomoses beyond the use
of both IMA and helps to achieve total arterial revascularization.
Graft ﬂow measurement may be useful in conﬁrming or exclud-
ing a technical graft problem indicated by haemodynamic in-
stability or inability to wean the patient from cardiopulmonary
bypass, new regional wall motion abnormalities on transoesopha-
geal echocardiography, or ventricular arrhythmias [619]. It has
also been shown to reduce the rate of adverse events and graft
failure, although interpretation can be challenging in sequential
grafts and T-grafts [619,620].
16.3.6 On-pump and off-pump procedures. Despite
improved techniques and experience, part of the morbidity
related to CABG is caused by the extracorporeal circulation
(cardiopulmonary bypass) and access for cardiopulmonary
bypass, prompting the off-pump approach. Two recent large,
international, randomized trials have shown no difference in
30-day or 1-year clinical outcomes between on- and off-pump
surgery, when performed by experienced surgeons [441,621,622].
There is also enough evidence to conclude that, for most patients
and surgeons, on-pump CABG provides the best—or equal—short-
and long-term outcomes [621–625]. For some surgeons, off-pump
CABG is associated with inferior early and late graft patency rates
and possibly compromised long-term survival; however,
complete off-pump procedures in the hands of highly trained
teams appear to be associated with a reduced risk of early
morbidity, such as stroke, wound and respiratory infections, as
well as fewer transfusions and shorter hospital stay [626–629]. In
the subgroup of patients with end-stage CKD, there is some
evidence that off-pump CABG is associated with lower in-hospital
mortality and need for new renal replacement therapy [380].
In the subgroup of patients with atherosclerotic changes of the
ascending aorta, a no-touch technique—avoiding any manipula-
tions of the ascending aorta either on- or off-pump—is essential to
reduce the risk of stroke [443]. The consistent cross-over rate of
around 5% from on-pump CABG to off-pump CABG in high-quality
RCTs suggests the necessity of routine ECG-gated CT scans of the
thoracic aorta before bypass surgery in patients over 70 years of
age or those with other risk factors for extensive atherosclerosis.
Procedural aspects of CABG
Recommendations Classa Level b Ref. c
It is recommended to perform procedures in a hospital structure and by a team specialized in cardiac
surgery, using written protocols.
I B 635,636
Endoscopic vein harvesting should be considered to reduce the incidence of leg wound complications. IIa A
577,578,580–582,
637,638
Routine skeletonized IMA dissection should be considered. IIa B 586–589
Skeletonized IMA dissection is recommended in patients with diabetes or when bilateral IMAs are harvested. I B 586–589
Complete myocardial revascularization is recommended. I B 594,598,600
Arterial grafting with IMA to the LAD system is recommended. I B 602,603,639
Bilateral IMA grafting should be considered in patients <70 years of age. IIa B
165,606–610,640,
641
Use of the radial artery is recommended only for target vessels with high-degree stenosis. I B 618,642
Total arterial revascularization is recommended in patients with poor vein quality independently of age. I C -
Total arterial revascularization should be considered in patients with reasonable life expectancy. IIa B 643
Minimization of aortic manipulation is recommended. I B 442,644
Off-pump CABG should be considered for subgroups of high-risk patients in high-volume off-pump centres. IIa B 626,627,629
Off-pump CABG and/or no-touch on-pump techniques on the ascending aorta are recommended in patients
with significant atherosclerotic disease of the ascending aorta in order to prevent perioperative stroke.
I B 443
Minimally invasive CABG should be considered in patients with isolated LAD lesions. IIa C
Electrocardiogram-triggered CT scans or epiaortic scanning of the ascending aorta should be considered in
patients over 70 years of age and/or with signs of extensive generalized atherosclerosis.
IIa C _
Routine intraoperative graft flow measurement should be considered. IIa C _
















ESC/EACTS Guidelines / European Journal of Cardio-Thoracic Surgery 563
16.3.7 Minimally invasive procedures. Minimally invasive
direct coronary artery bypass may represent an attractive
alternative to a sternotomy [630]. It has a similar safety and
efﬁcacy proﬁle to conventional on- and off-pump CABG, with
markedly reduced post-operative length of stay and an early
quality-of-life beneﬁt, although spreading of the ribs is associated
with increased post-operative pain [631–633].
16.4 Reporting perioperative outcome
Perioperative reporting of outcome after CABG procedures should
be done on a risk-adjusted basis. Early clinical outcome at 3
months after CABG is characterized by a 1–2% mortality rate and a
1–2% morbidity rate for each of the following events: stroke, renal,
pulmonary and cardiac failure, bleeding, and wound infections.
The early risk period after CABG extends up to 3 months, is multi-
factorial, and depends on the interface between technical variabil-
ity and patient comorbidity [634].
17. PROCEDURAL ASPECTS OF PERCUTANEOUS
CORONARY INTERVENTION
17.1 Percutaneous coronary intervention devices
17.1.1 Balloon angioplasty. Plain balloon angioplasty has been
displaced in the treatment of de novo coronary lesions after
demonstration of the superiority of BMS and, more recently, DES
in terms of repeat revascularization [645]. Its contribution to the
treatment of in-stent restenosis has also diminished after recent
studies demonstrated the advantages of DES and drug-coated
balloons for this indication [505,511]. However, balloon
angioplasty might be a valuable PCI option in all patients in whom
implantation of stents is technically not achievable, or in a vessel
that is too small to be stented (<2.0 mm), and in patients with
critical stenoses who require urgent surgery.
17.1.2 Coronary stents
Bare-metal stents
Coronary stents are very effective in repairing dissections and
have eliminated the need for urgent CABG due to abrupt vessel
closure. Fully covered stents can be life-saving in the rare event of
coronary perforation. The contribution of BMS is its approximately
30% lower rate of restenosis than with plain balloon angioplasty
[645]. Although many efforts have been made to further reduce re-
stenosis by modiﬁcation of stent design and materials, thinning of
stent struts has been the only proven modiﬁcation capable of redu-
cing restenosis of BMS [646,647]. Bare-metal stents have been asso-
ciated with favourable outcomes in terms of mortality, myocardial
infarction, and stent thrombosis [124]. However, owing to a 20–30%
rate of recurrence of angiographic stenosis within 6–9 months after
implantation, restenosis with BMS has often been referred to as the
’Achilles’ heel’ of PCI [645]. There is no indication for BMS over new-
generation DES, irrespective of patient and lesion subset. Similarly,
there is no clear evidence of a difference between DES and BMS in
the risk of stent thrombosis following unplanned disruption of
DAPT [648].
Early-generation drug-eluting stents
The risk of restenosis with BMS led to the development of DES,
which consist of a metallic stent platform with controlled release
of antiproliferative drugs, mostly controlled by surface polymers.
Early-generation DES released sirolimus (e.g. Cypher® [649] or
paclitaxel (e.g. Taxus®) [650]. Both in native vessels and saphenous
vein bypass grafts, DES potently reduced angiographic and
ischaemia-driven TVR [124,495]. Thus, the risk of clinical restenosis
with the use of early-generation DES was 50–70% lower than with
BMS, corresponding to a number-needed-to-treat of approxi-
mately 7–8 [124]. In RCTs, no signiﬁcant differences were observed
in the long-term rates of death or myocardial infarction after use
of DES or BMS [124,199]. Despite the superior anti-restenotic efﬁ-
cacy of early-generation DES over BMS, concerns have been gen-
erated by studies showing an increased propensity for very late
stent thrombosis [244,651,652]. Although early-generation DES
represented an important advance in the ﬁeld of PCI [653]. they
currently play an irrelevant role in the treatment of CAD and are
largely supplanted by new-generation DES [3].
New-generation drug-eluting stents
New-generation DES are characterized by thin-strut, metallic plat-
forms that release limus-based antiproliferative drugs from durable
polymers with improved biocompatibility and lower polymer mass
[654,655], biodegradable polymers [654,656–658], or polymer-free
surfaces [659,660]. Recent studies have shown the superiority of
several new-generation DES over early-generation DES, not only
with respect to efﬁcacy but also safety [128,129,661,662].
New-generation DES have addressed previous concerns of very late
stent thrombosis and are at least as safe as bare-metal stents during
long-term follow-up. Table 10 displays a list of Conformité
Européenne (CE)-approved new-generation DES, supported by RCT
evidence with clinical endpoints. Table 11 shows a list of
CE-approved new-generation DES, the proven efﬁcacy of which was
based on angiographic ﬁndings from studies with or without a
control group. These tables only provide a temporary ’snapshot’ of
available products, as new devices will be introduced or new evi-
dence of established devices will become available.
Indications for new-generation DES
Increased efﬁcacy and safety of new-generation DES have
enabled their unrestricted use in patients with CAD and an indica-
tion for PCI, including patients with diabetes, multivessel and LM
disease, acute myocardial infarction, SVG and restenotic lesions, and
chronic total occlusions [3]. New-generation DES should therefore
be considered by default in all clinical conditions and lesion subsets.
Among patients who require anticoagulation with NOACs, undergo
non-cardiac surgery, experience bleeding complications, or are non-
compliant with medication intake, previous concerns relating to dif-
ferences in the duration of DAPT and risks associated with DAPT
cessation are not substantiated in recent data sets [648,663].
17.1.3 Bioresorbable stents. Completely bioresorbable stents,
which dissolve after fulﬁlling their support function in the lesion site
of the coronary vessel, have been a perennial aim since the
introduction of the metallic stents. The combination of resorbable
stent platforms with drug-eluting properties has enhanced the
efﬁcacy of these devices. Current stent platforms are based on two
technologies: the manufacturing of drug-eluting, bioresorbable,
polymer-based stents and drug-eluting, resorbable, metallic
(magnesium) stents [684]. The resorption process of the stent
platforms takes from several months to 2 years, depending on
polymer composition. To date, bioresorbable stents have been
shown to dissolve completely over time, to restore the vasomotion
of treated segments, and to result in positive remodelling with late
lumen enlargement. In small series of patients with relatively simple
lesions, early results are promising and appear to be similar to
new-generation DES [685–687]. However, conﬁrmation in
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Table 10: CE-approved new-generation DES recommended for clinical use based on randomized trials with a primary clinical
endpoint (in alphabetical order)
960Ultimaster Cobalt–chrome PDLLA and PCL Sirolimus
DES Stent platform Polymer coating Drug References
Based on durable polymer coatings
Promus element Platinum–chrome PBMA and PVDF-HFP Everolimus 664,665
Resolute Cobalt–chrome
PBMA, PHMA, PVP, 
and PVA
Zotarolimus 655,665,666
Xience Cobalt–chrome PBMA and PVDF-HFP Everolimus 247, 654,667
Based on biodegradable polymer coatings
Biomatrix Stainless steel PDLLA Biolimus A9 248, 668
Nobori Stainless steel PDLLA Biolimus A9 656,658,669
Yukon Choice PC Stainless steel PDLLA Sirolimus 657
Orsiro Cobalt–chrome PLLA Sirolimus 961
CE = Conformité Européenne; DES = drug-eluting stent; PBMA = poly n-butyl methacrylate; PDLLA = poly(d,l)-lactic acid; PHMA = polyhexyl methacrylate;
PLLA = poly-L-lactic acid; PVA = polyvinyl acetate; PVDF-HFP = poly(vinylidene fluoride-cohexafluoropropylene).
Table 11: CE-approved DES with angiographic efficacy data from randomized or non-randomized studies (in alphabetical order)
DES Stent platform Polymer coating Drug References
Based on durable polymer coatings
DESyne Nx Cobalt–chrome PBMA Novolimus 670
STENTYS Nitinol PSU and PVP Paclitaxel 671
Based on biodegradable polymer coatings
Axxess Nitinol PDLLA Biolimus A9 672,673
BioMime Cobalt–chrome PLLA and PLGA Sirolimus 674
Combo Stainless steel
PDLLA and PLGA +
Additional coating with anti-
CD34
Sirolimus 675
DESyne BD Cobalt–chrome PLLA Novolimus
Stainless steel
PLLA, PLGA, PCL, 
and PVP
Paclitaxel 676
MiStent Cobalt–chrome PLGA Crystalline sirolimus 677
Supralimus Core Cobalt–chrome
PLLA, PLGA, PCL, 
and PVP
Sirolimus 678,679
Synergy Platinum–chrome PLGA Everolimus 680
Polymer-free
Amazonia Pax Cobalt–chrome – Paclitaxel
BioFreedom Stainless steel – Biolimus A9
Cre8 Cobalt–chrome – Sirolimus 681
Yukon Choice PF Stainless steel – Sirolimus 682,683
CE = Conformité Européenne; DES = drug-eluting stent; PBMA = poly n-butyl methacrylate; PCL = poly(L-lactide co-ε-caprolactone); PDLLA = poly(d,l)-lactic
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large-scale RCTs is required to establish the indications for these
devices. Table 12 includes the list of devices approved for use in
Europe.
17.1.4 Drug-coated balloons. The rationale of using drug-coated
balloons is based on the concept that, with highly lipophilic drugs,
even short contact times between the balloon surface and the vessel
wall are sufﬁcient for effective drug delivery. Using a paclitaxel-
coated balloon, three RCTs, Paclitaxel-Coated Balloon Catheter I
(PACCOCATH-I) and PACCOCATH–II [507,508], and Paclitaxel-Eluting
PTCA–Catheter In Coronary Disease (PEPCAD)-II [689], have targeted
in-stent restenosis following BMS implantation, while three others
have targeted in-stent restenosis in patients predominantly treated
with DES eluting limus-analogues [509–511]. By virtue of the positive
results achieved without additional stent implantation, drug-coated
balloons may represent an attractive option for patients with
restenosis after implantation of DES, although it is not known
whether they are as safe and effective for this indication as new-
generation DES that elute limus analogues.
In the randomized PEPCAD III study, the combination of a drug-
coated balloon with cobalt chromium stent implantation was infer-
ior to a sirolimus-eluting stent for de novo indications [690]. Also,
the Drug Eluting Balloon in Acute Myocardial Infarction (DEB-AMI)
trial showed that drug-coated balloons followed by BMS implant-
ation were inferior to paclitaxel-eluting stents in patients with
STEMI [691]. A recent angiographic study suggested that drug-
coated balloons may serve as an alternative to paclitaxel-eluting
stents for the treatment of lesions in small coronary vessels [692];
however, the role of drug-coated balloons in this setting has not
been evaluated against more effective, new-generation DES with
limus analogues. There are various types of drug-coated balloons
approved for use in Europe and their main characteristics are listed
in Table 13. Most of the differences are related to the drug carrier,
whereas paclitaxel is currently the sole active drug used. Although
speciﬁcally designed comparative studies are lacking, one cannot
assume a class effect for all drug-coated balloons [693].
17.1.5 Other devices. Although routine use of rotational
atherectomy did not improve outcomes after DES [698], such a
device might technically be required in cases of tight and calciﬁed
lesions, to allow subsequent passage of balloons and stents. There
is a resurgence in the use of rotational atherectomy for the
purpose of optimal lesion preparation among patients
undergoing implantation of bioresorbable stents.
17.2 Adjunctive invasive diagnostic tools
17.2.1 Intravascular ultrasound. Coronary angiography is
unable to visualize the atherosclerotic involvement of the arterial
wall. Intravascular ultrasound imaging allows a real-time,
tomographic assessment of lumen area and plaque composition,
size, and distribution. As a result of diffuse disease and
remodelling, coronary angiography underestimates the extent and
severity of the disease compared with IVUS [699]. Although
invasive by nature, IVUS is the established standard for accurate
Table 12: Bioresorbable stents providing drug-elution with angiographic efficacy data from non-randomized studies (in
alphabetical order)
Device Delivery platform Polymer Drug References
Absorb BVS PLLA PDLLA Everolimus 685,686
DESolve PLLA PLLA Novolimus 688
DREAMS Magnesium alloy PLGA Paclitaxel (revised version Sirolimus) 687
PDLLA = poly(d,l)-lactic acid; PLGA = poly(lactide-co-glycolide); PLLA = poly-L-lactic acid.
Table 13: CE-approved drug-coated balloons (in alphabetical order)
Device Carrier Drug References
Danubio BTHC Paclitaxel –
Dior II Shellac Paclitaxel 694,695
Elutax – Paclitaxel 693
IN.PACT Falcon Urea Paclitaxel 692
Moxy Polysorbate Paclitaxel 696
Pantera Lux BTHC Paclitaxel 697
Protégé NC BTHC Paclitaxel –
SeQuent Please Iopromide Paclitaxel 507–511
BTHC = butyryl-tri-hexyl citrate; CE = Conformité Européenne.
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measurement of plaque burden, and the technique has been
systematically used to determine the inﬂuence of different drugs
on coronary plaque progression or regression [700,701].
Several RCTs addressed the potential of IVUS in reducing re-
stenosis and adverse events after BMS implantation—with conﬂict-
ing results. Most of these RCTs focussed on optimizing stent
expansion using IVUS. Findings from meta-analyses subsequently
suggested that better clinical and angiographic results may be
obtained under IVUS guidance [702–704]. In the DES era, a thresh-
old of stent expansion (5.0–5.5 mm2) was proposed to predict the
occurrence of late events. In the subset of patients with LM
disease, observational studies suggest that IVUS-guided stent im-
plantation is associated with improved survival during long-term
clinical follow-up [705]. The use of intracoronary imaging has also
been advocated in patients with stent failure, including restenosis
and stent thrombosis, in order to explicate and correct underlying
mechanical factors. In a multicentre all-comers study to establish
the frequency, predictors, and timing of stent thrombosis, a pre-
speciﬁed substudy compared outcomes of IVUS against angio-
graphic guidance of DES implantation [706]. IVUS-guided DES im-
plantation (pre- and post-PCI in 63% of included cases) was
performed in 3349 of 8583 patients (39%). In propensity-adjusted
multivariable analysis, IVUS guidance was associated with reduced
rates of deﬁnite or probable stent thrombosis (adjusted HR 0.40;
95% CI 0.21–0.73; P = 0.003), myocardial infarction (adjusted HR
0.66; 95% CI 0.49–0.88; P = 0.004), and MACE (adjusted HR 0.70;
95% CI 0.55–0.88; P = 0.003) at 1 year. Notable limitations of this
study were the lack of randomization and lack of pre-speciﬁed
guidelines for performing and acting on IVUS ﬁndings.
In addition to conventional grey-scale IVUS, other ultrasound-
based techniques have been used to provide additional diagnostic
insights. Assessment of plaque composition may be further improved
by analysis of the complete radiofrequency signal using different
diagnostic algorithms, including those used in ‘virtual histology’.
17.2.2 Optical coherence tomography. Optical coherence
tomography is a light-based modality of intravascular imaging with
higher spatial resolution than IVUS (15 vs. 150 µm) and is ideally
suited to accurate detection of intraluminal structures. Plaque
composition, including the presence of lipid pools and intraluminal
thrombi, can also be determined [707]. Notably, this is the only
technique capable of providing accurate measurements of the
thickness of the ﬁbrous cap and to detect even minor cap
disruptions [707,708]. Early stages of cardiac allograft vasculopathy
are frequently angiographically silent, yet can be visualized with OCT
or IVUS and are associated with important prognostic implications
[708]. Optical coherence tomography requires complete blood
clearance from the lumen for imaging, has a limited penetration on
the vessel wall and is therefore unable to assess the complete plaque
burden. After stent implantation, OCT is more accurate than IVUS in
detecting subtle morphological details including malapposition,
residual thrombus, plaque prolapse, and residual dissections,
although the clinical signiﬁcance of these ﬁndings remains to be
determined [709,710]. During longitudinal follow-up investigations,
OCT is more accurate than IVUS for assessing even neointimal
thickness, strut apposition, and coverage. These ﬁndings are
important surrogate markers of the efﬁcacy and safety of DES and
are frequently used to compare new DES. A recent retrospective and
observational study suggested that OCT-guided stenting might
improve clinical outcomes [711]. Owing to its very high resolution,
OCT is used to reveal the underlying mechanisms in patients with
stent failure, including in-stent restenosis and stent thrombosis [516].
Likewise, intrastent neointimal tissuemay be characterized, including
the detection of neoatherosclerosis, which represents a potential link
between in-stent restenosis and stent thrombosis [516,712]. Further
studies are needed to deﬁne the clinical value of OCT.
17.2.3 Pressure-derived fractional ﬂow reserve. Fractional
ﬂow reserve is the current standard of care for the functional
assessment of lesion severity [713]. Imaging techniques provide
useful information (i.e. minimal lumen area) but FFR is able to
provide a physiological assessment. Initial studies suggested that the
cut-off ﬁgure of 0.75 was reliable for identifying ischaemia-
producing lesions, but subsequently the 0.80 criterion has gained
widespread acceptance and its clinical role has been validated in
outcome studies. Fractional ﬂow reserve evaluation is valuable in
patients undergoing diagnostic coronary angiography without prior
non-invasive functional testing in the presence of borderline lesions
and in patients with multivessel disease. The concept of avoiding
unnecessary treatment of lesions that are not haemodynamically
relevant was demonstrated in the DEFER and Fractional Flow
Reserve Vs. Angiography for Multivessel Evaluation (FAME) trials
[50,51]. More recently, the FAME II trial demonstrated that, in
patients with SCAD, FFR-guided PCI using DES resulted in less need
for urgent revascularization than with medical treatment [54]. While
FFR requires maximal and stable hyperaemia—usually obtained by
intravenous adenosine—new methods and indices [including
instantaneous wave-free ratio (iFR)] that do not rely on the concept
of maximal hyperaemia have been proposed, in order to simplify
studies and facilitate a wider adoption of physiological assessment.
Further studies will need to conﬁrm the value of these new indices
in clinical decision-making [714]. Fractional ﬂow reserve can also be
ascertained along the entire coronary tree using the anatomical
information obtained by multislice CT [715,716]. Although
appealing, owing to its non-invasive nature, CT-derived FFR requires
further clinical validation before its clinical use may be justiﬁed.
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17.3 Speciﬁc lesion subsets
17.3.1 Bifurcation stenosis. Bifurcation lesions are common
and represent 10–15% of all coronary interventions [717].
Coronary bifurcation lesions are deﬁned as stenosis of a main
branch at the origin of a side branch, with or without lesions
extending into the ostium of the side branch. They are best
described according to the Medina classiﬁcation, which uses the
three components of a bifurcation: the main branch proximal, the
main branch distal, and the side branch, giving a binary value (1 or
0) according to whether or not each of the segments previously
deﬁned is compromised [29].
PCI of bifurcation lesions is technically challenging, owing to
multiple factors that include anatomical variability related to bifur-
cation site, plaque burden and morphology, bifurcation angle,
and branch diameter [718–724]. Also, bifurcation anatomy may
have dynamic variability during PCI, with plaque shift or dissection
causing side-branch occlusion and requiring adjustments in the
interventional approach [720].
Despite many attempts with a variety of different stenting techni-
ques (T-stenting, V-stenting, crush and its modiﬁcations, culotte,
etc.), the optimal strategy for every anatomical subset has not yet
been established. Variables to be considered are plaque distribution,
size, and downstream territory of each vessel (main and side branch),
and the bifurcation angle. Stent implantation in the main vessel only,
followed by provisional balloon angioplasty with or without stenting
of the side branch, seems preferable to routine stenting of both
vessels [725,726], although some studies have reported similar or
improved results with speciﬁc strategies of complex stenting [727–
732]. Fractional ﬂow reserve data from side branches suggest that
angiography overestimates the functional severity of side-branch
stenosis. Final ‘kissing’ balloon dilation is recommended when two
stents are eventually required, with no advantage from ﬁnal kissing
with the one-stent technique [733,734]. Several stents, designed spe-
ciﬁcally for treatment of bifurcation lesions, have undergone exten-
sive evaluation with good angiographic and clinical results, especially
with side branch size >2.5 mm.
Percutaneous coronary intervention for left main bifurcations
Signiﬁcant unprotected LM disease is observed in 5–7% of
patients undergoing coronary angiography. For bifurcation and
LM lesions, DES are preferred, with special attention to adequate
sizing and deployment. Unprotected distal LM bifurcation PCI is a
challenging percutaneous procedure and has worse long-term
clinical outcome than the favourable results obtained with ostial-
or shaft-LM lesions [735,736]. There are few systematic data sup-
porting a speciﬁc stenting technique for LM bifurcation lesions
[737].
17.3.2 Chronic total coronary occlusion. Chronic total
occlusion is deﬁned as complete vessel occlusion with TIMI 0 ﬂow
within the occluded segment and an estimated occlusion duration
of ≥3 months [738]. In a consecutive series of patients without
previous CABG surgery or recent myocardial infarction, who
underwent angiography, totally occluded vessels were observed in
25% of cases [739]. Patients with CTO underwent PCI less frequently
than those without CTO (11% vs. 36%, respectively; P < 0.0001) but
were more frequently assigned to CABG or medical therapy [739].
Treatment of CTOs should be considered in the presence of
symptoms or objective evidence of viability/ischaemia in the terri-
tory of the occluded artery. Given the usually high procedural
contrast volume, the potential long-term risk of radiation
exposure and contrast-induced nephropathy should be consid-
ered. Ad hoc PCI is not recommended for CTOs. Observational
studies suggest that successfully revascularized CTOs confer a
long-term survival advantage over failed revascularization [740–
742,743,744]. In addition, better relief of angina and functional
status was observed after successful CTO recanalization [745]. In
the post hoc analysis of 4-year results of the SYNTAX trial, the pres-
ence of CTO was the strongest independent predictor of incom-
plete revascularization (46.6% in the PCI arm), and had an adverse
effect on clinical outcomes, including mortality [594].
The procedural success rate is lower for PCI of CTO than for
non-CTO lesions, with a similar rate of complications [746,747]. In
a meta-analysis of 13 studies encompassing 7288 patients, recana-
lization was successful in 69% of cases (ranging from 51–74%)
[743]. Success rates are strongly dependent on operator skills, ex-
perience with speciﬁc procedural techniques, and the availability
of dedicated equipment (specialized guide wires and catheters or
very low proﬁle CTO balloons). Bilateral angiography and IVUS
can be very helpful, as can special techniques such as guide-
anchoring, various retrograde approaches, and speciﬁc wiring ma-
nipulation techniques, including parallel or anchoring wire [748].
A retrograde approach via collateral pathways offers an additional
possibility of success after failure of antegrade crossing, especially
for right coronary artery and LAD occlusions [749]. In general, this
technique is not regarded as a ﬁrst-line approach and is generally
reserved for previous failed attempts. The overall success rate with
the retrograde approach in a multicentre registry of 175 patients
was 83.4% [750].
In recently published systematic reviews and one RCT with
long-term follow-up, DES provided superior clinical outcome to
BMS, mainly due to a lower risk of revascularization [751–754].
17.3.3 Ostial lesions. Ostial disease is deﬁned as a lesion arising
within 3 mm of the vessel origin. It may be classiﬁed by location
as aorto-ostial, non-aorto-ostial, or branch-ostial [755]. Coronary
ostial lesions are frequently not a manifestation of coronary
atherosclerosis, but rather related to aortitis or radiation exposure
[756–758].
Ostial lesions are usually recognized as ﬁbrotic, calciﬁed, and
relatively rigid [759,760]. Aorto-ostial disease is resistant to dilation
and prone to recoil, due to the greater thickness of muscular and
elastic tissue in the aortic wall [755]. Coronary stents—particularly
DES—have improved procedural efﬁcacy and safety.
In ostial coronary lesions, additional judgement and caution is
essential before proceeding to PCI [755].
(1) In aorto-ostial lesions coronary spasm has to be absent;
(2) In ostial LAD or LCx stenoses, a decision must be made on
whether to attempt precise positioning of the stent at the ostium
of the artery or whether stenting across the LCx/LAD ostium into
the LM artery is preferable.
Lesion assessment with IVUS may be helpful, particularly in LM
ostial stenosis, including assessment of the degree of calciﬁcation,
need for adjunctive devices and assessment of stent expansion.
Fractional ﬂow reserve measurement may also be valuable in the
assessment of angiographically borderline aorto-ostial and side-
branch ostial lesions [761], taking special care to avoid a wedge
position of the guiding catheter and using intravenous, rather than
intracoronary, adenosine.
Proper selection of the guiding catheter is important in
aorto-ostial lesions, to avoid deep intubation and compromise of
coronary ﬂow.
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Preparation and debulking of the lesion with rotational ather-
ectomy and special balloons, cutting or scoring, may be useful in
highly calciﬁed, rigid ostial lesions [762–765].
Drug eluting stents are the default devices for ostial lesions.
The accurate positioning of the stent, precisely in the coronary
ostium, may be technically challenging and some specialized
techniques have been described that achieve the optimal stent
placement [766–768].
Treatment of restenotic and saphenous vein graft lesions are
discussed in section 14.
Recommendations for the treatment of speciﬁc lesion
subsets
Recommendations Classa Levelb Refc
DES should be considered for PCI
of ostial lesions.
IIa B 769–772
For PCI of bifurcation lesions,
stent implantation in the main
vessel only, followed by
provisional balloon angioplasty
with or without stenting of the




CTOs should be considered in
patients with expected ischaemia
reduction in a corresponding






CTOs may be considered after a
failed anterograde approach or as
the primary approach in selected
patients.
IIb C






The choice, initiation, combination, and duration of antithrombo-
tic strategies for myocardial revascularization depend on the clin-
ical setting [SCAD, NSTE-ACS, STEMI], and the urgency and mode
(PCI vs. CABG) of the intervention. To maximize the effectiveness
of therapy and reduce the hazard of bleeding, ischaemic and
bleeding risks should be evaluated on an individual basis.
18.1 Percutaneous coronary intervention in stable
coronary artery disease
18.1.1 Oral antiplatelet therapy. Dual antiplatelet therapy
includes a 150–300 mg oral loading dose of acetylsalicylic acid
(ASA) (or 80–150 mg i.v.) followed by 75–100 mg per os (p.o.) daily
plus a clopidogrel 300–600 mg loading dose followed by 75 mg
daily [773–775]. Acetylsalicylic acid acts via irreversible inhibition
of platelet cyclo-oxygenase-1 (COX-1), which is normally
complete with chronic dosing ≥75 mg/day. Contrary to the
antiplatelet effects, the gastrointestinal side-effects of ASA
increase at higher doses. The optimal risk–beneﬁt ratio appears to
be achieved with an ASA dosage of 75–150 mg/day [774,776].
There is no evidence of beneﬁt for systematic clopidogrel pre-
loading before diagnostic coronary angiography in SCAD [777]. A
loading dose of 600 mg or more is recommended in patients
scheduled for elective PCI if coronary anatomy is known. The use
of a higher maintenance dose (150 mg) has been proposed in
patients with high thrombotic risk (e.g. in diabetes, after recurrent
myocardial infarction, after early and late stent thrombosis, for
complex lesions, or in life-threatening situations should occlusion
occur); however, no studies have established a short- or long-term
beneﬁt of a 150 mg daily maintenance dose. Speciﬁcally, the
Gauging Responsiveness with A VerifyNow assay: Impact on
Thrombosis And Safety (GRAVITAS) trial failed to show a beneﬁt of
doubling the clopidogrel maintenance dose in subjects deemed
to be non-responders [778].
Lifelong single antiplatelet therapy is recommended. Patients
should be instructed not to prematurely discontinue oral antipla-
telet therapy after stenting, due to the risks of stent thrombosis
and myocardial infarction [774,779]. Data from the Patterns of
Non-Adherence to Anti-Platelet Regimens In Stented Patients
(PARIS) registry indicate that cardiac events after cessation of
DAPT depend on the clinical circumstances and reason for cessa-
tion and that they attenuate over time [648]. Half of the cases in
which treatment was discontinued within 2 years of stent implant-
ation were due to a physician’s guidance, and did not result in any
adverse effect. Disruptions due to bleeding or non-compliance
represented 14% of the cessations and were associated with a sub-
stantially increased risk of MACE, although this association largely
attenuated after 30 days. Although the overall contribution of
DAPT cessation to cardiac risk was small—thereby challenging
existing paradigms for extension of antiplatelet treatment in other-
wise stable patients after PCI—these ﬁndings highlights the need
for patient education.
18.1.2 Intravenous antiplatelet therapy. Recent trials did not
demonstrate additional beneﬁt from GP IIb/IIIa inhibitors after a
clopidogrel loading dose of 600 mg [780–782]. Anecdotal
experience, however, suggests that GP IIb/IIIa inhibitors may be
beneﬁcial in ‘bail-out’ situations (intraprocedure thrombus
formation, slow ﬂow, threatened vessel closure) [86]. The use of
cangrelor is reviewed in section 18.4.2.
18.1.3 Anticoagulation. The Randomized Evaluation in PCI
Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial
demonstrated that outcome with bivalirudin and provisional GP
IIb/IIIa blockade is similar to that of unfractionated heparin (UFH)
plus planned GP IIb/IIIa inhibition during PCI for SCAD [783]. Sub-
sequently, Intracoronary Stenting and Antithrombotic Regimen–
Rapid Early Action for Coronary Treatment (ISAR-REACT) 3,
performed in patients pre-treated with clopidogrel, showed similar
net clinical outcomes to bivalirudin and UFH [784], but UFH
dosage was higher (140 U/kg) than recommended, leading to an
excess in major bleeding in patients preferentially undergoing
procedures via femoral access. In view of the primary endpoint
results and a trend towards a lower risk of myocardial infarction,
anticoagulation with UFH with an i.v. bolus of 70–100 U/kg
remains the standard anticoagulant treatment for elective PCI.
Among PCI patients with negative biomarkers, bivalirudin reduced
bleeding without affecting mortality and might therefore be
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The Safety and Efﬁcacy of Intravenous Enoxaparin in Elective
Percutaneous Coronary Intervention Randomized Evaluation
(STEEPLE) trial has demonstrated lower bleeding with intravenous
enoxaparin (0.5 mg/kg; P = 0.01; 0.75 mg/kg; P = 0.05) and 57%
less major bleeding with both doses (P < 0.01 for both), when
compared with UFH with similar efﬁcacy [786]. Yet a signiﬁcant
beneﬁt with respect to the primary endpoint was found only in
the low-dose arm, which was stopped prematurely because of a
non-signiﬁcant trend towards excess mortality not related to is-
chaemic events and not conﬁrmed at 1 year of follow-up [787]. A
recent meta-analysis conﬁrmed the favourable safety proﬁle [788].
18.2 Non-ST-segment elevation acute coronary
syndrome
High ischaemic risk is associated with dynamic ST-segment and
troponin changes (primary indications), diabetes status, a GRACE
score >140, LV function <40%, creatinine clearance <60 ml/min,
recent PCI, and post-myocardial infarction angina (secondary
indicators) [180]. Bleeding risk can be assessed using risk scores,
which may remain valid despite the increased use of the radial
route to perform PCI [808,809].
18.2.1 Oral antiplatelet therapy. Dual antiplatelet therapy
includes ASA with an oral loading dose of 150–300 mg (or 80–150
mg i.v.), followed by 75–100 mg p.o. daily, and a P2Y12-receptor
antagonist, as discussed below [774].
Prasugrel and ticagrelor
Prasugrel (60 mg loading and 10 mg daily maintenance dose), a
prodrug that irreversibly blocks the P2Y12 platelet receptor with a
faster onset and a more potent antiplatelet inhibition, has been
tested in the TRial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet InhibitioN with Prasugrel–
Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI-38) trial
against the 300 mg loading dose of clopidogrel—both started in
the catheterization laboratory after diagnostic angiography in
thienopyridine-naïve patients—and proved beneﬁcial with respect
to a composite ischaemic outcome [518]. Patients with NSTE-ACS
treated conservatively were not included in this study. Recurrent
cardiovascular events were fewer in prasugrel-treated patients
(from 11.2% to 9.3%; RRR 0.82; 95% CI 0.73–0.93; P = 0.002),
mostly driven by a signiﬁcantly lower risk for myocardial infarction
(from 9.2% to 7.1%; RRR 23.9%; 95% CI 12.7–33.7; P < 0.001). Severe
bleeding complications were more common with prasugrel than
with clopidogrel (TIMI non-CABG major bleeding 2.4% vs. 1.8%,
respectively; HR 1.32; 95% CI 1.03–1.68; P = 0.03), driven mostly
by an increase in spontaneous bleeds (1.6% vs. 1.1%, respectively;
HR 1.51; 95% CI 1.09–2.08; P = 0.01), but also in fatal bleeding (0.4%
vs. 0.1%, respectively; HR 4.19; 95% CI 1.58–11.11; P = 0.002).
Recommendations for antithrombotic treatment in SCAD patients undergoing PCI
Recommendations for PCI Classa Levelb Refc
Pretreatment with antiplatelet therapy
Treatment with 600 mg clopidogrel is recommended in elective PCI patients once anatomy is known and decision to
proceed with PCI preferably 2 hours or more before the procedure. I A 789–792
Pretreatment with clopidogrel may be considered in patients with high probability for significant CAD. IIb C
In patients on a maintenance dose of 75 mg clopidogrel, a new loading dose of 600 mg or more may be considered
once the indication for PCI is confirmed. IIb C
Antiplatelet therapy during PCI 
ASA is indicated before elective stenting. I B 776,793,794
ASA oral loading dose of 150–300 mg (or 80-150 mg i.v.) is recommended if not pre-treated. I C
Clopidogrel (600 mg loading dose or more, 75 mg daily maintenance dose) is recommended for elective stenting. I A 795–798
Antiplatelet therapy after stenting
DAPT is indicated for at least 1 month after BMS implantation. I A 791,799–801
DAPT is indicated for 6 months after DES implantation. I B 799,802,803
Shorter DAPT duration (<6 months) may be considered after DES implantation in patients at high bleeding risk.   IIb A 804,805
Life-long single antiplatelet therapy, usually ASA, is recommended. I A 776,794
Instruction of patients about the importance of complying with antiplatelet therapy is recommended. I C -
DAPT may be used for more than 6 months in patients at high ischaemic risk and low bleeding risk. IIb C -
GP IIb/IIIa antagonists should be considered only for bail-out. IIa C
Anticoagulant therapy
Unfractionated heparin 70–100 U/kg. I B 806
Bivalirudin (0.75 mg/kg bolus, followed by 1.75 mg/kg/hour for up to 4 hours after the procedure) in case of
heparin-induced thrombocytopenia. I C -
Bivalirudin (0.75 mg/kg bolus, followed by 1.75 mg/kg/hour during the procedure) in patients at high bleeding risk. IIa A 783–785
Enoxaparin i.v. 0.5 mg/kg. IIa B 786,788,807
ASA = acetylsalicylic acid; BMS = bare-metal stent; CAD = coronary artery disease; DAPT = dual antiplatelet therapy; DES = drug-eluting stent; GP =
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Bleeding was also increased in prasugrel-treated patients referred
for early CABG. Excluding patients with a higher bleeding risk, pra-
sugrel offers signiﬁcant beneﬁt over clopidogrel with respect to
cardiovascular events (HR 0.74; 95% CI 0.66–0.84; P < 0.001)
without signiﬁcantly increasing major bleeding (HR 1.24; 95% CI
0.91–1.69; P = 0.17) [518]. In diabetic patients presenting with ACS,
prasugrel confers a particularly greater treatment effect than clo-
pidogrel, without signiﬁcantly increased bleeding [337]. Prasugrel
should be considered in patients who present with stent throm-
bosis despite adherence to clopidogrel therapy [810]. Prasugrel is
contraindicated in patients with prior stroke or TIA. Treatment
with prasugrel is generally not recommended for patients of ≥75
years of age. If, after a careful individual risk–beneﬁt evaluation by
the prescribing physician, treatment is deemed necessary in the
≥75 years age or low body weight (<60 kg) groups then, following
a loading dose of 60 mg, a reduced maintenance dose of 5 mg
should be prescribed.
Alternatively, ticagrelor can be administered [811]. Ticagrelor
[180 mg loading dose; 90 mg b.i.d. (twice daily) daily maintenance
dose] a cyclopentyltriazolopyrimidine, is an oral, reversibly
binding P2Y12 inhibitor with a plasma half-life of approximately
6–12 hours. The Study of Platelet Inhibition and Patient Outcomes
(PLATO) study randomly assigned ACS patients—with or without
prior loading with clopidogrel and irrespective of strategy (inva-
sive vs. non-invasive)—to treatment with ticagrelor or clopidogrel
and showed signiﬁcantly superior results in favour of ticagrelor in
the composite ischaemic endpoint (11.7% in the clopidogrel
group and 9.8% in the ticagrelor group; HR 0.84; 95% CI 0.77–
0.92; P < 0.001) and mortality (from 5.1% to 4.0%, respectively; HR
0.79; 95% CI 0.69–0.91; P = 0.001) [341]. Patients undergoing PCI,
with moderate- to high-risk NSTE-ACS, were allowed to receive an
additional blinded 300 mg loading dose of clopidogrel (total
loading dose 600 mg) or its placebo after the initial loading dose.
Those patients with a ﬁnal diagnosis of non-ST-segment elevation
myocardial infarction (NSTEMI) had a signiﬁcantly lower primary
endpoint result with ticagrelor than with clopidogrel (11.4% vs.
13.9%, respectively; HR 0.83, CI 0.73–0.94) in contrast to patients
with a ﬁnal diagnosis of unstable angina (8.6% vs. 9.1%, respective-
ly; HR 0.96, CI 0.75–1.22). The rate of TIMI major non-CABG-
related bleeding was similar to that with prasugrel in the
TRITON-TIMI 38 trial and was higher, at 2.8%, in the ticagrelor
group, than the 2.2% of the clopidogrel group (HR 1.25; 95% CI
1.03–1.53; P = 0.03). TIMI major CABG-related bleeding occurred
in 5.3% of the patients in the ticagrelor group and in 5.8% in the
clopidogrel group. There was no difference in the overall rates of
fatal haemorrhage (0.3% in both groups) despite a higher rate of
fatal intracranial haemorrhage in the ticagrelor group (0.1% vs.
0.001%; P = 0.02). Ticagrelor was associated with an increased rate
of adverse effects including dyspnoea, increased frequency of
ventricular pauses, and asymptomatic increases in uric acid.180
Clopidogrel
Clopidogrel is a prodrug that is converted in active metabolites
through a two-step reaction involving cytochrome P450 (CYP450)
enzymes, leading to an irreversible blockade of the P2Y12 recep-
tor. Compared with prasugrel and ticagrelor, this conversion
results in a slower onset of action and a larger variability in oral
bioavailability. The Clopidogrel and Aspirin Optimal Dose Usage
to Reduce Recurrent Events − Seventh Organization to Assess
Strategies in Ischemic Syndromes 7 (CURRENT-OASIS) 7 trial
tested whether a double-dose regimen of clopidogrel (600 mg
loading dose followed by 150 mg maintenance dose from day 2
to day 7, then 75 mg maintenance dose) was superior to a
standard-dose regimen of clopidogrel (300 mg loading dose fol-
lowed by 75 mg maintenance dose) in ACS patients (treated con-
servatively and invasively). Overall, the higher dose regimen was
no more effective than the conventional dosage, with a similar
30-day rate of the composite endpoint of cardiovascular death,
myocardial infarction, or stroke (4.2% vs. 4.4%, respectively; HR
0.94; 95% CI 0.83–1.06; P = 0.30), but was associated with increased
30-day rates of TIMI major bleeding (1.7% vs. 1.3%; HR 1.26; 95% CI
1.03–1.54; P = 0.03) and the need for blood transfusion (2.2% vs.
1.7%; HR 1.28, 1.07–1.54; P = 0.01) [519]. The primary efﬁcacy end-
point did not differ according to ASA dose (high vs. low) nor did the
safety endpoint, major bleeding. When analysing the results from
the pre-speciﬁed subgroup of 17 263 patients with ACS who under-
went PCI, the double-dose regimen of clopidogrel led to 14% fewer
cardiovascular events (3.9% vs. 4.5%; HR 0.86; 95% CI 0.74–0.99;
P = 0.039); however, the P-value for interaction was 0.03 and did
not meet the pre-speciﬁed criterion (P < 0.01) that rendered these
results statistically signiﬁcant. Therefore, the beneﬁt was formally
restricted to the 31% lower risk of stent thrombosis (1.6% vs. 2.3%;
HR 0.69; 95% CI 0.56–0.87; P = 0.001) [812]. Major bleeding was
more common with double-dose than with standard-dose clopido-
grel (1.6% vs. 1.1%; HR 1.41; 95% CI, 1.09–1.83; P = 0.009). It is difﬁ-
cult to disentangle the impact of the chosen strategy of a short (1
week) treatment period with 150 mg. High-dose and low-dose ASA
did not differ for the primary efﬁcacy outcome (4.1% vs. 4.2%, re-
spectively; HR 0.98; 95% CI 0.84–1.13; P = 0.76) and the safety
outcome major bleeding (1.5% vs. 1.3%; HR 1.18; 95% CI, 0.92–1.53;
P = 0.20). Based on these ﬁndings, the high-dose clopidogrel
regimen of 600 mg loading dose and 150 mg maintenance dose in
the ﬁrst week may be considered only when prasugrel and ticagre-
lor are not available or if they are contraindicated.
18.2.2 Intravenous antiplatelet therapy. In the era before
DAPT, trials of adequately dosed GP IIb/IIIa inhibitors in patients
undergoing balloon angioplasty and coronary stent implantation
demonstrated a lower incidence of composite ischaemic events in
favour of GP IIb/IIIa treatment in combination with UFH, than
with UFH alone, primarily through a reduction in myocardial
infarction [813]. In the ISAR-REACT 2 trial, this beneﬁt—according
to the primary endpoint of death, myocardial infarction, or urgent
TVR within 30 days—was maintained despite clopidogrel
pre-treatment with a loading dose of 600 mg in patients with
NSTEMI (13.1% vs. 18.3%; RR 0.71; 95% CI 0.54–0.95; P = 0.02), but
not in unstable angina without biomarker protein elevation (4.6%
vs. 4.6%; RR 0.99; 95% CI 0.56–1.76; P = 0.98) [814].
The ACUITY trial—which compared a regimen of bivalirudin
alone (with bail-out GP IIb/IIIa inhibitors in 7.4%) against UFH plus
GP IIb/IIIa inhibitors—found a signiﬁcant beneﬁt of bivalirudin
alone with respect to the primary 30-day composite endpoint of
ischaemic and bleeding complications (10.1% vs. 11.7%, respect-
ively; RR 0.86; 95% CI 0.77–0.97; P = 0.02), driven by a reduction in
major bleeding complications (3.0% vs. 5.7%, respectively; RR
0.53; 95% CI 0.43–0.65; P < 0.001) without a signiﬁcant increase in
ischaemic complications (7.8% vs. 7.3%, respectively; RR 1.08; 95%
CI 0.93–1.24; P = 0.32) [815]. This beneﬁt of bivalirudin was found
regardless of whether GP IIb/IIIa inhibitors were administered
downstream or upstream and was maintained during 1-year
follow-up [816]. The more recent ISAR-REACT 4 trial in PCI
patients with NSTEMI did not ﬁnd a signiﬁcant beneﬁt of UFH
with abciximab, compared with bivalirudin alone. The primary
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major bleeding within 30 days occurred in 10.9% of patients in the
heparin-plus-abciximab group, as opposed to 11.0% in the bivalir-
udin group (RR 0.99; 95% CI 0.74–1.32; P = 0.94) [817]. However,
heparin plus abciximab was associated with signiﬁcantly more
major bleeding than bivalirudin (4.6% vs. 2.6%, respectively; RR
1.84; 95% CI 1.10–3.07; P = 0.02).
Consistent with ACUITY and ISAR-REACT 4, the EARLY-ACS trial
did not conﬁrm a beneﬁt from upstream eptiﬁbatide, with or
without clopidogrel pre-treatment (9.3% vs. 10.0%, respectively; OR
0.92; 95% CI 0.80–1.06; P = 0.23), but was associated with a higher
bleeding risk with eptiﬁbatide (TIMI major haemorrhage 2.6% vs.
1.8%, respectively; OR 1.42; 95% CI 1.07–1.89; P = 0.02) [357].
In TRITON-TIMI 38, 7414 patients (54.5% of the total study
population) received a GP IIb/IIIa inhibitor and, in terms of redu-
cing the risk of cardiovascular death, myocardial infarction or
stroke, a consistent advantage was observed from prasugrel when
compared with clopidogrel, irrespective of the use of GP IIb/IIIa
inhibitors (with GP IIb/IIIa inhibitors: HR 0.76; 95% CI 0.64–0.90;
without GP IIb/IIIa inhibitors: HR 0.78; 95% CI 0.63–0.97; P-value
for interaction 0.83). The risk of TIMI major or minor bleeding was
not signiﬁcantly different with either prasugrel or clopidogrel, re-
gardless of whether or not patients were treated with GP IIb/IIIa
inhibitors (P-value for interaction 0.19) [818].
Overall, there is no evidence for an additional beneﬁt of routine
upstream use of GP IIb/IIIa inhibitors in NSTE-ACS patients sched-
uled for coronary angiography.
18.2.3 Anticoagulation. A general rule is to avoid crossover
between antithrombins (with the exception of adding UFH to
fondaparinux)—especially between UFH and low-molecular-weight
heparin (LMWH) [819,820]—and to discontinue antithrombins after
PCI except in speciﬁc situations (e.g. LV aneurysm and/or thrombus,
AF, prolonged bed rest, deferred sheath removal).
Among patients with high-risk ACS—as evidenced by positive
biomarkers, ST-segment changes, or a GRACE risk score >140 with
an intended urgent or early invasive strategy—bivalirudin plus pro-
visional GP IIb/IIIa receptor inhibitors is recommended as an al-
ternative to UFH plus GP IIb/IIIa receptor inhibitors, particularly in
patients with a high risk of bleeding. ACUITY demonstrated the su-
periority of bivalirudin over UFH or low molecular weight heparin
(LMWH) plus GP IIb/IIIa inhibitor, a regimen previously shown to
be superior to heparin alone [815]. For patients with NSTEMI
undergoing PCI, ISAR-REACT 4 presented additional evidence in
favour of bivalirudin, with a better safety proﬁle than the combin-
ation of UFH and abciximab. The use of bivalirudin preserves the
option for bail-out GP IIb/IIIa inhibition [817]. However, in lower-
Recommendations for antithrombotic treatment in patients with NSTE-ACS undergoing PCI
Recommendations Classa Level b Ref c
Antiplatelet therapy
ASA is recommended for all patients without contraindications at an initial oral loading dose of 150–300 mg
(or 80–150 mg i.v.), and at a maintenance dose of 75–100 mg daily long-term regardless of treatment strategy.
I A 774,776,794
A P2Y12 inhibitor is recommended in addition to ASA, and maintained over 12 months unless there are
contraindications such as excessive risk of bleeding. Options are:
I A 337,341,825
• Prasugrel (60 mg loading dose, 10 mg daily dose) in patients in whom coronary anatomy is known and who are
proceeding to PCI if no contraindication
I B 337
• Ticagrelor (180 mg loading dose, 90 mg twice daily) for patients at moderate-to-high risk of ischaemic events,
regardless of initial treatment strategy including those pre-treated with clopidogrel if no contraindication
I B 341
• Clopidogrel (600 mg loading dose, 75 mg daily dose), only when prasugrel or ticagrelor are not available or are
contraindicated I B 812,825
GP IIb/IIIa antagonists should be considered for bail-out situation or thrombotic complications. IIa C
Pre-treatment with prasugrel in patients in whom coronary anatomy is not known, is not recommended. III B 826
Pre-treatment with GP IIb/IIIa antagonists in patients in whom coronary anatomy is not known, is not recommended. III A 357,815
Anticoagulant therapy
Anticoagulation is recommended for all patients in addition to antiplatelet therapy during PCI. I A 180
The anticoagulation is selected according to both ischaemic and bleeding risks, and according to the efficacy–safety
profile of the chosen agent. I C
Bivalirudin (0.75 mg/kg bolus, followed by 1.75 mg/kg/hour for up to 4 hours after the procedure) is recommended
as alternative to UFH plus GP IIb/IIIa receptor inhibitor during PCI. I A 815–817
UFH is recommended as anticoagulant for PCI if patients cannot receive bivalirudin. I C
In patients on fondaparinux (2.5 mg daily s.c.), a single bolus UFH (85 IU/kg, or 60 IU/kg in the case of concomitant 
use of GP IIb/IIIa receptor inhibitors) is indicated during PCI. I B 827
Enoxaparin should be considered as anticoagulant for PCI in patients pre-treated with subcutaneous enoxaparin. IIa B 788
Discontinuation of anticoagulation should be considered after an invasive procedure unless otherwise indicated. IIa C
Crossover of UFH and LMWH is not recommended. III B 820
ASA = acetylsalicylic acid; GP = glycoprotein; i.v. = intravenous; LMWH = low-molecular-weight heparin; NSTE-ACS = non-ST-segment elevation acute
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risk patients pre-treated with clopidogrel, bivalirudin does not
appear to offer an advantage over heparin [821]. We acknowledge
that most of the evidence in support of bivalirudin is derived from
trials in which the comparator was UFH plus GP IIb/IIIa inhibitor, a
combination that is no longer routinely applied.
A substantial number of patients will undergo catheterization
after a conservative treatment phase. Many of these patients will
be on fondaparinux, an indirect factor Xa inhibitor, as recom-
mended by current guidelines based on the Optimal Antiplatelet
Strategy for Interventions (OASIS)-5 trial [180,822]. In this trial, the
combined ischaemic event rate was similar, but severe bleeding
complications were signiﬁcantly lower with fondaparinux than
with enoxaparin. This favourable net clinical outcome included
reduced long-term mortality and stroke rates. Because of a higher
rate of catheter thrombosis in patients undergoing PCI treated
with fondaparinux alone, full-dose intravenous UFH (85 U/kg)
must be added to prevent formation of catheter thrombi [823].
Earlier studies on ACS patients receiving predominantly conser-
vative treatment demonstrated the superiority of enoxaparin over
UFH [824]. The more recent studies in the setting of PCI did not
ﬁnd an advantage of enoxaparin over UFH when pre-
randomization anticoagulation was not consistent with the study
treatment or when there was a post-randomization cross-over
[819,820]. A beneﬁt of enoxaparin over UFH in reducing mortality
and bleeding complications was recently reported in a
meta-analysis covering NSTE-ACS patients [788].
18.3 ST-segment elevation myocardial infarction
Patients undergoing primary PCI should receive a combination of
DAPT with ASA and a P2Y12 receptor blocker as early as possible
before angiography, and a parenteral anticoagulant.
18.3.1 Oral antiplatelet therapy. An oral loading dose of ASA
150–300 mg (or i.v. 80–150 mg) followed by 75–100 mg p.o. daily
should be given to ensure inhibition of TXA2-dependent platelet
aggregation [887].
The preferred P2Y12 inhibitors are prasugrel (60 mg p.o. loading
dose; 10 mg maintenance dose) and ticagrelor (180 mg p.o.
loading dose; 90 mg maintenance dose b.i.d.) [341,518]. In the
pre-speciﬁed subgroups of patients with STEMI undergoing PCI in
the TRITON–TIMI 38 trial, the beneﬁt of prasugrel was consistent
for the primary endpoint at 15 months (prasugrel 10.0% vs. clopi-
dogrel 12.4%; HR 0.79; 95% CI 0.65–0.97; P = 0.02), without a sig-
niﬁcant increase in non-CABG-related bleeding risk (2.4% vs. 2.1%,
respectively; HR 1.11; 95% CI 0.70–1.77; P = 0.65). There was a
lower risk of stent thrombosis (1.6% vs. 2.8%, respectively; HR 0.58;
95% CI 0.36–0.93; P = 0.02), as well as of cardiovascular mortality
(1.4% vs. 2.4%, respectively; HR 0.61; 95% CI 0.37–1.00; P = 0.047
[828] in favour of prasugrel at 30-day and 15-month follow-up
(2.4% vs. 3.4%, respectively; HR 0.74; 95% CI 0.50–1.09; P = 0.129).
Notably, two-thirds of STEMI patients underwent PCI as the
primary revascularization strategy and one-third underwent late
or secondary PCI after ﬁbrinolysis or lack of early revasculariza-
tion. Prasugrel is contraindicated in patients with prior stroke or
TIA. Treatment with prasugrel is generally not recommended for
patients aged 75 years or more. In the ≥75 years age group—if
treatment is deemed necessary after a careful, individual risk–
beneﬁt evaluation by the prescribing physician—then, following a
loading dose of 60 mg, a reduced maintenance dose of 5 mg
should be prescribed [811]. In patients with body weight less than
60 kg, a maintenance dose of 5 mg is also recommended; this was
shown to result in lower platelet reactivity—to a similar extent to
prasugrel 10 mg/day in high body weight patients—and in greater
platelet inhibition and lower HPR than with clopidogrel 75 mg/
day, with similar bleeding rates [829].
In the subset of patients with STEMI randomized in the PLATO
trial, the beneﬁt of ticagrelor over clopidogrel for the primary end-
point (9.4% vs. 10.8%, respectively; HR 0.87; 95% CI 0.75–1.01;
P = 0.07; P-value for interaction 0.29) [823], was consistent with
the overall results, without higher risk of bleeding (TIMI
non-CABG major 2.5% vs. 2.2%, respectively; HR 1.09; 95% CI
0.80–1.48; P = 0.60) but with a trend towards a lower risk of cardio-
vascular mortality at 1 year (4.7% vs. 5.4%, respectively; HR 0.84;
95% CI 0.69–1.03; P = 0.07). In a pooled analysis of 48 599 patients,
of whom 94% presented with acute coronary syndrome and 84%
had PCI, novel P2Y12 inhibitors—including prasugrel and ticagrelor
—have been associated with a mortality beneﬁt and no signiﬁcant
excess of major bleeding among STEMI patients [830].
Importantly, the more potent agents (prasugrel and ticagrelor)
should not be used in patients with prior haemorrhagic stroke or
with moderate-to-severe liver disease. When neither of these
agents is available (or if they are contraindicated), clopidogrel
600 mg p.o. should be given instead, according to the pre-
speciﬁed PCI analysis of CURRENT-OASIS 7 [812].
18.3.2 Intravenous antiplatelet therapy. Several trials—
performed before the use of pre-loading with thienopyridines
and mostly using abciximab (i.v. bolus followed by infusion of
0.125 µg/kg/min up to a maximum of 10 µg/min for 12 hours)—
documented clinical beneﬁts from GP IIb/IIIa inhibitors as adjunct
to primary PCI performed with UFH [242,831–833], including a
signiﬁcant 1-year survival beneﬁt that was revealed in a
meta-analysis of GP IIb/IIIa inhibitors with abciximab [831].
The large Facilitated Intervention with Enhanced Reperfusion
Speed to Stop Events (FINESSE) study tested whether or not up-
stream administration at the time of ﬁrst medical contact might
improve the clinical efﬁcacy of GP IIb/IIIa inhibitors, compared
with administration at the time of primary PCI. In this trial, patients
were randomly assigned to upstream abciximab vs. abciximab in
the catheterization laboratory [271]. Upstream vs. in-cath-lab ad-
ministration of abciximab had no signiﬁcant effect on the primary
endpoint of death, recurrent myocardial infarction, and heart
failure, but signiﬁcantly increased the risk of bleeding. In subgroup
analyses, a beneﬁt was observed with early use of abciximab in
patients recruited by the ambulance system or in high-risk
patients presenting rapidly at ‘spoke’ centres and requiring transfer
for primary PCI [834]. The randomized, double-blind Continuing
TIroﬁban in Myocardial infarction Evaluation (On-TIME-2) trial,
using high-dose tiroﬁban, demonstrated a signiﬁcant beneﬁt of
upstream compared with downstream provisional administration
on the primary surrogate endpoint of ST-segment resolution and
on the primary composite clinical endpoint of death, recurrent
myocardial infarction, urgent target vessel re-intervention or
thrombotic bail-out [835]. However, the clinical beneﬁt was
related predominantly to a reduction in the perceived need for
bail-out tiroﬁban. After pooling the On-TIME-2 data with the 414
patients of an open-label run-in phase, using the same inclusion
and exclusion criteria and concomitant treatment, the rate of
MACE was signiﬁcantly reduced by systematic high-dose tiroﬁban
versus no tiroﬁban or placebo (5.8% vs. 8.6%; P = 0.043), with
reduced mortality (2.2% vs. 4.1%, respectively; P = 0.051) and no
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P = 0.58) [836]. It remains unclear whether the effects observed in
On-TIME-2 are due to upstream vs. downstream administration or
due to systematic vs. provisional administration. However, time
from symptom onset to study drug in FINESSE was twice as long
as in On-TIME 2 [837]; only about 40% of patients needed to be
transferred from a hospital without a catheterization facility to a
hospital with such a facility, and a handful were recruited by the
ambulance system. This may account for the differences between
the two trials.
Intracoronary—as compared with intravenous—administration
of GP IIb/IIIa inhibitors has been tested in several small studies
and was associated with some beneﬁts, which have not been con-
ﬁrmed in larger trials [838,839].
In the event of angiographic evidence of large thrombus, slow-
or no-reﬂow, and other thrombotic complications, use of GP IIb/
IIIa inhibitors as bail-out therapy appears reasonable, although
this has not been tested in a randomized trial.
18.3.3 Anticoagulation. In the Harmonizing Outcomes with
Revascularization and Stents in Acute Myocardial Infarction
(HORIZONS-AMI) trial, an RCT involving 3602 patients with
STEMI, bivalirudin with bail-out GP IIb/IIIa inhibitors (in 7.2% of
patients) was found superior to systematic GP IIb/IIIa inhibitors
(mostly abciximab) plus UFH in respect of the two primary
endpoints of net adverse clinical events (9.2% vs. 12.1%,
respectively; RR 0.76; 95% CI 0.63–0.92; P = 0.005) and major
bleeding (4.9% vs. 8.3%, respectively; RR 0.60; 95% CI 0.46–0.77;
P < 0.001) [840]. The clinical beneﬁt comprised a signiﬁcant
survival beneﬁt from bivalirudin as compared with the GP IIb/IIIa
inhibitor arm, both at 30 days and at 3 years (2.1% vs. 3.1%,
respectively; P = 0.049 and 5.9% vs. 7.7%; P = 0.03; respectively).
However, there was a higher incidence of stent thrombosis during
the ﬁrst 24 hours in the bivalirudin group (1.3% vs. 0.3%;
P < 0.001), which diminished during follow-up, while
pre-randomization UFH and 600 mg clopidogrel loading dose
were independent predictors of lower risk of acute and subacute
stent thrombosis. The more recent, open-label European
Ambulance Acute Coronary Syndrome Angiography (EUROMAX)
trial compared a strategy of pre-hospital bivalirudin with UFH or
LMWH with optional use of glycoprotein IIb/IIIa inhibitors (69%)
in 2218 STEMI patients, with frequent use of radial access (47%)
and pre-treatment with P2Y12 inhibitors (98%) [841]. The primary
endpoint of death or non-CABG major bleeding at 30 days was
signiﬁcantly lower with pre-hospital administration of bivalirudin
than with UFH plus optional GP IIb/IIIa inhibitors (5.1% vs. 8.5%,
respectively; RR 0.60; 95% CI 0.43–0.82; P < 0.001). There were no
differences in death (2.9% vs. 3.1%, respectively; RR 0.96; 95% CI
0.60–1.54; P = 0.86), but there was a lower risk of major bleeding
(2.6% vs. 6.0%, respectively; RR 0.43; 95% CI 0.28–0.66; P < 0.001)
mainly driven by differences in blood transfusion, whereas rates of
TIMI major bleeding were not signiﬁcantly reduced (1.3% vs. 2.1%,
respectively; RR 0.62; 95% CI 0.32–1.20; P = 0.15). Sensitivity
analyses showed results to be consistent without signiﬁcant
interactions with arterial access site; however, stent thrombosis
was more frequent in the bivalirudin group (1.6% vs. 0.5%,
respectively; RR 2.89; 95% CI 1.14–7.29; P = 0.02) at 30 days, solely
driven by a difference during the ﬁrst 24 hours, which was
paralleled by a trend towards a higher rate of re-infarction (1.7%
Recommendations for antithrombotic treatment in patients with STEMI undergoing primary PCI
Recommendations Classa Levelb Refc
Antiplatelet therapy
ASA is recommended for all patients without contraindications at an initial oral loading dose of 150–300 mg
(or 80–150 mg i.v.) and at a maintenance dose of 75–100 mg daily long-term regardless of treatment strategy.
I A 776,794
A P2Y12 inhibitor is recommended in addition to ASA and maintained over 12 months unless there are
contraindications such as excessive risk of bleeding. Options are:
I A –
• Prasugrel (60 mg loading dose, 10 mg daily dose) if no contraindication I B 828
• Ticagrelor (180 mg loading dose, 90 mg twice daily) if no contraindication I B 823
• Clopidogrel (600 mg loading dose, 75 mg daily dose), only when prasugrel or ticagrelor are not available or are
contraindicated.
I B 812
It is recommended to give P2Y12 inhibitors at the time of first medical contact. I B 777,846–848
GP IIb/IIIa inhibitors should be considered for bail-out or evidence of no-reflow or a thrombotic complication. IIa C –
Upstream use of a GP IIb/IIIa inhibitor (vs. in-lab use) may be considered in high-risk patients undergoing transfer





Anticoagulation is recommended for all patients in addition to antiplatelet therapy during PCI. I A –
The anticoagulation is selected according to both ischaemic and bleeding risks, and according to the efficacy–safety
profile of the chosen agent.
I C
Unfractionated heparin: 70–100 U/kg i.v. bolus when no GP IIb/IIIa inhibitor is planned; 50–70 U/kg i.v. bolus with
GP IIb/IIIa inhibitor.
I C
Bivalirudin 0.75 mg/kg i.v. bolus followed by i.v. infusion of 1.75 mg/kg/h for up to 4 hours after the procedure. IIa A 243,840,841
Enoxaparin i.v. 0.5 mg/kg with or without GP IIb/IIIa inhibitor. IIa B
788,842–844,
850
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vs. 0.9%, respectively; RR 1.93; 95% CI 0.90–4.14; P = 0.08) despite
use of novel P2Y12 inhibitors in more than half of the patients. The
mortality beneﬁt observed in the HORIZONS-AMI trial was not
conﬁrmed by EUROMAX, and the excess of stent thrombosis
remained despite prolonged infusion of bivalirudin. The How
Effective are Antithrombotic Therapies in PPCI (HEAT-PCI) study is
a single-centre randomised trial comparing bivalirudin and
unfractionated heparin in 1829 STEMI patients planned to
undergo primary PCI [842]. The study represents contemporary
practice with restriction of GP IIb/IIIa inhibitors to bail-out
situations (in 15% of the randomised patients population), the
frequent use of novel P2Y12 inhibitors (89% of the patients), radial
approach and predominant DES implantation. Among the 1812
patients included in the ﬁnal analysis, 1491 actually underwent
primary PCI. The primary efﬁcacy outcome measure, a composite
of all-cause mortality, stroke, recurrent infarction and unplanned
target lesion revascularization, was higher in the bivalirudin than
in the UFH group (8.7% vs. 5.7%, respectively; HR 1.52; 95% CI
1.09–2.13; P = 0.01) including an increase in stent thrombosis
(3.4% vs. 0.9%, respectively, RR 3.91; 95% CI 1.61–9.52; P = 0.001)
but no signiﬁcant difference in mortality (5.1% vs. 4.3%,
respectively). The primary safety outcome—deﬁned as major
BARC 3-5 bleeding—was 3.5% in the bilvalirudin group vs. 3.1% in
the UFH group (P = 0.59). The Bavarian Reperfusion Alternatives
Evaluation (BRAVE) 4 trial examined the question of whether a
strategy of prasugrel plus bivalirudin (n = 269) was superior to a
strategy with clopidogrel plus UFH (n = 275) in primary PCI STEMI
patients and was interrupted due to slow patient recruitment
[843]. The primary endpoint—a composite of death, myocardial
infarction, unplanned revascularization of the infarct-related
artery, stent thrombosis, stroke or major bleeding evaluated at 30
days—occurred in 15.6% vs. 14.5%, respectively (RR 1.09; 95% CI
0–1.79; P = 0.68), the secondary composite ischaemic endpoint
(death, myocardial infarction, revascularization of the infarct-
related artery, stent thrombosis or stroke) was seen in 4.8% vs.
5.5%, respectively (RR 0.89; 95% CI 0.40–1.96; P = 0.89) and the
secondary bleeding endpoint (non-CABG related bleeding
according to the HORIZONS-AMI deﬁnition) in 14.1% vs. 12.0%,
respectively (RR 1.18; 95% CI 0.74–1.88 P = 0.54). In summary,
recent trials comparing bivalirudin with UFH without systematic
use of GP IIb/IIIa antagonists uphold concerns over an excess risk
for acute stent thrombosis with bivalirudin, while differences in
major bleeding are small.
Enoxaparin [0.5 mg/kg i.v. followed by subcutaneous (s.c.) treat-
ment] was compared with UFH in one randomized, open-label
trial, known as Acute STEMI Treated with primary PCI and intraven-
ous enoxaparin Or UFH to Lower ischaemic and bleeding events at
short- and Long-term follow-up (ATOLL) trial. The primary compos-
ite endpoint of 30-day death, complication of myocardial infarc-
tion, procedural failure, and major bleeding was not signiﬁcantly
lower for the enoxaparin arm (−17%; P = 0.063), but there were
reductions in the composite main secondary endpoint of death, re-
current myocardial infarction or ACS, or urgent revascularization,
and in other secondary composite endpoints—such as death, or
resuscitated cardiac arrest and death, or complication of myocardial
infarction. There was no indication of higher incidence of bleeding
from use of enoxaparin over UFH. In the per-protocol analysis of
the ATOLL trial—pertinent to more than 87% of the study popula-
tion—i.v. enoxaparin was superior to UFH in reducing the primary
endpoint (RR 0.76; 95% CI 0.62–0.94; P = 0.012) but also ischaemic
endpoints, mortality (RR 0.36; 95% CI 0.18–0.74; P = 0.003) and
major bleedings (RR 0.46; 95% CI 0.21—1.01; P = 0.050),
contributing to the improvement of the net clinical beneﬁt (RR
0.46; 95% CI 0.3—0.74; P = 0.0002) in patients undergoing primary
PCI. Based on these considerations, enoxaparin may be considered
as an alternative to UFH as anticoagulant to primary PCI [844].
Use of fondaparinux in the context of primary PCI was asso-
ciated with potential harm in the OASIS-6 trial and is therefore
not recommended [845]. In particular, when used alone during
primary PCI, fondaparinux is associated with the risk of catheter
thrombosis. Thus, an additional anticoagulant with anti-IIa activity
(unfractionated heparin or enoxaparin) should be administered.
18.4 Points of interest and special conditions
18.4.1 Pre-treatment with P2Y12 inhibitors
Clopidogrel
The concept of pre-treatment with P2Y12-receptor blockers is
based on the observation that the risk of PCI depends on the
intraprocedural level of platelet inhibition. The three largest clinic-
al studies supporting this concept are (i) Clopidogrel in Unstable
Angina to Prevent Recurrent Events (CURE), with the PCI-CURE
subset, (ii) Clopidogrel for the Reduction of Events During
Observation (CREDO) with the subset of patients with sufﬁcient
delay between intake of clopidogrel 300 mg and PCI, and (iii) Do
Tiroﬁban and Reo- Pro Give Similar Efﬁcacy Outcome Trial
(TARGET), with its non-randomized pre-treatment towards a back-
ground of GP IIb/IIIa inhibition [791,825,851]. Additional circum-
stantial evidence for pre-treatment with P2Y12-receptor blockers
comes from the notion that beneﬁt of GP IIb/IIIa inhibition over
placebo in historic studies is mitigated in more recent studies with
systematic upstream P2Y12-receptor inhibition [269,817,821].
A recent meta-analysis evaluated the relationships of clopido-
grel pre-treatment vs. no treatment with mortality and major
bleeding among patients undergoing PCI. Pre-treatment with clo-
pidogrel had no effect on death (OR 0.80; 95% CI 0.57–1.11) or
the risk of major bleeding (OR 1.18; 95% CI 0.93–1.50) but the risk
of major cardiac events was signiﬁcantly reduced (OR 0.77; 95% CI
0.66–0.89; P < 0.001) [777]. There was substantial heterogeneity
according to the type of clinical presentation of SCAD, NSTE-ACS,
and STEMI, suggesting the lack of a consistent treatment effect—
especially with respect to mortality—across the entire clinical
spectrum. The beneﬁt of pre-treatment was greater with increas-
ing severity of clinical presentation.
In particular, clopidogrel pre-loading did not improve ischae-
mic outcomes in PCI for SCAD, with a trend towards more bleed-
ings [777]. In NSTE-ACS, there was a signiﬁcant reduction in major
cardiovascular events (OR 0.78; 95% CI 0.66–0.91; P = 0.002)
driven mainly by myocardial infarction, with a trend towards more
TIMI major bleeds (OR 1.28; 95% CI 0.98–1.67; P = 0.07). In
primary PCI for STEMI, a single trial has evaluated the administra-
tion of DAPT before hospital admission, rather than in hospital,
and has been terminated prematurely due to slow recruitment,
with a trend towards a higher proportion of TIMI 2 or 3 ﬂow and
fewer ischaemic events in the pre-treatment group [846].
However, this common practice in Europe is supported by a lower
mortality (OR 0.50; 95% CI 0.26–0.96) without signiﬁcant excess in
major bleedings (OR 0.78; 95% CI 0.42–1.45) [777].
Prasugrel and ticagrelor
A Comparison of Prasugrel at the Time of Percutaneous
Coronary Intervention (PCI) Or as Pre-treatment At the Time of
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Infarction (NSTEMI) (the ACCOAST study) is the largest and the
only pre-treatment study that has investigated the use of prasugrel
(30 mg) vs. placebo before PCI in 4033 NSTE-ACS patients.
Overall, 69% of patients underwent PCI and 5% CABG. When PCI
was performed, an additional dose of 30 mg prasugrel was given
after diagnostic coronary angiography in the pre-treatment group
and 60 mg prasugrel was given in the placebo group. The primary
endpoint—a composite of cardiovascular death, myocardial infarc-
tion, stroke, urgent revascularization, and bail-out GP IIb/IIIa in-
hibitor use at 7 days—was similar for both groups (HR with
pre-treatment, 1.02; 95% CI 0.84–1.25; P = 0.81). The rate of the
safety endpoint of TIMI major bleeding, through day 7, was higher
with pre-treatment (HR 1.90; 95% CI 1.19–3.02; P = 0.006). The
study was stopped 1 month before the end of enrolment due to
an excess of major bleeding, and further highlights the lack of
beneﬁt of pre-treatment in NSTE-ACS patients [826].
Pre-treatment with 30 mg prasugrel, with an average time delay of
6 hours before angiography, led to a much faster and more pro-
found inhibition of platelet aggregation than a 600 mg clopidogrel
loading dose as given in Antiplatelet therapy for Reduction of
MYocardial Damage during Angioplasty (ARMYDA)-5 [789].
Within one hour after PCI, there was a catch-up phenomenon of
the pharmacodynamic proﬁle of pre-treatment and in-lab treat-
ment group with 60 mg prasugrel. These very different pharmaco-
dynamic proﬁles may account for the excess of periprocedural
major bleedings reported in the pre-treatment group, namely
access site-related bleeds and pericardium drainage. No such dra-
matic differences were observed with 600 mg clopidogrel, with
which safety proﬁles of in-lab vs. pre-treatment were similar [789].
A pre-treatment strategy, compared with a delayed administra-
tion of ticagrelor, has not so far been tested. In PLATO, all patients
had received pre-treatment with clopidogrel or ticagrelor, irre-
spective of treatment strategy (invasive vs. non-invasive) and
patients undergoing PCI had received P2Y12 receptor inhibitors at
a median of 4 hours prior to the intervention. Therefore, the risk–
beneﬁt ratio of pre-treatment using ticagrelor prior to diagnostic
coronary angiography is not known.
18.4.2 Intravenous P2Y12 inhibitors. Cangrelor is a direct
reversible, short-acting (half-life 3 min) P2Y12 inhibitor that does not
require metabolic conversion, although it is not available for oral
administration. It has been used during PCI with mixed results. In
Cangrelor vs. Standard Therapy to Achieve Optimal Management of
Platelet Inhibition (CHAMPION)-PHOENIX, a double-blind,
placebo-controlled trial, 11 145 patients who were undergoing
either urgent or elective PCI and received guideline-recommended
therapy, were randomized to receive a bolus and infusion of
cangrelor (30 µg/kg; 4 µg/kg/min) or a loading dose of 300 mg or
600 mg of clopidogrel. The rate of the primary efﬁcacy endpoint—
deﬁned as a composite of death, myocardial infarction, ischaemia-
driven revascularization, or stent thrombosis at 48 hours after
randomization—was 4.7% in the cangrelor group and 5.9% in the
clopidogrel group (adjusted OR 0.78; 95% CI 0.66–0.93; P = 0.005)
[852]. Stent thrombosis developed in 0.8% of the patients in the
cangrelor group and in 1.4% in the clopidogrel group (OR 0.62; 95%
CI 0.43–0.90; P = 0.01). Severe bleeding at 48 hours did not differ
signiﬁcantly. Although the universal deﬁnition of myocardial
infarction was used, the incidence of Q-wave myocardial infarction
did not differ between the study groups [852]. The pre-speciﬁed
pooled analysis of patient-level data from the three cangrelor trials
(CHAMPION-PCI, CHAMPION-PLATFORM, and CHAMPION-
PHOENIX) conﬁrmed the lower rates of PCI periprocedural
thrombotic complications (3.8% for cangrelor vs. 4.7% for control;
OR 0.81; 95% CI 0.71–0.91; P = 0.0007) and of stent thrombosis
(0.5% vs. 0.8%, respectively; OR 0.59; 95% CI 0.43–0.80; P = 0.0008)
with no difference in Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary Arteries (GUSTO)
major bleeding [853]. These early beneﬁts were maintained at 30
days and found to be consistent across all the pre-speciﬁed
subgroups. There was no correlation between treatment effect and
clinical presentation and there was a signiﬁcant lower incidence of
Q-wave myocardial infarction in favour of cangrelor. Altogether,
cangrelor seems to be a good therapeutic option in P2Y12
inhibitor-naïve patients undergoing coronary stent implantation. It
should be pointed out that there was no effect on mortality and that
the beneﬁt of cangrelor was mainly derived from preventing
intraprocedural stent thrombosis [853].
In addition, the use of cangrelor allows platelet inhibition to be
maintained up to surgery in patients discontinuing oral antiplate-
let therapy, without any excess of perioperative bleeding, in con-
trast to interruption of oral P2Y12 several days before CABG
surgery [854].
Cangrelor has not yet been approved by the European Medical
Agency or the Federal Drug Administration and therefore no spe-
ciﬁc recommendation about its use can be given.
18.4.3 Anticoagulation after percutaneous coronary
intervention in acute coronary syndrome patients. The
recent trial known as Anti-Xa Therapy to Lower cardiovascular
events in Addition to Standard therapy in subjects with Acute
Coronary Syndrome–Thrombolysis In Myocardial Infarction 51
(ATLAS ACS 2–TIMI 51) demonstrated that the addition of
rivaroxaban—either 2.5 mg or 5.0 mg, twice daily—to ASA and
clopidogrel among ACS patients lowered the composite primary
efﬁcacy endpoint of cardiovascular death, myocardial infarction,
and stroke (9.1% vs. 10.7%, respectively; HR 0.84; 95% CI 0.74–
0.96; P = 0.008) but was associated with a near four-fold increased
risk of non-CABG-associated major bleeding (2.1% vs. 0.6%,
respectively; HR 3.96; 95% CI 2.46–6.38; P < 0.001) and an
increased risk of intracranial haemorrhage [855]. The twice-daily
2.5 mg dose of rivaroxaban resulted in signiﬁcantly lower rates of
all-cause and cardiovascular mortality, which was not observed
with the twice-daily 5.0 mg dose. The composite of deﬁnite and
probable stent thrombosis was lower in the pooled (1.9% vs. 1.5%,
respectively; HR 0.65; P = 0.017) and 2.5 mg twice-daily groups
(1.9% vs. 1.5%, respectively; HR 0.61; P = 0.023) with a trend
towards lower incidences in the 5 mg twice-daily treatment group
(1.9% vs. 1.5%, respectively; HR 0.70; P = 0.089) [856]. The ATLAS
ACS 2-TIMI 51 trial did not test the combination of rivaroxaban
with prasugrel or ticagrelor, which might be associated with an
even higher bleeding risk. This trial suggests that low-dose
rivaroxaban (2.5 mg twice daily) may be considered in patients
who receive ASA and clopidogrel after ACS, particularly after
STEMI [857]. However, a phase III trial of apixaban, another factor
Xa antagonist, the Apixaban for Prevention of Acute Ischemic and
Safety Events (APPRAISE-2) [858], which compared full-dose
apixaban (5 mg b.i.d.) in combination with DAPT against DAPT
alone, was stopped early due to safety concerns related to an
excess bleeding risk in the absence of a beneﬁt in ischaemic
outcomes in high-risk ACS patients. Notably, the study population
carried higher comorbidities and the apixaban dose regimen was
the full dose used to prevent cardioembolic stroke in non-valvular
atrial ﬁbrillation. Finally, darexaban and dabigatran were both
tested in phase II dose-ranging trials in post-ACS patients
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[859,860]. In both cases, dose-dependent increases in major
bleeding were observed, but there was no sign of added efﬁcacy
when adding anticoagulant therapy to antiplatelet therapy in this
setting. Conversely, the phase II dose-ranging trials with
rivaroxaban and apixaban demonstrated a dose-dependent
higher incidence in major bleeding but a signiﬁcantly lower rate
of death, myocardial infarction or stroke than with placebo for
rivaroxaban and a trend for apixaban [861,862]. Pharmacological
features of direct oral anticoagulants are summarized in Table 14.
In conclusion, the role of direct oral anticoagulants in combin-
ation with DAPT in secondary prevention of ACS is promising, but
interpretation of the totality of evidence for the class of oral antic-
oagulants is inconclusive and requires further study.
18.4.4 Anticoagulation during percutaneous coronary
intervention in patients on oral anticoagulation. A sizeable
proportion of patients (6–8%) undergoing PCI have an indication
for long-term oral anticoagulation with a vitamin K antagonist
(VKA) or NOAC, due to various conditions such as
moderate-to-high embolic risk AF, mechanical heart valves, or
venous thromboembolism. Interruption of VKA therapy may
expose the patient to an increased risk of thromboembolic
episodes [863]. Percutaneous coronary intervention may be a
delicate process under full VKA anticoagulation or NOAC.
In elective PCI, no additional anticoagulation is needed if the
international normalized ratio (INR) is >2.5. Radial access should
be the preferred choice, to reduce the risk of periprocedural
bleeding. PCI without interruption of VKAs, to avoid bridging
therapy that may lead to more bleeding or ischaemic complica-
tions, should be the preferred strategy. The use of GP IIb/IIIa inhi-
bitors, unless for bail-out, should be also avoided.
Primary PCI in patients on therapeutic oral anticoagulation
should be performed via a radial approach with use of additional
parenteral anticoagulation, regardless of the timing of the last
dose of oral anticoagulant. Given its short-term action of 25
minutes and lower bleeding risk bivalirudin—used during the pro-
cedure and discontinued immediately after primary PCI—may be
preferred over UFH or enoxaparin, especially when patients are
exposed to dabigatran. Enoxaparin should be the preferred paren-
teral anticoagulant in cases of prior exposure to direct anti-Xa
inhibitors (rivaroxaban or apixaban) to avoid cross-over. Unless
for bail-out situations, glycoprotein IIb/IIIa inhibitors should gen-
erally be avoided.
18.4.5 Antithrombotic therapy after percutaneous
coronary intervention in patients requiring oral anti-
coagulation. Long-term exposure of patients to triple therapy is
associated with a high risk of bleeding [864]. Fatal bleeds represent
1 in 10 of all bleeds, of which half are of intracranial origin and
half from the gastrointestinal tract [865]. Evidence is too weak to
provide clear guidance [866,867]. Triple therapy, consisting of
ASA, clopidogrel, and (N)OAC after PCI, should only be given if a
compelling indication exists (i.e. paroxysmal, persistent, or per-
manent AF with Cardiac failure, Hypertension, Age ≥75 [Doubled],
Diabetes, Stroke [Doubled]–Vascular disease, Age 65–74 and Sex
category [Female] (CHA2DS2-VASc) score ≥2; mechanical valves;
recent or recurrent history of deep venous thrombosis or pulmon-
ary embolism).
Triple therapy should be limited in duration, depending on the
clinical setting, thromboembolic (CHA2DS2-VASc score) and bleed-
ing risks Hypertension, Abnormal renal/liver function, Stroke,
Bleeding history or predisposition, Labile INR, Elderly, Drugs/
alcohol (HAS-BLED) score. The use of prasugrel or ticagrelor as part
of triple therapy should be avoided, given the lack of established
beneﬁt and the greater risk of major bleeding compared with clopi-
dogrel (HR 4.6; 95% CI 1.9–11.4; P < 0.001) in an observational study
[868]. Gastric protection should be implemented with a proton
pump inhibitor. The dose intensity of oral anticoagulation should
be carefully monitored with a target INR of 2.0–2.5 in the case of
vitamin K antagonists and use of lower tested dose for stroke pre-
vention in the case of NOACs (dabigatran 110 mg b.i.d.; rivaroxaban
15 mg once daily, etc.). Recommendations on stent type (DES vs.
BMS) are difﬁcult in the absence of conclusive data. Although DAPT
is routinely recommended for a duration of at least 1 month after
Table 14: Pharmacological features of novel oral anticoagulants
Dabigatran Rivaroxaban Apixaban
Target  Factor IIa (thrombin) Factor Xa Factor Xa
Tmax (h) 0.5–2 2–4 3–4














Protein binding (%) 35 93 87
Half-life (h) 12–14 9–13 8–15
Renal excretion (%) 80 33 27
Dose regimen 110 and 150 mg b.i.d.
2.5 mg b.i.d. for ACS;
15 and 20 mg q.d. for AF 2.5 and 5 mg b.i.d.
ACS = acute coronary syndrome; AF = atrial fibrillation; b.i.d. = bis in diem (twice daily); BRCP = breast cancer resistance protein; q.d. = quaque die; Tmax = time to
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BMS and for 6 months after DES, the risk of stent thrombosis (and
other ischaemic endpoints) between 1 and 12 months after stenting
appears similar with both stent platforms [124,352,869]. In addition,
recent data on the risk of adverse events among patients who have
ceased DAPT medicatio [648] and patients undergoing non-cardiac
surgery suggest no differences between BMS and DES [663]. Until
data from randomized trials become available, this task force
recommends the use of new-generation DES over BMS in patients
requiring oral anticoagulation who are at low bleeding risk
(HAS-BLED score ≤2). Among patients undergoing PCI who require
oral anticoagulation and have a high bleeding risk (HAS-BLED score
≥3) the choice between BMS and new-generation DES needs to be
decided on an individual basis.
Omission of ASA while maintaining clopidogrel has been evalu-
ated in the What is the Optimal antiplatElet and anticoagulant
therapy in patients with oral anticoagulation and coronary
StenTing (WOEST) trial, which randomized 573 patients either to
dual therapy with oral anticoagulation and clopidogrel (75 mg
daily) or to triple therapy with oral anticoagulation, clopidogrel,
and ASA 80 mg daily. Treatment was continued for 1 month after
BMS placement in 35% of the patients and for 1 year after DES
placement in the remaining 65%; follow-up was for 1 year [870].
Percutaneous coronary intervention was performed on VKA in
half of the patients and one-third presented with NSTE-ACS. The
primary endpoint of any TIMI bleeding was signiﬁcantly lower in
the dual therapy arm (19.5% vs. 44.9%; HR 0.36; 95% CI 0.26–0.50;
P < 0.001). The rates of myocardial infarction, stroke, TVR, or stent
thrombosis did not differ signiﬁcantly, but all-cause mortality was
lower in the dual therapy group (dual 2.5% vs. triple 6.4%;
P = 0.027) at 1 year. However, differences were driven by minor
bleeding as major bleeding was not signiﬁcantly lower, femoral
access was used in the majority of patients (74%), and triple
therapy was extended to 1 year. Although the trial was too small
to assess ischaemic outcomes, dual therapy with clopidogrel and
oral anticoagulants may be considered as an alternative to triple
therapy in patients with high bleeding risk.
18.4.6 Duration of dual antiplatelet therapy after
percutaneous coronary intervention. In the pivotal studies
establishing the value of early-generation DES, the duration of
DAPT was 2–3 months for the sirolimus-eluting stent and 6
months for the paclitaxel-eluting stent. Following concerns of a
greater risk of stent thrombosis and ischaemic adverse events
[651], several guideline documents recommended DAPT for 1
Recommendations for antithrombotic treatment in patients undergoing PCI who require oral anticoagulation
Recommendations Classa Levelb Ref c
In patients with a firm indication for oral anticoagulation (e.g. atrial fibrillation with CHA2DS2-
thromboembolism, LV thrombus, or mechanical valve prosthesis), oral anticoagulation is
recommended in addition to antiplatelet therapy.
I C
New-generation DES are preferred over BMS among patients requiring oral anticoagulation if bleeding risk is
low (HAS-BLED 2). IIa C
In patients with SCAD and atrial fibrillation with CHA2DS2-VASc score 2 at low bleeding risk (HAS-BLED
2), initial triple therapy of (N)OAC and ASA (75–100 mg/day) and clopidogrel 75 mg/day should be
considered for a duration of at least 1 month after BMS or new-generation DES followed by dual therapy
with (N)OAC and aspirin 75–100 mg/day or clopidogrel (75 mg/day) continued up to 12 months.
IIa C
DAPT should be considered as alternative to initial triple therapy for patients with SCAD and atrial fibrillation
with a CHA2DS2-VASc score 1.
In patients with ACS and atrial fibrillation at low bleeding risk (HAS-BLED 2), initial triple therapy of
(N)OAC and ASA (75–100 mg/day) and clopidogrel 75 mg/day should be considered for a duration of
6 months irrespective of stent type followed by (N)OAC and aspirin 75–100 mg/day or clopidogrel




In patients requiring oral anticoagulation at high bleeding risk (HAS BLED 3), triple therapy of (N)OAC and
ASA (75–100 mg/day) and clopidogrel 75 mg/day should be considered for a duration of 1 month followed
by (N)OAC and aspirin 75–100 mg/day or clopidogrel (75 mg/day) irrespective of clinical setting (SCAD or
ACS) and stent type (BMS or new-generation DES).




The use of ticagrelor and prasugrel as part of initial triple therapy is not recommended. III C
VASc score 2,
venous
Anticoagulation therapy after PCI in ACS patient
In selected patients who receive ASA and clopidogrel, low-dose rivaroxaban (2.5 mg twice daily) may be
considered in the setting of PCI for ACS if the patient is at low bleeding risk. IIb B 855
Anticoagulation during PCI in patients on oral anticoagulation
It is recommended to use additional parenteral anticoagulation, regardless of the timing of the last dose of
(N)OAC. I C
Periprocedural parenteral anticoagulants (bivalirudin, enoxaparin or UFH) should be discontinued
immediately after primary PCI. IIa C
ACS = acute coronary syndrome; ASA = acetylsalicylic acid; BMS = bare-metal stent; CHA2DS2-VASc = Cardiac failure, Hypertension, Age ≥75 [Doubled],
Diabetes, Stroke [Doubled]–Vascular disease, Age 65–74 and Sex category [Female]); DAPT = dual antiplatelet therapy; DES = drug-eluting stent; (N)
OAC = (non-vitamin K antagonist) oral anticoagulant; HAS-BLED = hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition,
labile INR, elderly, drugs/alcohol; INR = international normalized ratio; LV = left ventricular; PCI = percutaneous coronary intervention; SCAD = stable coronary
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year or longer after DES implantation [779]. Detailed analyses
comparing early-generation DES with BMS conﬁrmed no safety
issue, with similar rates of death, and myocardial infarction, during
long-term follow-up throughout 5 years with heterogeneous
duration of DAPT, ranging from 2 months up to 1 year
[124,649,650]. Although very late stent thrombosis was more
frequent, this infrequent event was offset by a somewhat lower
rate of early stent thrombosis and a lower risk of myocardial
infarction related to repeat revascularization. More recently,
new-generation DES have been shown to have a safety proﬁle
similar to or even better than BMS, including the risk of very late
stent thrombosis [125,129–132].
Currently available data do not support prolonging DAPT fol-
lowing DES beyond 1 year. A randomized trial called The
Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-
Eluting Stent Implantation for Coronary Lesions - Late Coronary
Arterial Thrombotic Events/REAL-world Patients Treated with
Drug-Eluting Stent Implantation and Late Coronary Arterial
Thrombotic Events (ZEST-LATE/REAL-LATE) assigned stable
patients, 1 year after DES implantation, to continuation with clopi-
dogrel plus ASA or to ASA alone [871]. After a median follow-up of
19 months, there was a non-signiﬁcantly higher rate of myocardial
infarction, stroke, and death in the patients who had continued
clopidogrel treatment than in those who stopped clopidogrel at
random assignment 1 year after implantation.
Several randomized trials including Efﬁcacy of Xience/Promus
vs. Cypher in reducing Late Loss After stenting (EXCELLENT) [803],
Real Safety and Efﬁcacy of a 3-month Dual Antiplatelet Therapy
Following Zotarolimus-eluting Stents Implantation (RESET) [805],
Optimized Duration of Clopidogrel Therapy Following Treatment
With the Zotarolimus-Eluting Stent in Real-World Clinical Practice
(OPTIMIZE [804] and PROlonging Dual Antiplatelet Treatment
In Patients With Coronary Artery Disease After Graded Stent-
induced Intimal Hyperplasia studY (PRODIGY) [799], compared
short duration (3–6 months) of DAPT against extended duration
(12–24 months) and consistently showed a lack of beneﬁt in terms
of ischaemic outcome but a higher risk of bleeding. A recent
meta-analysis of data comparing brief vs. prolonged DAPT
(beyond 12 months) duration concluded that extension of DAPT
beyond 6 months increased the risk of bleeding without reducing
ischaemic events [802]. It should be pointed out that none of
these trials were powered for ischaemic endpoints; all were open-
label and the time from stenting to randomization varied.
Therefore, weighing the quality of available evidence is difﬁcult
and these inferences need be conﬁrmed by continuing large-scale
trials including Intracoronary Stenting and Antithrombotic
Regimen: Safety And eFﬁcacy of a 6-month DAT after drug-Eluting
stenting (ISAR-SAFE; NCT00661206) and DAPT (NCT00977938).
In view of the well-established risks of bleeding associated with
DAPT beyond 12 months, and the lack of evidence of a beneﬁt in
the prevention of ischaemic complications, routine extension of
DAPT beyond 6 months after new-generation DES implantation in
SCAD cannot be recommended based on currently available data.
Observational data from new-generation zotarolimus-eluting and
everolimus-eluting stents suggest that even shorter durations of
DAPT may be sufﬁcient [872,873]. In the OPTIMIZE trial, clinical
non-inferiority of 3 months vs. 12 months of DAPT was assessed
in patients undergoing PCI with zotarolimus-eluting stents [804].
The rate of net adverse clinical events did not differ between
short-term DAPT and extended-duration DAPT (6.0% vs. 5.8%, re-
spectively; risk difference, 0.17; 95% CI −1.52 to 1.86). Rates of
bleeding, major or otherwise, were not statistically different.
Owing to the paucity of high-quality data for a 3-month (or
shorter) duration of DAPT with new-generation DES, this regimen
should be reserved for patients at high risk of bleeding or requir-
ing oral anticoagulation.
In patients undergoing myocardial revascularization for high-
risk ACS, DAPT is recommended for 1 year, irrespective of stent
type. This recommendation is based on the early CURE study—
which demonstrated a continuously increasing beneﬁt of DAPT
over ASA during the entire study follow-up period—as well as the
more recent results of TRITON-TIMI 38 and PLATO, which showed
a continuously increasing beneﬁt of DAPT with the new more
potent P2Y12-receptor blockers. After stenting for ACS, particularly
STEMI, extended DAPT reduces the risk of stent thrombosis,
re-infarction, and cardiovascular mortality [825], and more potent
DAPTs are associated with the greatest post-ACS clinical beneﬁts
of any type [830]. It is important to inform patients and their phy-
sicians about the need to avoid premature discontinuation of
DAPT.
In summary, it is recommended that DAPT be administered for
at least 1 month after BMS implantation in SCAD [86], for 6
months after new-generation DES implantation in SCAD [86], and
for up to 1 year in patients after ACS, irrespective of revasculariza-
tion strategy [180].
18.4.7 Drug interactions: a clopidogrel-related topic. Those
statins which are substrates of the CYP3A4 isoform (i.e,
simvastatin, atorvastatin and lovastatin) may interact with
clopidogrel metabolism, a drug interaction that has little, if any,
clinical relevance.
European and USA regulatory agencies have issued warnings
about diminished clopidogrel action when combined with proton
pump inhibitors (especially omeprazole and esomeprazole).
Treatment with proton pump inhibitors should be carefully con-
sidered in patients with previous gastrointestinal complications or
risk factors for gastro-intestinal bleedings (e.g. the elderly, con-
comitant use of warfarin, glucocorticoids, non-steroidal anti-
inﬂammatory drugs, or Helicobacter pylori infection) who require
DAPT. Several studies have shown a proton pump inhibitor-
related impact on the pharmacodynamics of antithrombotic
drugs, whereas few studies support signiﬁcant effects on clinical
outcomes. There is insufﬁcient data to discourage the use of
proton pump inhibitors in patients treated with ASA, prasugrel,
ticagrelor, dabigatran, or one of the oral factor Xa inhibitors
(rivaroxaban and apixaban). By far the most extensively investi-
gated proton pump inhibitor interaction is with clopidogrel.
Notwithstanding, potential interactions between the antiplatelet
effect of clopidogrel and proton pump inhibitors are controversial,
without ﬁrm conclusions on clinical implications. Clopidogrel is
most often prescribed with ASA, and patients on DAPT have an
increased risk of gastrointestinal bleeding; however, proton pump
inhibitors should not be used automatically in these patients but
should be prescribed to patients with previous gastrointestinal
complications or who are at an increased risk of bleeding.
Pharmacodynamic studies—but not clinical outcome studies—
support the use of newer proton pump inhibitors such as panto-
prazole instead of omeprazole [874].
18.4.8 Renal dysfunction. Renal dysfunction is present in 30–
40% of patients with CAD and the extent of CKD is strongly related
to the risk of in-hospital adverse outcomes. Impaired clinical
outcomes of patients with CKD are possibly explained by more
frequent pre-existing cardiovascular disease, more extended
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revascularization rates, and under-utilization of evidence-based
therapies, with potential overdosing of medication in patients
whose metabolism and excretion depend on renal function.
Creatinine clearance should be calculated with the Cockroft–Gault
formula, to comply with drug labelling and avoid overdosing with
antithrombotics—a frequent situation in patients with CKD—
leading to increased bleeding risk [875,876]. In patients referred
for acute PCI, the ﬁrst dose of an antithrombotic drug does not
usually add to the risk of bleeding in the case of CKD. Repeated
infusion or intake might lead to drug accumulation and increased
bleeding risk. Accordingly, in the absence of contraindications,
patients with CKD should receive the same ﬁrst-line treatment as
any other patient. Thereafter, dose adaptation with respect to
kidney function is essential and speciﬁc antithrombotic agents
may be preferred (Table 15). It is important, in minimizing the risk
of CIN, to ensure proper hydration during and after primary PCI
and to limit the dose of contrast agents (see section 11.4).
Renal dysfunction was one of several risk criteria that had to be
considered in the PLATO study and only patients with end-stage
renal failure requiring dialysis were excluded. Patients with CKD
(21%) did particularly beneﬁt from ticagrelor, with a 23% RRR for
the primary ischaemic endpoint (compared with a non-signiﬁcant
10% lower ﬁgure in patients without CKD), and an even more pro-
nounced 4.0% absolute and 28% RRR in all-cause mortality [877].
18.4.9 Surgery in patients on dual antiplatelet therapy.
Management of patients on DAPT who are referred for surgical
procedures depends on the level of emergency and the
thrombotic and bleeding risk of the individual patient (Figure 4)
[878]. Most surgical procedures can be performed on DAPT or at
least on ASA alone with acceptable rates of bleeding. A
multidisciplinary approach is required (cardiologist, anaesthe-
siologist, haematologist, and surgeon) to determine the patient’s
risk (bleeding and thrombosis) and to choose the best strategy.
Indeed, surgery-related bleeding increases 30-day and long-term
mortality [573].
Observational data from a large cohort study (124 844 BMS or
DES implantations) indicate that the strongest risk factors for
MACE following non-cardiac surgery are the need for non-elective
surgery, a history of myocardial infarction within 6 months of
surgery and advanced cardiac disease. While timing of surgery
was associated with MACE during the ﬁrst 6 months after PCI, this
was no longer apparent beyond 6 months [663]. Notably, stent
type (BMS vs. DES) was not associated with MACE after surgery. In
order to reduce the risk of bleeding and thrombosis, it is recom-
mended that elective non-cardiac surgery be delayed until com-
pletion of the full course of recommended DAPT (ideally 6
months in SCAD and 1 year in ACS patients) and that surgery be
performed without discontinuation of aspirin, if possible. Shorter
duration of DAPT may be justiﬁable if surgery cannot be delayed.
In preparation for surgical procedures with high-to-very-high
bleeding risk, it is recommended that clopidogrel be discontinued
5 days before surgery to reduce bleeding and the need for trans-
fusion, while maintaining ASA throughout the perioperative
period [879]. Prasugrel should be stopped 7 days before surgery,
based on its prolonged and more effective platelet inhibition than
clopidogrel. Interestingly, despite higher levels of observed TIMI
major bleeding (OR 4.73; 95% CI 1.9–11.8), platelet transfusion,
and surgical re-exploration for bleeding, prasugrel was associated
with a lower rate of death after CABG than with clopidogrel in the
small subgroup of patients in the TRITON-TIMI 38 trial (2.3% vs.
8.7%, respectively; adjusted OR 0.26; P = 0.025) [880]. Most cases
Table 15: Antithrombotic drugs dose adjustment in patients with CKD
Recommendations
ASA No dose adjustment.
Clopidogrel No dose adjustment.
Prasugrel No dose adjustment. No experience with end-stage renal disease/dialysis.
Ticagrelor No dose adjustment. No experience with end-stage renal disease/dialysis.
Enoxaparin
No adjustment needed for i.v. use in particular for PCI. Dose adjustment for subcutaneous injection in patients with creatinine 
clearance <30 ml/min: half dose.
Unfractionated heparin No adjustment of bolus dose.
Fondaparinux Contraindicated in patients with severe renal impairment (GFR <20 ml/min). 
Bivalirudin
• No reduction in the bolus dose is needed.
Abciximab
≥30 to <50 ml/min), an i.v. bolus of 180 µg/kg should be administered, followed





ASA = acetylsalicylic acid; CKD = chronic kidney disease; GFR = glomerular filtration rate; i.v. = intravenous; o.d. = omni diem (every day); PCI = percutaneous
coronary intervention; q.d. = quaque die; s.c. = subcutaneous.
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of CABG were planned and undertaken after discharge from the
qualifying event, and the study drug was usually resumed after
CABG. In the PLATO trial, in the subgroup of patients undergoing
CABG within 7 days after the last study drug intake (3–5 days), tica-
grelor, compared with clopidogrel, was also associated with lower
all-cause mortality (4.6% vs. 9.2%, respectively; P = 0.002) without
excess risk of CABG-related bleeding [881]. More than half of the
cases of CABG were undertaken during the qualifying event. This
was accounted for by fewer deaths associated with bleeding and
infection as well as fewer ischaemic events. A total of 37% did not
restart study medication within 7 days of discharge.
Accordingly, withdrawal of P2Y12 inhibitors is not recom-
mended in high-risk cohorts, such as those with continuing is-
chaemia and high-risk anatomy (e.g. LM or severe proximal
multivessel disease). These patients should undergo CABG while
maintaining P2Y12 inhibition, while paying particular attention to
reducing bleeding. It may be reasonable—though only in patients
whose risk of bleeding is very high—to withhold P2Y12 inhibitors
before surgery, even among those with active ischaemia, and to
consider bridging strategies (see below). Dual antiplatelet therapy
should be resumed as soon as possible, including a loading dose
for clopidogrel, ticagrelor, or prasugrel (if possible within 24 hours
of surgery), although the optimal timing for resumption of medi-
cation following CABG surgery remains uncertain.
Treatment monitoring, using bedside tests, has been suggested
as an option for guiding interruption of treatment, rather than use
of an arbitrary, speciﬁed period. Platelet inhibitory response to
clopidogrel determines CABG-related bleeding [882], and a strat-
egy based on pre-operative platelet function testing, to determine
the timing of CABG in clopidogrel-treated patients, led to 50%
shorter waiting time than recommended in the current Guidelines
[883]. For these reasons, the 2012 update of the Society of
Thoracic Surgeons guidelines suggested that a delay of even a day
or two is reasonable, to decrease bleeding and thrombotic risk in
ACS patients [879].
In very high-risk situations, such as in the ﬁrst weeks after
stent implantation, it has been suggested that, 5 days before
surgery, a patient may be switched from clopidogrel to a re-
versible antiplatelet agent with a short half-life (e.g. the i.v. GP
IIb/IIIa inhibitors tiroﬁban or eptiﬁbatide), stopping the infusion
4 hours before surgery [884], but there is no clinical evidence,
based solely on pharmacokinetic or pharmacodynamic studies,
to support this approach. In the Bridging Anticoagulation in
Patients who Require Temporary Interruption of Warfarin
Therapy for an Elective Invasive Procedure or Surgery (BRIDGE)
study, the use of cangrelor, an intravenous, reversible P2Y12
platelet inhibitor for bridging thienopyridine-treated patients to
CABG surgery, was evaluated against placebo [854]. Oral P2Y12
inhibitors were stopped 48 hours before CABG. Cangrelor
resulted in a higher rate of maintenance of platelet inhibition
(primary endpoint, P2Y12 reaction units <240; 98.8% (83/84) vs.
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Bridging with a prolonged infusion of cangrelor did not in-
crease major bleeding before surgery.
The substitution of DAPT with LMWH or UFH is ineffective [885].
In surgical procedures with low-to-moderate bleeding risk, sur-
geons should be encouraged to operate while maintaining DAPT.
Resuming clopidogrel after CABG appears to be safe and effect-
ive according to a recent meta-analysis of ﬁve randomized trials
and six observational studies that included 25 728 patients who,
when clopidogrel was added to ASA, as opposed to ASA alone,
showed a better early vein graft patency (RR 0.59; 95% CI 0.43–
0.82; P = 0.02) and lower in-hospital or 30-day mortality (0.8% vs.
1.9%; P < 0.0001) [886]. The mortality beneﬁt after CABG in PLATO
and in TRITON-TIMI 38 suggests that ticagrelor and prasugrel may
be restarted after CABG; however, the evidence is limited, with
only one-third of patients restarting ticagrelor in PLATO and no
randomized evaluation [881].
18.4.10 Antiplatelet therapy monitoring and genetic
testing. Platelet function testing has provided a measure of
certainty to the understanding of cardiovascular diseases: agents
that provide powerful and consistent inhibition of P2Y12-
mediated reactivity reduce post-procedural myocardial infarction
and stent thrombosis, conﬁrming the mechanistic hypothesis
that P2Y12-receptor signalling is a major component of
pathophysiological thrombus formation in patients with ACS
treated with PCI [774]. In the Assessment of Dual AntiPlatelet
Therapy with Drug-Eluting Stents (ADAPT-DES) trial—the largest
observational platelet function study conducted to date—close to
50% of 30-day post-PCI stent thrombosis was attributable to high
platelet reactivity, deﬁned as a P2Y12 reaction unit value of >208
when using the VerifyNow® bedside test [887]. However, even if
on-treatment platelet reactivity appears as a reliable and
independent measure of the risk of future events [888,889], the
concept of selective, intensive antiplatelet therapy based on a
measured drug effect has never been successfully proven [890].
Randomized trials examining the platelet function test hypothesis,
namely GRAVITAS and Testing Platelet Reactivity In Patients
Undergoing Elective Stent Placement on Clopidogrel to Guide
Alternative Therapy With Prasugrel (TRIGGER-PCI), have been
limited by low event rates, insufﬁcient pharmacodynamic
intervention, potential selection bias for low-risk patients, and an
intervention in patients deemed to be non-responders after stent
placement [778,891]. The recent Assessment by a double
Randomization of a Conventional antiplatelet strategy vs. a
monitoring-guided strategy for drug-eluting stent implantation
and, of Treatment Interruption vs. Continuation 1 year after
stenting (ARCTIC) trial, which randomized the use of a bedside
platelet function test, with repeated measures of ASA and
clopidogrel response before and after platelet function test, with
numerous pharmacodynamic interventions in poor responders
(including the use of GP IIb/IIIa inhibitors, reloading, and
switching to more potent P2Y12 inhibitors) was neutral [892]. This
study was appropriately powered, with a signiﬁcantly more
aggressive pharmacological intervention in non-responders
leading to a two-fold reduction in the rate of non-responders. In
summary, measuring treatment response by platelet function
assays should be limited to clinical research but should not be
routinely used in clinical practice.
Genetic variability in metabolism and absorption of clopidogrel
is a key factor, responsible for the inefﬁcient generation of the
active drug metabolite. The two-step hepatic cytochrome P450
(CYP)-dependent oxidative metabolism of the prodrug appears to
be of particular importance. Pharmacogenomic analyses have
identiﬁed loss-of-function variant alleles of CYP 2C19—and specif-
ically the 2C19*2 allele—as the predominant genetic mediators of
the antiplatelet effect of clopidogrel. Carriers have been shown to
have lower active metabolite levels of clopidogrel, higher platelet
reactivity and associated poorer outcomes [893–896]. Rapid and
accurate point-of-care genetic tests are available to identify these
alleles. There are pending questions about the role of such testing,
such as patient selection and whether personalized treatment
based on genotype has a positive impact on clinical outcome and
economy [897]. At present, genetic testing cannot be recom-
mended in routine clinical practice, due to insufﬁcient prospective
data.
In conclusion, platelet function testing or genetic testing may
be considered in speciﬁc high-risk situations (e.g. history of stent
thrombosis; compliance issue; suspicion of resistance; high bleed-
ing risk).
18.4.11 Patients with hypersensitivity to acetylsalicylic
acid. In patients with ASA hypersensitivity, and in whom ASA
therapy is necessary, a rapid desensitization procedure may be
performed [898]. Clopidogrel 75 mg daily is an appropriate
alternative in patients who are intolerant of, or allergic to, ASA as
long-term treatment [899]. Alternatively, in cases of aspirin
intolerance, a more potent, novel P2Y12 inhibitor (prasugrel or
ticagrelor) may be preferred over clopidogrel as single antiplatelet
therapy for a limited duration (1 to 6 months) after PCI.
18.4.12 Heparin-induced thrombocytopaenia. In patients
with a history of heparin-induced thrombocytopaenia, neither
UFH nor LMWH should be used, owing to concerns over
cross-reactivity. In this case, bivalirudin is the best option for
anticoagulation; other possible options are argatroban, hirudin,
lepirudin, and danaparoid.
General recommendations on antiplatelet therapy
Recommendations Classa Levelb Ref c
A proton pump inhibitor in
combination with DAPT is
recommended in patients with
a history of gastrointestinal
haemorrhage or peptic ulcer,
and appropriate for patients
with multiple other risk factors
(e.g. Helicobacter pylori infection,
age 65 years, and concurrent
use of anticoagulants, NSAIDs,
or steroids). 
I A 900,901
Clopidogrel 75 mg daily is
indicated as an alternative in
case of ASA intolerance in
patients with SCAD.
I B 899
Platelet function testing or
genetic testing may be
considered in specific high-risk
situations (e.g. history of stent
thrombosis; compliance issue;
suspicion of resistance; high
bleeding risk).
IIb C
Routine platelet function testing
or genetic testing (clopidogrel
and ASA) to adjust antiplatelet
therapy before or after elective
stenting is not recommended.
III A 778,892
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Recommendations Classa Levelb Ref c
Treatment interruption





In patients on P2Y12 inhibitors
who need to undergo non-
emergency major surgery
(including CABG), it should be
considered to postpone
surgery for at least 5 days after
cessation of ticagrelor or
clopidogrel, and for 7 days for
prasugrel, if clinically feasible
and unless the patient is at high
risk of ischaemic events should
be considered.
IIa C
It should be considered to
resume clopidogrel after CABG
surgery as soon as considered
safe.
IIa C
It should be considered to
resume ticagrelor or prasugrel
after CABG surgery as soon as
considered safe.
IIa C
Platelet function testing should
be used to guide antiplatelet
therapy interruption rather
than arbitrary use of a specified
period of delay in patients
undergoing CABG surgery.
IIa C
ASA = acetylsalicylic acid; CABG = coronary artery bypass grafting;
DAPT = dual antiplatelet therapy; NSAID = non-steroidal




19. VOLUME–OUTCOME RELATIONSHIP FOR
REVASCULARIZATION PROCEDURES
Operator experience inﬂuences outcomes, in particular in critical,
complex situations. The greater total experience of an entire hos-
pital team—consisting of supporting members in the operating
room or catheterization laboratory and those responsible for post-
operative care—results in favourable outcomes. Therefore, the
Leapfrog initiative has promoted PCI and CABG in high-volume
centres [902].
19.1 Coronary artery bypass grafting
A meta-analysis, evaluating the impact of hospital volume on
in-hospital mortality, showed that among seven studies comprising
1 470 990 patients in 2040 hospitals, high-volume hospitals had
lower mortality rates (OR 0.85; 95% conﬁdence interval 0.83–0.91)
even after adjustment for differences in case-mix [903]. The volume
of cases handled by a particular hospital may be high, but the
number of procedures per surgeon may vary, making the surgeon–
volume relationship a better marker. Although a recent study
reported no signiﬁcant difference in rates of in-hospital complica-
tions and 5-year mortality between surgical trainees and consultant
surgeons after multivariable adjustment for differences in baseline
characteristics (HR 1.02; 95% CI 0.87–1.20) [904], the data substanti-
ating a relationship is quite strong. Birkmeyer and co-authors found
that surgeons’ case volume, as a continuous variable, was inversely
related to operative mortality (adjusted OR 1.36; 95% CI 1.28–1.45)
[905]. Moreover, when hospital case volume was taken into account,
the impact of the surgeon’s case volume changed only marginally
and remained a strong predictor (adjusted OR 1.33; 95% CI 1.25–
1.42). Hospital volume itself had an OR of 1.13 (95% CI 1.03–1.24) if
corrected for surgeon volume. It has been suggested, especially for
the technically more challenging procedure of off-pump CABG, that
surgical experience is of importance [906].
Although the evidence accumulated over the years indicates
that both surgeon and hospital case volumes matter [907], several
studies suggest that quality measures are more important than
volume per se and high volume does not necessarily result in
better quality [908,909]. Statistics on the rate of use of an IMA and
on perioperative use of medication, and allowing data collection
and monitoring by national registries, are several examples of
these quality measures, all of which have been shown to be vital
for improvement of outcomes. An observational cohort study of
81 289 CABG procedures performed by 1451 surgeons at 164 hos-
pitals in North Carolina, USA, reported that missing quality indica-
tors strongly predicted hospital mortality, irrespective of surgeon-
or hospital case volume [910].
Taking into consideration these data, the current American
College of Cardiology Foundation/American Heart Association
(ACCF/AHA) guidelines on CABG surgery provide a IIb recom-
mendation that cardiac surgery programmes with less than 125
CABG procedures annually be afﬁliated with high-volume tertiary
centres [level of evidence (LoE) C] [285].
19.2 Percutaneous coronary intervention
Numerous studies have investigated the relationship between
volume of procedures and outcomes of PCI, suggesting a
volume–outcome relationship at operator level, as well as institu-
tional level [903,911–915]. In a meta-analysis of 10 studies in-
cluding over 1.3 million patients undergoing PCI at 1746
institutions between 1984 and 2005, treatment at high-volume
centres was associated with a 13% RRR for in-hospital mortality
(OR 0.87; 95% CI 0.83–0.91) compared with treatment at low-
volume centres [903]. Using a meta-regression analysis of mean
study year, the effect size did not attenuate appreciably over
time. These ﬁndings are consistent with a population-based
study from the PCI reporting system of New York, indicating that
hospital case volumes of <400 PCIs per year and operator case
volumes of <75 PCIs per year were associated with impaired out-
comes [911]. Some have suggested that procedural outcomes
were levelled by technological improvements in PCI material,
with progressive narrowing of outcome disparities and compli-
cation rates between high-volume and low-volume centres in
the case of elective procedures [916]. However, ﬁndings from
studies carried out in the coronary stent era indicate that both
operator- and hospital-volume experience continue to correlate
with outcomes, with a relationship suggesting that the best out-
comes are obtained with high-volume operators practising in
high-volume institutions [912,917].
Among patients with ACS, particularly STEMI, operator and hos-
pital volume play an important role. A large study in the USA
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PCI, shorter door-to-balloon times and lower in-hospital mortality
resulted in institutions with higher primary PCI volumes [918].
Similar results were observed in three more recent European ob-
servational studies [914,919,920]. In another analysis of 29 513
patients with acute myocardial infarction who underwent primary
PCI, treatment in high-volume centres was associated with a sig-
niﬁcantly lower door-to-balloon time than at medium- and low-
volume centres (88 vs. 90 vs. 98 minutes, respectively; P-value for
trend <0.001), although in-hospital mortality did not differ signiﬁ-
cantly (OR 1.22; 95% CI 0.78–1.91 for low-volume centres, and OR
1.14; 95% CI 0.78–1.66 for high-volume centres) [921]. Nallamothu
and colleagues showed a direct relationship between degree of an
institution’s specialization (operator and hospital experience,
24-hour/7-day availability, early activation of catheterization la-
boratory, written processes for emergency care) and outcomes in
terms of in-hospital mortality among patients with acute myocar-
dial infarction undergoing primary PCI [913].
Current ACCF/AHA guidelines recommend that elective PCI
should be performed by operators with annual case volumes of
at least 75 procedures, at high-volume centres handling at least
400 procedures per year (Class I C) or, alternatively, by operators
with annual volume of at least 75 procedures at centres handling
at least 200 procedures per year (Class IIa C). In the case of
primary PCI, it is recommended that, annually, operators should
perform at least 75 elective procedures and ideally 11 primary
PCI procedures in institutions that perform more than 400
elective PCIs per year and more than 36 primary procedures for
STEMI [922]. The ESC Guidelines on STEMI recommend that
primary PCI should be performed only in centres providing
24-hour/7-day coverage [201]. Owing to the continuing expan-
sion of knowledge pertinent to PCI, increasing demands on tech-
nical skills needed to independently and expertly perform PCI,
and the importance of Heart Teams in the management of
patients with CAD, the ESC/EACTS Task Force on myocardial
revascularization has issued recommendations on operator
training and competence.
Training in interventional cardiology
A European training programme in interventional cardiology
has been proposed by the European Association for Percutaneous
Cardiovascular Interventions (EAPCI) in order to ensure high
quality of patient care and clinical excellence [923]. The pro-
gramme should last 1–2 years at high-volume institutions that
handle at least 800 PCIs per year and that have established
24-hour/7-day service for the treatment of patients with ACS.
During the programme, trainees should perform at least 200
PCI procedures as ﬁrst- or only operator, acting under supervision
for one-third (>66) of these procedures in emergency or ACS
patients before becoming independent. Additionally, trainees are
required to attend at least 30 days (240 hours) of formal learning,
including attendance at accredited national and international
courses in interventional cardiology [923].
Recommendations for training, proficiency, and operator/institutional competence in CABG and PCI
Recommendations
It should be considered that trainees in cardiac surgery perform at least 200 CABG procedures under
supervision before being independent. IIa C
CABG should be performed with an annual institutional volume of at least 200 CABG cases. IIa C
Routine use of the internal mammary artery at a rate >90% is recommended. I B 162,924
Routine reporting of CABG outcome data to national registries and/or the EACTS database is recommended. I C
Physicians training in interventional cardiology should complete formal training according to a 1–2 year
curriculum at institutions with at least 800 PCIs per year and an established 24-hour/7-day service for
the treatment of patients with ACS.
IIa C
Physicians training in interventional cardiology should have performed at least 200 PCI procedures as first or
only operator with one-third of PCI procedures in emergency or ACS patients under supervision before
becoming independent.
IIa C
National Societies of the ESC should develop recommendations on annual operator and institutional PCI
volume. This Task Force recommends, the operator and hospital volumes listed below: IIa C
• PCI for ACS should be performed by trained operators with an annual volume of at least 75 procedures
at institutions performing at least 400 PCI per year with an established 24-hour/7-day service for the
treatment of patients with ACS.
• PCI for SCAD should be performed by trained operators with an annual volume of at least 75
procedures at institutions performing at least 200 PCI per year.
Non-emergency high-risk PCI procedures, such as distal LM disease, complex bifurcation stenosis, single
remaining patent coronary artery, and complex chronic total occlusions, should be performed by adequately
experienced operators at centres that have access to circulatory support and intensive care treatment, and
preferentially have cardiovascular surgery on-site.
IIa C
• Institutions with an annual volume of fewer than 400 PCI should consider collaboration in networks
with high-volume institutions (more than 400 PCI per year), with shared written protocols and
exchange of operators and support staff.
IIa C
Classa Levelb Ref c
ACS = acute coronary syndromes; CABG = coronary artery bypass grafting; EACTS = European Association for Cardio-Thoracic Surgery; EAPCI = European
Association for Percutaneous Cardiovascular Interventions; ESC = European Society of Cardiology; LM = left main; PCI = percutaneous coronary intervention;
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20. MEDICAL THERAPY, SECONDARY
PREVENTION, AND STRATEGIES FOR FOLLOW-UP
Myocardial revascularization must be accompanied by medical
therapy and other secondary prevention strategies for risk factor
modiﬁcation and permanent lifestyle changes [925]. Secondary
prevention and cardiac rehabilitation are an integral part of the
management strategy after revascularization, because such mea-
sures reduce future morbidity and mortality in a cost-effective way
and can further ameliorate symptoms.
Although the need to detect restenosis has diminished in the
DES era, the recurrence of symptoms due to disease progression
or restenosis deserves attention. Likewise, the durability of CABG
results has increased with the use of arterial grafts, and ischaemia
stems mainly from SVG attrition and/or progression of CAD in
native vessels.
21. ADDENDA
ESC National Cardiac Societies actively involved in the review
process of the 2014 ESC/EACTS Guidelines on myocardial revascu-
larization:
Austria, Austrian Society of Cardiology, Franz Weidinger;
Azerbaijan, Azerbaijan Society of Cardiology, Firdovsi Ibrahimov;
Belgium, Belgian Society of Cardiology, Victor Legrand; Bosnia
and Herzegovina, Association of Cardiologists of Bosnia and
Herzegovina, Ibrahim Terzic;́ Bulgaria, Bulgarian Society of
Cardiology, Arman Postadzhiyan; Croatia, Croatian Cardiac
Society, Bosko Skoric; Cyprus, Cyprus Society of Cardiology,
Georgios M. Georgiou; Czech Republic, Czech Society
of Cardiology, Michael Zelizko; Denmark, Danish Society
of Cardiology, Anders Junker; Estonia, Estonian Society of
Cardiology, Jaan Eha; Finland, Finnish Cardiac Society, Hannu
Long-term medical therapy after myocardial revascularization to improve prognosis and recommendations for lifestyle changes
and participation in cardiac rehabilitation programmes
Recommendations Classa Level b Ref.c
Coronary artery disease
Statin therapy with an LDL-C goal <70 mg/dl (<1.8 mmol/l) is indicated to start and continue in all patients 
with CAD after revascularization, unless contraindicated.
I A 926–928
Low-dose ASA (75–100 mg/day) is recommended in all patients with CAD.d I A 774,794
In patients who cannot tolerate ASA, clopidogrel is recommended as an alternative. I B 899
ACE inhibitors are recommended in all patients with CAD if there is presence of other conditions (e.g. heart
failure, hypertension or diabetes). ARBs are an alternative, if ACE inhibitors are not tolerated.
I A 929–935
All patients should be advised on lifestyle changes (including smoking cessation, regular physical activity, and a 
healthy diet).
I A 936,937
Participation in a cardiac rehabilitation programme to modify lifestyle habits and increase adherence to
treatment should be considered for all patients requiring hospitalization or invasive intervention after an acute




Coronary artery disease and hypertension
A systolic blood pressure goal <140 mmHg should be considered in patients with CAD. IIa A 944–946
A DBP goal of <90 mmHg is recommended in all patients. In patients with diabetes a DBP goal <85 mmHg is
recommended.
I A 947,948
Coronary artery disease and type 2 diabetes
A target for HbA1c of <7.0% is recommended, which is particularly well established for the prevention of
microvascular disease.
I A 949,950
Coronary artery disease and chronic heart failure
It is recommended to start and continue ACE-inhibitors in all patients with heart failure or myocardial
infarction with LVEF <40%, unless contraindicated.
I A 929,930
ARBs are indicated in patients who are intolerant of ACE inhibitors and have heart failure or myocardial
infarction with LVEF <40%.
I A 931,932
Beta-blocker therapy is indicated in all patients with heart failure or LV dysfunction, unless contraindicated. I A 951–954
Aldosterone receptor antagonist therapy is indicated in patients with persisting symptoms (NYHA class II–IV)
and an EF <35%, despite treatment with an ACE inhibitor (or an ARB) and a beta-blocker.
I A 955–957
Ivabradine should be considered to reduce the risk of hospitalization for heart failure in patients in sinus 
rhythm with an EF <35%, a heart rate >70 b.p.m., and persisting symptoms (NYHA class II–IV) despite 
treatment with an evidence-based dose of a beta-blocker (or maximum tolerated), ACE inhibitor (or ARB),
and a mineralocorticoid receptor antagonist (or ARB).
IIa B 958,959
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; ASA = acetylsalicylic acid; b.p.m. = beats per minute; CAD = coronary artery
disease; DBP = diastolic blood pressure; EF = ejection fraction; HbA1c = glycated haemoglobin A1c; LDL-C = low-density lipoprotein cholesterol; LVEF = left
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Romppanen; France, French Society of Cardiology, Jean-Louis
Bonnet; Georgia, Georgian Society of Cardiology, Alexander
Aladashvili; Germany, German Cardiac Society, Rainer
Hambrecht; Hungary, Hungarian Society of Cardiology, Dávid
Becker; Iceland, Icelandic Society of Cardiology, Thorarinn
Gudnason; Israel, Israel Heart Society, Amit Segev; Italy, Italian
Federation of Cardiology, Raffaele Bugiardini; Kazakhstan,
Association of Cardiologists of Kazakhstan, Orazbek Sakhov;
Kyrgyzstan, Kyrgyz Society of Cardiology, Aibek Mirrakhimov;
Luxembourg, Luxembourg Society of Cardiology, Bruno Pereira;
Malta, Maltese Cardiac Society, Herbert Felice; Norway,
Norwegian Society of Cardiology, Thor Trovik; Poland, Polish
Cardiac Society, Dariusz Dudek; Portugal, Portuguese Society of
Cardiology, Hélder Pereira; Serbia, Cardiology Society of Serbia,
Milan A. Nedeljkovic; Slovakia, Slovak Society of Cardiology,
Martin Hudec; Spain, Spanish Society of Cardiology, Angel
Cequier; Sweden, Swedish Society of Cardiology, David Erlinge;
Switzerland, Swiss Society of Cardiology, Marco Rofﬁ; The
Former Yugoslav Republic of Macedonia, Macedonian FYR
Society of Cardiology, Sasko Kedev; Tunisia, Tunisian Society of
Cardiology and Cardio-Vascular Surgery, Faouzi Addad; Turkey,
Turkish Society of Cardiology, Aylin Yildirir; United Kingdom,
British Cardiovascular Society, John Davies.
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